Hyaluronic Acid

PubMed ID: 27353769

Large RCT showed clinically meaningful pain improvement in knee OA with HA formulation.

PubMed ID: 28453454

Intra-articular hyaluronate reduced pain (VAS) in adhesive capsulitis.

PubMed ID: 31278705

Single IA HA injection improved shoulder pain in adhesive capsulitis, albeit less than ketorolac.

PubMed ID: 33723790

Large RCT of intra‑articular HA+sorbitol showed sustained pain/function improvement in knee OA.

PubMed ID: 34680131

Single Synolis VA (HA+sorbitol) produced pain/function benefit up to 6 months.

PubMed ID: 41385821

HA+manniol improved WOMAC function though primary VAS pain not superior to saline.

PubMed ID: 37686801

Multi‑ingredient oral supplement containing low‑MW HA reduced knee pain vs placebo (cannot attribute solely to HA).

PubMed ID: 22205098

Postoperative IA hyaluronan after microfracture improved ankle pain and function vs surgery alone.

PubMed ID: 22253252

IA HA reduced pain and improved ankle function for osteochondral talar lesions (PRP superior).

PubMed ID: 25825393

Adjunct IA HA after talar microfracture improved function and pain vs saline control.

PubMed ID: 25763853

HA after microfracture produced better cartilage repair and improved ankle function.

PubMed ID: 27681813

Both injected HA and an oral HA‑containing product improved knee pain/function in early OA (oral product had other actives).

PubMed ID: 20151251

Randomized IA sodium hyaluronate increased synovial HA and reduced pain vs baseline with clinical benefit comparable to steroid — direct evidence of improved joint comfort.

PubMed ID: 26133944

Single‑injection HA+CS gave greater and longer pain/function improvement vs steroid in tennis elbow (clinical relevance to local joint/tendon comfort).

PubMed ID: 26577936

Large prospective study: three IA injections of HA+CS produced large, sustained reductions in knee pain up to 6 months.

PubMed ID: 26978418

Comparative study of combo formulations (one containing HA) showed faster symptomatic benefit — supports symptomatic joint comfort though multi‑component.

PubMed ID: 31381494

Randomized trial of HA-containing eggshell membrane reduced knee pain and improved walking performance — directly supports joint comfort.

PubMed ID: 30794553

Topical/magnetophoretic HA+GAG device reduced worst pain vs topical diclofenac in a pilot trial — supports local comfort.

PubMed ID: 32598683

Injectable hyaluronate/chondroitin (with NSAIDs) reduced walking pain by ~30% in knee OA — supports symptomatic joint comfort.

PubMed ID: 33213125

Pilot RCT of an oral combo including HA showed improved WOMAC/Lequesne scores in knee OA (small sample but clinically relevant).

PubMed ID: 33592868

Oral low‑MW HA (in a multi‑ingredient product) produced early, significant reductions in knee pain and improved function vs placebo.

PubMed ID: 40561485

Multi‑ingredient regimen including HA produced large pain reductions in knee OA exacerbations (attribution to HA limited by combination).

PubMed ID: 26905565

Knee IA HA produced clinically meaningful pain reduction and function improvement (randomized trial).

PubMed ID: 31855906

IA HA improved pain in knee OA; benefit increased when combined with polynucleotides (HA alone still beneficial).

PubMed ID: 33904585

HA improved symptoms in knee OA but biochemical marker changes were lacking; clinical benefit moderate.

PubMed ID: 35331859

IA‑HA produced symptom improvement in a large trial despite biomarker changes; clinical pain benefit present.

PubMed ID: 24274358

Placebo‑controlled oral multi‑ingredient (small HA) supplement reduced self‑reported joint pain; HA contribution plausible but confounded.

PubMed ID: 25388643

IA HA produced clinically meaningful WOMAC pain reductions versus placebo and vs glucosamine.

PubMed ID: 28862770

TMJ OA study showed lower pain scores when glucosamine added to HA injections.

PubMed ID: 29864430

Modest long‑term pain/function improvement in TMJ when glucosamine added to HA.

PubMed ID: 38223641

Knee injections (ozone+HA) gave substantially lower VAS pain vs HA alone.

PubMed ID: 15906109

IA HA reduced synovial NO and improved WOMAC pain/function in knee OA.

PubMed ID: 1814964

Small study: IA sodium hyaluronate produced short‑term symptomatic benefit in TMJ RA.

PubMed ID: 1468245

HA combined with low‑dose steroid produced faster/larger symptom improvement in knee OA.

PubMed ID: 8403580

Randomized knee OA trial showed substantially greater pain relief and global improvement with intra‑articular HA.

PubMed ID: 8445463

Intra‑articular HA reduced pain and improved function in TMJ disc‑displacement subgroup vs saline.

PubMed ID: 8886085

One‑year placebo‑controlled trial showed reduced pain and improved function after weekly knee HA injections.

PubMed ID: 15449510

Large multicenter double‑blind trial found HA improved Lequesne functional index vs low‑dose control.

PubMed ID: 8689462

In inflammatory knee OA HA trended toward longer‑term pain relief among completers (mixed ITT results).

PubMed ID: 8689457

Hylan G‑F 20 provided superior pain/function at 26 weeks versus NSAID, supporting durable symptom relief.

PubMed ID: 9219678

Hyalgan injections improved quality of life and symptoms vs control, indicating symptomatic joint benefit.

PubMed ID: 9175299

Double‑blind trial: intra‑articular sodium hyaluronate reduced knee pain and improved motion for ~3 months.

PubMed ID: 9663358

Multicenter trial: hylan G‑F 20 produced substantial, lasting reductions in weight‑bearing pain versus saline.

PubMed ID: 9818665

Large RCT: five weekly HA injections reduced walking pain and improved function versus placebo to 26 weeks.

PubMed ID: 10093796

Small randomized study: adding HA to steroid+exercise improved pain and motion in frozen shoulder vs steroid alone.

PubMed ID: 10461471

Randomized observer‑blind trial: five weekly HA injections improved walking pain and functional scores through 6 months.

PubMed ID: 10509850

Randomized comparison: higher‑MW, higher‑viscosity HA reduced knee pain more than lower‑MW product.

PubMed ID: 10870655

Head‑to‑head trial showed differences in short‑term efficacy between two intra‑articular HA products (supports efficacy of HA injections).

PubMed ID: 11302304

Randomized trial: intra‑articular sodium hyaluronate significantly improved knee pain and global symptoms vs saline (strong clinical evidence).

PubMed ID: 11408900

Weekly HA injections improved shoulder pain/function comparably to steroid (moderate symptomatic benefit).

PubMed ID: 11381380

Adding intra‑articular sodium hyaluronate to TMJ arthrocentesis improved pain/function vs arthrocentesis alone.

PubMed ID: 12202120

Within‑patient study: five HA injections substantially reduced pain and improved function and strength vs untreated knee.

PubMed ID: 12410458

Randomized trial: cross‑linked HA reduced knee pain and improved some function measures for up to 1 year (mixed endpoints).

PubMed ID: 11822921

Randomized trial: intra‑articular HA reduced pain and improved walking/fitness measures vs NSAID/placebo.

PubMed ID: 12127830

Large study: adding hylan G‑F 20 to usual care gave markedly greater WOMAC pain improvement over 1 year.

PubMed ID: 12421996

Pooled HA injections showed a modestly longer duration of symptomatic knee benefit vs placebo.

PubMed ID: 11826641

HA injections into TMJ produced higher clinical response and reduced IL‑6 vs steroid, supporting symptomatic benefit.

PubMed ID: 11844036

Small randomized trial in TMJ showed reduced pain and improved function with intra‑articular HA vs saline.

PubMed ID: 12172954

In rheumatoid knees HA injections (with arthrocentesis) were associated with fewer relapses, implying clinical joint benefit.

PubMed ID: 12851342

Knee OA: HA improved pain/function over 6 months, similar to corticosteroid.

PubMed ID: 12740675

Weekly IA HA reduced knee pain versus steroid and improved function at 3 months.

PubMed ID: 12893153

Knee OA: Hyalgan injections produced outcomes comparable to arthroscopic washout.

PubMed ID: 12951310

Large RCT: Hylan GF-20 produced meaningful, sustained improvement in Lequesne index vs usual care.

PubMed ID: 14760806

Hylan G-F 20 gave greater and longer pain/function improvement than steroid over 26 weeks.

PubMed ID: 15262244

Single NASHA injection benefited patients with OA confined to the treated knee (subgroup efficacy).

PubMed ID: 15487709

Small RCT: IA HA reduced adhesion-molecule levels and improved pain/function over 3 weeks.

PubMed ID: 14999424

IA hyaluronan reduced synovial IL‑6 and effusion and was associated with symptomatic improvement.

PubMed ID: 15088306

Five weekly IA HA injections produced modest but significant improvements in WOMAC pain and stiffness.

PubMed ID: 15564311

Hylan G‑F 20 produced more clinically meaningful OA responders on WOMAC.

PubMed ID: 15599642

Randomized knee OA study: less pain and improved WOMAC vs saline.

PubMed ID: 16242353

Three IA injections improved long‑term pain in thumb CMC OA vs steroid.

PubMed ID: 16242361

Large RCT in knee OA showed substantial pain relief vs comparator—clear joint comfort benefit.

PubMed ID: 16206349

HMW HA suggested symptom improvement in knee OA (responder signal).

PubMed ID: 16371798

Thumb‑base HA injections reduced pain and later improved fine hand function.

PubMed ID: 15694572

Hylan G‑F 20 produced large, sustained WOMAC pain improvements.

PubMed ID: 16342083

HA added to rehab produced the largest pain and functional gains vs other groups.

PubMed ID: 15776267

Three HA injections produced large absolute improvement in knee function and satisfaction.

PubMed ID: 16319156

Facet‑joint sodium hyaluronate provided lasting pain relief comparable to steroid.

PubMed ID: 15959784

HA injections improved WOMAC stiffness and effect persisted versus placebo.

PubMed ID: 15647968

Hip OA injections reduced pain/function by ~38–40% for 6 months.

PubMed ID: 15703953

HA (with/without steroid) improved knee pain and function over 1 year; steroid gave faster early relief.

PubMed ID: 16091920

Frozen shoulder: SH injections improved pain and function though PT was superior.

PubMed ID: 15694571

Hylan G‑F 20 doubled responder rates at 12 months vs care—clinically meaningful symptom relief.

PubMed ID: 16089139

Knee HA injection plus topical ointment improved function and 1‑yr effectiveness vs injection alone (confounded by topical).

PubMed ID: 15918064

Intra-articular HA fluid after arthroscopy reduced early postoperative pain and swelling.

PubMed ID: 15895892

Large randomized trial: both high- and low-MW HA improved knee pain/function for up to 1 year.

PubMed ID: 16652426

Weekly IA HA reduced pain and improved function vs placebo at 3 weeks (early symptomatic benefit).

PubMed ID: 16751166

Intra-articular hylan reduced knee pain and gave greater functional gains than TENS at 6 months.

PubMed ID: 17187274

Post-arthroscopy HA instillation produced sustained pain and function benefits vs lavage alone up to 1 year.

PubMed ID: 16416102

Hyaluronan injections improved knee-OA pain and function vs baseline.

PubMed ID: 17968921

Large RCT shows viscosupplement HA formulations provide meaningful 6‑month pain relief in knee OA (class effect supporting joint comfort).

PubMed ID: 17620777

Periarticular HA for acute ankle sprain reduced pain vs placebo in athletes, indicating improved joint comfort.

PubMed ID: 17650168

IA sodium hyaluronate reduced pain in TMJ OA vs steroid (strong clinical effect).

PubMed ID: 17620776

Intra‑articular HA during ACL rehab improved functional scores and strength.

PubMed ID: 18180567

Arthroscopy + IA HA associated with reduced pain and better function, though multiple interventions confound attribution.

PubMed ID: 17257536

IA sodium hyaluronate reduced pain and improved function vs steroid in hallux rigidus (human RCT).

PubMed ID: 17590369

IA hyaluronate into thumb CMC reduced pain and improved function in OA patients.

PubMed ID: 18204873

Large RCT showed substantial and significant walking-pain improvement vs placebo.

PubMed ID: 18565251

Intra‑articular HA improved ankle function and pain numerically more than exercise, though group differences were not clear.

PubMed ID: 18430574

Hylan G‑F20 produced large, sustained knee pain reductions vs lower‑MW HA (strong evidence for joint pain relief).

PubMed ID: 18451387

Sodium hyaluronate reduced shoulder pain substantially in the osteoarthritis subgroup up to ~6 months.

PubMed ID: 19060515

Adding intra‑articular HA after arthroscopy improved pain/function at 12 months vs surgery alone.

PubMed ID: 18261664

Hylan injections for thumb‑base arthritis gave longer‑lasting pain relief and improved grip over 6 months.

PubMed ID: 18365224

Various hylan G‑F20 regimens produced clinically meaningful 24‑week knee pain reductions.

PubMed ID: 18785414

Five weekly IA injections of sodium HA reduced ankle pain at 3 months versus saline (small RCT).

PubMed ID: 18940487

Single intra‑articular HA injection improved TMJ pain and function vs oral analgesics (randomized trial).

PubMed ID: 19138610

TMJ study: inferior-space HA gave greater pain relief vs superior-space injections.

PubMed ID: 19539353

Large RCT in knee OA showing significant and durable pain relief vs saline.

PubMed ID: 20048489

Periarticular HA after ankle sprain produced large pain reductions and clinical benefit.

PubMed ID: 20003205

Ultrasound-guided IA Hyalubrix improved hip OA pain and reduced NSAID use vs mepivacaine.

PubMed ID: 20145786

Knee arthroscopy + IA HA reduced postoperative pain versus surgery alone.

PubMed ID: 20023357

Knee OA study reported significant VAS/WOMAC pain reductions after HA injections.

PubMed ID: 19240522

Weekly IA HA reduced pain in TMJ disc displacement over 12 months.

PubMed ID: 19137352

Within-patient RCT in thumb-base OA with durable, significant pain reduction at 24 weeks.

PubMed ID: 19380288

Single high-viscosity knee injection decreased pain and improved clinical function over 12 weeks.

PubMed ID: 19362003

Five injections improved knee pain and clinical scores similarly to steroid in trial.

PubMed ID: 19137353

Trapeziometacarpal OA: HA effective for pain but less durable than steroid.

PubMed ID: 19963403

Randomized placebo-controlled trial with large, sustained pain and function improvements for rotator-cuff/shoulder.

PubMed ID: 20030435

Large RCT: single cross‑linked IA HA produced significant, durable knee pain reduction vs placebo.

PubMed ID: 20954664

Post‑meniscectomy IA HA reduced early pain (15 mm VAS) vs saline (human RCT).

PubMed ID: 20111953

Knee OA intra‑articular HA produced large, clinically meaningful VAS pain reductions vs baseline.

PubMed ID: 19304567

Single 6 mL hylan injection gave modest but significant pain relief vs placebo over 26 weeks.

PubMed ID: 20185343

TMJ HA injections reduced inflammatory markers and correlated with pain reduction.

PubMed ID: 20697938

HA intra‑articular injections lowered knee symptoms and inflammatory cytokines.

PubMed ID: 20467406

Placebo‑controlled trial reported HA reduced VAS pain and improved function vs saline.

PubMed ID: 20144496

Post‑arthroscopy intra‑articular HA reduced postoperative TMJ pain vs control.

PubMed ID: 21875678

Large RCT showed a large WOMAC pain reduction (~32 points) with purified HA.

PubMed ID: 21722501

Well-powered RCT: intra‑articular hyaluronan reduced knee pain and improved function over 24 weeks (direct evidence for joint comfort).

PubMed ID: 21852252

Large long-term RCT showing substantial pain relief and responder benefit in knee OA.

PubMed ID: 21545190

Trigger finger treatment (corticosteroid+HA) produced high short-term symptom relief; HA contribution uncertain.

PubMed ID: 21978211

Well-powered trial showing significant reductions in knee pain vs saline over 25 weeks.

PubMed ID: 22178274

Arthrocentesis with HA injections improved TMJ pain and function vs baseline (both techniques).

PubMed ID: 21820521

Open‑label extension: repeat IA hyaluronate maintained small pain improvements and acceptable safety.

PubMed ID: 22509642

Weekly HA injections improved pain and function more than single steroid injection in knee OA.

PubMed ID: 22512127

IA preparation (including HA comparator) improved postoperative knee articular function vs no use.

PubMed ID: 23176112

Three HA injections gave moderate, sustained knee symptom improvements comparable to PRP.

PubMed ID: 22294639

Large RCT of intra‑articular low‑MW HA showed clinically meaningful pain reduction in knee OA.

PubMed ID: 22342928

Single cross‑linked HA injection reduced knee pain vs saline in a large RCT (short‑term benefit).

PubMed ID: 22476807

HA injections reduced knee pain and improved function vs meloxicam (slower onset, longer duration).

PubMed ID: 23451445

Intra‑articular HA reduced knee pain and improved function for ~6 months vs baseline.

PubMed ID: 22933671

Single intra‑articular HA at ACL surgery reduced early postoperative pain/swelling.

PubMed ID: 23063625

HA with capsular distension improved shoulder pain similar to steroid injection.

PubMed ID: 23053658

HA‑CMC reduced pain after mastectomy vs control (improved ROM/pain outcomes).

PubMed ID: 22366365

Subacromial HA injections produced substantial pain reduction vs steroid at 12 weeks, directly supporting joint comfort.

PubMed ID: 22939642

Both HA formulations improved TMJ pain and function after arthrocentesis, indicating reduced joint pain.

PubMed ID: 22513879

Cohort showed HA improved symptoms but less than PRP, indicating some joint comfort effect.

PubMed ID: 24168077

NASHA showed benefit in a subgroup (no effusion) indicating some symptomatic pain relief.

PubMed ID: 24185114

Single-injection NASHA relieved knee OA pain comparably to steroid with longer durability, supporting comfort.

PubMed ID: 24075613

HA injections improved knee OA symptoms (though inferior to PRGF), supporting modest pain benefit.

PubMed ID: 23380230

Intra‑articular HA after cartilage drilling supported repair and subjective outcomes, consistent with comfort benefits.

PubMed ID: 23326188

IA HA produced large, sustained pain reductions in knee OA (randomized trial).

PubMed ID: 23417236

High‑MW intra‑articular HA relieved knee pain over 26 weeks (large RCT).

PubMed ID: 24162762

Repeated IA HA after surgery reduced NSAID use and improved cartilage volume, consistent with symptom benefit.

PubMed ID: 24579221

HA injections improved pain/function in hip OA comparably to PRP in a randomized trial.

PubMed ID: 24089302

Two intra‑articular hyaluronan doses after wrist arthroscopy improved Mayo wrist scores vs arthroscopy alone (clinician/patient impressions).

PubMed ID: 24443804

Large RCT: IA hyaluronic acid provided pain/function relief comparable to oral NSAID with better tolerability—direct evidence for joint comfort.

PubMed ID: 25311256

Ultrasound‑guided IA HA improved pain and function in thumb OA with sustained benefit in worse‑symptom patients.

PubMed ID: 24853591

IA hyaluronic acid gave better short‑term pain relief and jaw function in TMJ disorder vs steroids/other agents.

PubMed ID: 25619045

Randomized trial in knee OA showed clinically significant pain and function improvement with IA sodium hyaluronate vs SYSADOA.

PubMed ID: 24703391

Knee OA viscosupplementation produced symptomatic improvement comparable to polynucleotide injections.

PubMed ID: 25579006

Inferior TMJ HA injection improved jaw function—direct joint comfort benefit.

PubMed ID: 26340807

HA improved hand function in trigger finger at 3 months—functional joint/tendon relevance.

PubMed ID: 26233594

HA improved symptoms in early knee OA vs saline (less than multiple PRP)—relevant to joint comfort.

PubMed ID: 25889322

Large multicenter RCT: single‑injection HA non‑inferior to multi‑injection HA for pain/function in knee OA.

PubMed ID: 26555862

Large IA HA trial showing ~50 mm VAS movement pain reductions and improved function.

PubMed ID: 25887932

Phase‑2 HA formulations reduced WOMAC pain/stiffness/function vs comparator, smaller trial.

PubMed ID: 26346122

Long‑term lower pain and fewer replacements with HA+LLLT vs control, but combined intervention.

PubMed ID: 25952818

Large RCT: PRP did not outperform standard HA; both produced clinically meaningful knee improvements.

PubMed ID: 26685691

HA injections (±rehab) improved short‑term pain with best relief when combined with exercise.

PubMed ID: 25415767

Oral high‑MW HA pilot reduced chronic pain and analgesic use (small, short study).

PubMed ID: 25882438

IA HA improved TMJ‑OA symptoms short‑term (1–3 months) though PRP better long‑term.

PubMed ID: 25631505

IA sodium hyaluronate reduced synovial IL‑1β, providing plausible anti‑inflammatory mechanism for symptom relief.

PubMed ID: 26551066

Intra‑articular sodium hyaluronate at arthroscopy significantly reduced postoperative pain and improved WOMAC for 3–6 weeks.

PubMed ID: 25704621

Multiple TMJ HA treatments produced larger pain decreases at 6 months vs single‑session.

PubMed ID: 28146403

Knee OA injections with HA improved pain (primary outcome similar to PRP) though inferior on some secondary outcomes.

PubMed ID: 27252432

Single HA knee injection produced similar 6‑month pain/function to steroid (less rapid short‑term relief).

PubMed ID: 27384560

HA injections improved pain/function in knee OA patients (overall comparable to PRP in this trial).

PubMed ID: 27364372

Arthrocentesis+HA improved TMJ pain vs baseline (pain VAS improvements reported).

PubMed ID: 27466224

Single HA injection after ACL gave modest short‑term symptom/ROM benefits vs control.

PubMed ID: 28002896

Hybrid HA produced greater short‑term symptom relief in athletes with knee cartilage lesions vs PRP.

PubMed ID: 27993154

MSC+HA cohorts showed clinically meaningful pain/function reductions (safety established).

PubMed ID: 27358159

Combined IA HA+oxygen‑ozone gave superior short‑term knee OA symptom relief vs either alone.

PubMed ID: 27639439

Peritendinous HA reduced pain and improved function more than ESWT in Achilles tendinopathy.

PubMed ID: 27981279

In hip OA HA produced benefit at 16 weeks (pain/WOMAC improvements reported).

PubMed ID: 27244700

HYADD 4 injections improved knee OA symptoms more than steroid up to ~6 months.

PubMed ID: 27257981

Both single cross‑linked and three‑dose linear HA improved knee OA pain/function; three‑dose possibly better.

PubMed ID: 27056686

HA improved pain/function for months in mild‑moderate knee OA (PRP superior at 12 months).

PubMed ID: 27709863

Hip injections of HA reduced pain and sometimes improved later function in femoroacetabular impingement.

PubMed ID: 27070534

Intra‑tendinous LMW‑HA gave quicker pain/function improvement for rotator cuff tendinopathy.

PubMed ID: 27250845

Large RCT (Gel‑200) showed modest, clinically meaningful knee pain relief vs control.

PubMed ID: 26488145

Draining joint fluid before HA injection resulted in greater pain/function improvement.

PubMed ID: 28058962

Pilot RCT in RA foot/ankle showed significant short‑term pain improvement after HA.

PubMed ID: 28291178

Single cross‑linked HA injection produced sustained knee pain reduction up to 6 months.

PubMed ID: 28946838

Single large HA knee injection produced symptom relief comparable to multi‑injection regimen.

PubMed ID: 29202568

Hybrid HA injections relieved pain more than high‑MW HA in obese OA patients.

PubMed ID: 29164399

Randomized trial: single UHMW‑HA hip injection relieved pain and improved function similarly to two‑dose regimen.

PubMed ID: 28535076

Large RCT (knee OA) showed clinically meaningful pain/function improvement with HA+steroid; supports symptomatic joint comfort.

PubMed ID: 28549436

Large RCT: single cross‑linked intra‑articular HA produced substantial pain reduction comparable to multi‑dose HA.

PubMed ID: 28791808

Knee HA injections (ultrasound‑guided) improved pain/function more than blind injections → better symptom relief.

PubMed ID: 28856435

Hylan GF20 provided early functional/pain improvements in severe knee OA (peaked ~3 months) → moderate–strong short-term benefit for comfort.

PubMed ID: 28128473

Post-hoc RCT analysis found ~68% responders to intra‑articular HA at 6 months → supports clinically meaningful comfort in many patients.

PubMed ID: 30545242

Long follow-up RCT showed HA improved knee symptoms over time (although PRP had some advantages) → supportive evidence for symptomatic comfort.

PubMed ID: 30159738

Large RCT (Monovisc) showed clinically meaningful knee pain relief vs saline up to 26 weeks → strong evidence for improved joint comfort.

PubMed ID: 29388085

In knee OA HA improved pain/function vs baseline, though less than combined PRP approaches.

PubMed ID: 30395961

Adding HA‑CMC to selective nerve root block reduced short‑term rebound pain vs anesthetic/steroid alone.

PubMed ID: 29644875

Large RCT (Gel‑200) showed significant pain and overall WOMAC improvement vs saline at 12–26 weeks.

PubMed ID: 29664106

HA injection + therapeutic exercise gave greater short‑term pain/function gains than saline+exercise.

PubMed ID: 29983409

6‑month RCT found hyaluronan injections produced clinically meaningful pain and function improvement in knee OA.

PubMed ID: 31601466

TMJ trial: HA injections produced symptom improvement, although less than bone‑marrow concentrate.

PubMed ID: 29366744

Single IA HA injection produced clinically meaningful WOMAC/VAS improvements in knee OA.

PubMed ID: 29261533

Intra-articular hyaluronate reduced pain by ~39% at 1 month and improved function vs steroid comparably.

PubMed ID: 29878617

HA improved pain/function in KOA but was less effective than PRP.

PubMed ID: 29888570

Weekly IA sodium hyaluronate injections produced significant reductions in VAS/WOMAC vs baseline.

PubMed ID: 30623236

HA injections improved WOMAC/VAS vs baseline though inferior to PRP long-term.

PubMed ID: 31064359

High‑MW IA HA increased responder rate and modestly improved pain/function over 52 weeks.

PubMed ID: 31821355

Large RCT: single IA HA produced substantial, lasting pain and function improvement (WOMAC A reductions).

PubMed ID: 30814387

Arthrocentesis for TMJ produced large pain reductions; added value of HA limited but some benefit noted.

PubMed ID: 30199423

SH + PRP around rotator-cuff tears produced greater pain and function improvements than either alone.

PubMed ID: 31166260

Intra-articular HA reduced TMJ palpation pain (PRP was superior), so HA still confers pain relief.

PubMed ID: 31451342

TMJ trial: HA injections (and arthrocentesis+HA) reduced pain on chewing and improved QoL.

PubMed ID: 31778431

Knee viscosupplementation RCT improved WOMAC pain and function, indicating better comfort.

PubMed ID: 31230119

Immediate IA HA after tibial plateau fracture reduced KOOS pain vs control at follow-up.

PubMed ID: 31421686

IA hyaluronic acid reduced pain and improved function in knee OA at 6 months in a sizable trial.

PubMed ID: 32000598

HA injections improved trigger‑digit symptoms comparably to steroid over time (symptom relief).

PubMed ID: 31902736

Single intra‑articular HA improved hip pain and function over 12 months (moderate benefit).

PubMed ID: 32898379

Single HA injection produced moderate pain improvement for knee OA at 6 months (but less than CRFA).

PubMed ID: 32931308

Single HA injection reduced pain and improved function in lateral epicondylalgia (tennis elbow).

PubMed ID: 32517739

Single HA injection offered transient knee OA symptom relief in a randomized study (short‑lived benefit).

PubMed ID: 32358661

HA knee injection produced significant pain/function improvements in OA patients in RCT — supports joint comfort.

PubMed ID: 32144974

HA injections gave sustained pain reduction vs ozone in older knee OA — supports comfort.

PubMed ID: 32129141

Single large HA knee injection produced sustained WOMAC improvements at 12 months — supports lasting comfort.

PubMed ID: 32043426

HA used as part of combination therapy with cells/microfracture produced functional benefit; HA’s independent contribution uncertain but plausibly supportive.

PubMed ID: 33091549

PRP+HA produced larger, durable pain reductions in knee OA vs HA or PRP alone (direct symptomatic benefit).

PubMed ID: 32895353

IA HA improved knee OA pain/function at 2 months vs atorvastatin (early, transient pain benefit).

PubMed ID: 32151101

IA HA (with splint) improved TMJ pain vs splint alone (direct joint pain benefit).

PubMed ID: 32909439

IA HA improved knee pain regardless of neuropathic features and halved NP prevalence at 24 weeks (symptom improvement).

PubMed ID: 33045417

HA vehicle with intradiscal cells was associated with durable reductions in low‑back pain and disability (symptomatic benefit though HA was vehicle).

PubMed ID: 33506798

HA injections gave the most durable pain relief in thumb‑base OA vs PRP/steroid at 12 weeks (direct benefit).

PubMed ID: 32799851

IA high‑MW HA produced clinically meaningful WOMAC/VAS improvements in knee OA up to 6 months (direct joint pain benefit).

PubMed ID: 32233245

Intra‑articular sodium hyaluronate reduced VAS pain substantially over 6 months (direct joint symptom improvement).

PubMed ID: 33536010

RCT IA-HA for knee OA showed moderate pain and function improvement (WOMAC, VAS).

PubMed ID: 34958762

HA alone improved pain/function but combo with steroid gave greater benefit; HA still active.

PubMed ID: 33523756

Single-injection HA produced modest symptomatic improvement vs baseline in knee OA RCT.

PubMed ID: 33749997

Large RCT of diclofenac-HA showed small but significant reductions in pain vs placebo.

PubMed ID: 33858205

HA showed only marginal benefit over saline for subacromial bursitis (small effect).

PubMed ID: 33407337

After arthroscopic lateral release, adjunct HA modestly improved early pain and function.

PubMed ID: 34666767

Enhanced plasma+HA showed numeric WOMAC pain improvement versus reference (pooled signals favored HA formulations).

PubMed ID: 35172440

HA improved knee OA symptoms for up to 18 months (PRP was superior long‑term but HA still produced benefit).

PubMed ID: 33591125

Single IA low‑MW HA produced clinically and statistically greater shoulder pain relief vs physiotherapy.

PubMed ID: 32514702

Injection route delivering HA to patellofemoral cartilage produced greater symptom relief than alternate route.

PubMed ID: 34511091

PN+HA provided greater and longer pain reduction vs HA alone, supporting symptomatic benefit of HA formulations.

PubMed ID: 33567859

Single injection (high‑ or low‑MW) reduced rotator cuff pain for ≥3 months.

PubMed ID: 34736768

New cross‑linked IA HA produced substantial weight‑bearing pain reduction vs active comparator.

PubMed ID: 33899526

Repeated PRP+HA injections improved knee symptoms at 6–12 months (HA was part of an effective regimen).

PubMed ID: 33675704

HA after TMJ arthrocentesis improved pain and mouth opening compared with baseline (adipose therapy was superior).

PubMed ID: 33006602

Intra‑articular diclofenac–HA conjugate reduced knee pain versus placebo (WOMAC/daily pain improvements).

PubMed ID: 33420185

Crosslinked HA + PRP improved pain/function in knee OA more than PRP alone at some timepoints.

PubMed ID: 34162365

Single crosslinked HA produced larger/longer pain and function improvements vs linear HA in knee OA.

PubMed ID: 34833411

Comparative cohort showed HA improved symptoms vs baseline though BMAC performed better; supports modest HA benefit.

PubMed ID: 36096771

HA injections in hip OA produced moderate pain/function improvements vs baseline (PRP was superior).

PubMed ID: 35316820

Intra‑articular HA gave clinically meaningful pain and disability improvements at 12 months in arthritic shoulders.

PubMed ID: 35997833

HA used with PRP showed sustained knee pain/function improvements vs baseline (combination study limits attribution to HA alone).

PubMed ID: 36013495

Single crosslinked HA produced significant WOMAC (pain/function) improvement in knee OA through 6 months comparable to PRP.

PubMed ID: 35439521

HA injections with dextrose improved functional measures and self-reported function versus HA+saline, indicating symptomatic benefit.

PubMed ID: 36372680

Intra‑articular HA after TMJ arthrocentesis reduced pain at 6 months vs arthrocentesis alone.

PubMed ID: 36078628

In patellar OA, HA injections produced longer-term pain improvement compared with comparator therapies.

PubMed ID: 35686864

Peritendinous HA combined with shockwave therapy reduced shoulder pain faster and more than shockwave alone.

PubMed ID: 34983471

Single intra‑articular HA after meniscectomy produced significant early pain reduction (VAS) vs control at 2 weeks.

PubMed ID: 35443676

Diclofenac‑conjugated HA gave clinically meaningful pain/function benefit for hip OA over 12 weeks.

PubMed ID: 36329428

Large symptom improvements seen when HA was given combined with PRP, but HA effect is confounded by PRP.

PubMed ID: 36128500

HA + PRP after arthroscopic debridement produced greater pain/function improvements than surgery alone (HA confounded with PRP).

PubMed ID: 36800668

In knee OA IA HA improved symptoms at 6 months (and increased femoral cartilage thickness).

PubMed ID: 35679902

IA HA for TMJ OA after arthrocentesis substantially reduced pain vs baseline and improved mouth opening.

PubMed ID: 35545190

Computer‑guided sodium hyaluronate injections produced faster improvements in mouth opening vs conventional technique.

PubMed ID: 37296122

RCT showing intra‑articular high‑MW HA produced clinically meaningful pain/function improvements in knee OA.

PubMed ID: 37240135

IA HA gave significant short‑term pain/function improvement comparable to another active therapy (ozone) in knee OA.

PubMed ID: 37697666

Hydrodilatation with HA + PT improved pain and function in adhesive capsulitis versus PT alone (better short‑term comfort).

PubMed ID: 37852892

Intra‑articular HA improved TMJ pain/function vs baseline (measurable but smaller than PRP).

PubMed ID: 36255262

HA viscosupplementation reduced knee pain in OA trials (pain relief demonstrated though inferior to polynucleotide).

PubMed ID: 37001332

Sodium hyaluronate reduced pain/WOMAC versus baseline (PRP superior), supporting symptomatic joint comfort effect.

PubMed ID: 39367905

HA injections reduced knee OA pain/function at 6–12 months (but no clear advantage vs PRP or combination).

PubMed ID: 38525999

HA provided comparable 26‑week WOMAC pain relief vs a device hydrogel—supports symptomatic relief.

PubMed ID: 39172722

Subacromial HA injections produced substantial pain and function improvements in rotator cuff tendinopathy.

PubMed ID: 39128172

Adjunct intra‑articular ozonized PRP+HA after meniscal repair gave larger long‑term pain/function benefits vs meniscectomy alone.

PubMed ID: 39317566

Pericapsular polynucleotide+HA significantly reduced TMJ pain vs physiotherapy (strong pain benefit).

PubMed ID: 38720327

Intra‑articular HA (with CGF) produced meaningful pain relief and functional improvement in TMJ OA.

PubMed ID: 38160332

Multiple IA HMW‑HA regimens produced clear improvements in pain and function in knee OA.

PubMed ID: 38311348

HA injections (active comparator) produced symptomatic improvement in multicompartment knee OA, though inferior to SVF.

PubMed ID: 38359676

Objective gait kinematic changes after HA showed reduced maximal flexion and increased extension, consistent with reduced joint stiffness.

PubMed ID: 39098893

Arthrocentesis + HA for TMJ reduced pain vs baseline and improved symptoms (jaw joint comfort).

PubMed ID: 39983793

Intra‑articular HA after ACL reduced pain substantially in first 1–2 months (clear short‑term joint comfort benefit).

PubMed ID: 40943401

HA intra‑articular improved WOMAC/pain vs baseline—direct evidence for symptomatic joint comfort.

PubMed ID: 40069683

Adding HA to corticosteroid improved ankle OA pain/function more than steroid alone—direct support for comfort.

PubMed ID: 39924508

Standard HA knee injections reduced pain/function vs baseline (less than comparator) — supports symptomatic relief.

PubMed ID: 40865738

HA injections reduced knee OA pain (both groups improved); combination with ozone did better, but HA alone still provided benefit.

PubMed ID: 40858216

Intra‑articular HA reduced knee pain and improved function in patellofemoral OA (direct RCT evidence of pain/function benefit).

PubMed ID: 40660843

Randomized IA HA improved knee OA pain and function vs ozone from 3 months onward, directly supporting pain/comfort benefit.

PubMed ID: 39892589

Addition of HA to steroid injections at the thumb base produced greater reduction in activity pain at 3 months.

PubMed ID: 40659059

HA in TMJ arthrocentesis significantly reduced pain; no dose-response between concentrations.

PubMed ID: 41248880

Single IA HA injection produced comparable medium‑term pain/function to steroid (supports HA provides sustained joint comfort though slower onset).

PubMed ID: 41619174

HA used as control produced some symptom improvement but was inferior to investigational therapy.

PubMed ID: 28255655

High‑MW HA injections reduced heel pain in plantar fasciopathy more than placebo at 5 weeks, easing movement.

PubMed ID: 41248880

Single IA HA produced similar 6‑month function to steroid (supports medium‑term mobility benefit).

PubMed ID: 40349001

Single HA knee injection modestly preserved tibial internal rotation during squat at 12 weeks, a biomechanical mobility measure.

PubMed ID: 39892589

HA + steroid reduced activity pain at thumb base, consistent with improved use and mobility.

PubMed ID: 40660843

Intra‑articular HA improved knee function and KOOS scores versus ozone, indicating better mobility.

PubMed ID: 40858216

IA HA reduced pain and improved function in patellofemoral OA, translating into greater comfort during movement.

PubMed ID: 40865738

HA injections (with or without ozone) improved pain and QoL in knee OA patients, indicating improved movement comfort though study small.

PubMed ID: 40069683

CS+HA improved ankle OA function (AOS) more than CS alone — supports mobility improvements.

PubMed ID: 40943401

HA improved WOMAC function and reduced symptoms in early knee OA versus baseline; MRI structural results favored ADSC but HA still improved mobility/function.

PubMed ID: 39983793

Early HA after ACL decreased pain with activity and sped return of function — better comfort with movement early post‑op.

PubMed ID: 39098893

TMJ arthrocentesis + HA increased maximum mouth opening and reduced joint symptoms (improved mobility of TMJ).

PubMed ID: 38359676

Objective 3‑D gait kinematics improved after IA HA (increased extension, altered rotation) indicating improved mobility.

PubMed ID: 38311348

HA comparator arm showed functional improvements in knee OA though inferior to autologous SVF.

PubMed ID: 39348919

HA injections for Morton's neuroma improved long‑term pain and function (comfort while walking) though slower vs steroid.

PubMed ID: 38160332

HA injections in knee OA improved WOMAC function and TUG, reflecting better mobility across dosing regimens.

PubMed ID: 38720327

CGF+HA group in TMJ OA had superior functional (Helkimo) improvements and mouth opening measures versus HA alone.

PubMed ID: 39128172

Ozonized PRP+HA after meniscal repair produced superior long‑term function and mobility vs meniscectomy alone.

PubMed ID: 39172722

Subacromial HA injections improved pain, CMS and ROM—patients experienced better comfort during movement.

PubMed ID: 37001332

Sodium hyaluronate produced functional improvements though PRP had larger effects—still supports mobility benefit.

PubMed ID: 36255262

HA viscosupplementation improved functional outcomes in knee OA consistent with better mobility.

PubMed ID: 37852892

HA injections improved maximum mouth opening (MMO) in TMJ‑OA, indicating improved joint mobility.

PubMed ID: 37697666

Hydrodilatation with HA + PT improved constant score and ROM vs PT alone in adhesive capsulitis.

PubMed ID: 37240135

IA HA and ozone both improved WOMAC/KOOS measures including functional components.

PubMed ID: 37296122

IA high‑MW HA produced meaningful improvements in pain/function, likely translating to better mobility in knee OA.

PubMed ID: 35545190

Computer‑guided HA injections improved MUMO faster than conventional technique in TMJ internal derangement.

PubMed ID: 35679902

TMJ IA HA increased maximum mouth opening substantially compared with baseline.

PubMed ID: 36800668

HA in knee OA improved symptoms and was associated with increased femoral cartilage thickness; functional mobility improved.

PubMed ID: 36128500

HA + PRP post‑debridement produced greater WOMAC and VAS improvements consistent with better mobility (HA confounded with PRP).

PubMed ID: 35443676

DF‑HA improved pain and joint‑specific function in hip OA over 12 weeks, enhancing movement comfort.

PubMed ID: 34983471

IA HA after partial meniscectomy improved knee ROM at 2 weeks vs control.

PubMed ID: 35686864

HA added to ESWT produced faster and larger reductions in pain/disability enabling better movement comfort.

PubMed ID: 36372680

HA after TMJ arthrocentesis increased maximum mouth opening by ~10 mm at 6 months.

PubMed ID: 35439521

HA + dextrose improved walking speed, stair climb and other performance measures vs HA+saline up to 6 months.

PubMed ID: 36013495

HA and PRP produced significant and comparable improvements in pain and function in early knee OA, reflecting better comfort during movement.

PubMed ID: 35316820

Single HA shoulder injection improved pain and disability at 12 months, consistent with functional/mobility gains.

PubMed ID: 34162365

Single crosslinked HA produced larger and longer improvements in pain/function vs linear HA, consistent with better mobility.

PubMed ID: 33420185

HA+PRP improved function measures (WOMAC/Lequesne) at some timepoints vs PRP alone.

PubMed ID: 33006602

IA diclofenac–HA conjugate reduced pain and improved daily pain measures in knee OA, enabling better function/mobility.

PubMed ID: 34736768

Cross‑linked HA improved KOOS/WOMAC function and reduced weight‑bearing pain, implying better mobility.

PubMed ID: 33567859

Single HA injection reduced pain and improved function in rotator cuff tendinopathy.

PubMed ID: 34511091

PN+HA improved KSS and WOMAC function more than HA alone across follow‑up.

PubMed ID: 32514702

Medial mid‑patellar HA injection route produced greater WOMAC/function improvements.

PubMed ID: 33591125

HA injection improved ROM and quality‑of‑life vs physiotherapy in shoulder tendinopathy.

PubMed ID: 33407337

HA after arthroscopic release improved Kujala scores and function vs placebo.

PubMed ID: 33749997

Diclofenac-HA produced modest physical function gains vs placebo.

PubMed ID: 33536010

IA-HA improved WOMAC and function in knee OA, indicating better mobility.

PubMed ID: 32233245

Sodium hyaluronate increased Lysholm scores and improved function through 6 months (direct mobility benefit).

PubMed ID: 32799851

HA injections improved WOMAC/VAS/Lequesne indices indicating better mobility in knee OA.

PubMed ID: 33506798

HA injections for thumb‑base OA preserved grip/pinch and function at 12 weeks relative to PRP/steroid (improved hand mobility/function).

PubMed ID: 32151101

IA HA (with splint) increased pain‑free mouth opening and functional mouth opening in TMJ disorders (direct mobility benefit).

PubMed ID: 33091549

PRP+HA produced superior function improvements in knee OA up to 24 months (direct mobility/function gains).

PubMed ID: 32129141

Single large‑dose HA knee injection maintained WOMAC improvements up to 12 months — supports lasting mobility/function benefits.

PubMed ID: 32358661

HA improved pain and function but sometimes less than other injectables; still supports mobility gains vs baseline.

PubMed ID: 32931308

HA reduced pain and improved function in tennis elbow, improving comfort during arm movement.

PubMed ID: 32898379

HA provided moderate improvements in function for knee OA at 6 months compared with baseline.

PubMed ID: 31902736

HA injection for hip OA improved function (HHS), indicating better joint mobility.

PubMed ID: 32000598

HA and steroid injections both improved trigger finger outcomes over time, improving movement comfort of the digit.

PubMed ID: 31421686

HA injections for knee OA improved pain and function contributing to greater comfort during movement for many patients.

PubMed ID: 31778431

HA viscosupplementation improved pain, stiffness and muscle strength, supporting improved comfort during movement.

PubMed ID: 31451342

TMJ arthrocentesis + HA improved mouth opening and chewing efficiency—functional mobility benefits.

PubMed ID: 30199423

SH+PRP around rotator cuff tears led to superior functional improvements vs either alone.

PubMed ID: 31821355

Large RCT showed significant WOMAC function improvements (C) indicating better joint mobility after IA HA.

PubMed ID: 31064359

HMW IA HA increased responder rates and improved KOOS function over 52 weeks.

PubMed ID: 29888570

Weekly IA HA improved pain and WOMAC function, likely improving comfort with movement.

PubMed ID: 29261533

HA injections for presumed facet joint pain reduced pain and improved function for months, improving movement comfort.

PubMed ID: 29366744

HA injection improved WOMAC and pain, suggesting improved mobility in knee OA patients.

PubMed ID: 29983409

Hyaluronan injections improved function tests (WOMAC, TUG/SLS in some comparisons) at 6 months.

PubMed ID: 29664106

HA plus exercise led to greater functional improvements over 8 weeks than saline+exercise.

PubMed ID: 29644875

Gel‑200 improved WOMAC function and pain compared with saline, consistent with better mobility.

PubMed ID: 30159738

Monovisc improved pain and physical function (WOMAC), indicating better mobility after IA HA.

PubMed ID: 30545242

Both HA and PRP improved IKDC/subjective function over follow-up, indicating mobility improvement with HA.

PubMed ID: 28856435

Hylan GF20 improved functional scores early (Lysholm, KSS) → supports short-term mobility gains.

PubMed ID: 28237253

After TMJ arthroscopy HA improved mouth opening, though PRGF performed better for long‑term pain.

PubMed ID: 28791808

Ultrasound‑guided knee HA injections gave greater function improvements vs blind injections.

PubMed ID: 28549436

Single cross‑linked HA injection produced significant improvements in weight‑bearing pain and WOMAC function (mobility).

PubMed ID: 27353769

HA+manniotol provided function improvements comparable to high‑MW HA in knee OA.

PubMed ID: 28453454

Hyaluronate injections improved shoulder range of motion (PROM) in adhesive capsulitis.

PubMed ID: 31278705

IA HA improved shoulder pain in adhesive capsulitis with some improvement in movement comfort (less effective than ketorolac).

PubMed ID: 33723790

IA HA+sorbitol produced sustained improvements in WOMAC function (mobility) in knee OA.

PubMed ID: 34680131

Synolis VA showed improvements in WOMAC function at 6 months.

PubMed ID: 22205098

IA hyaluronan after microfracture improved ankle‑hindfoot functional scores vs surgery alone.

PubMed ID: 22253252

IA HA improved ankle AOFAS and subjective global function over follow‑up (PRP gave larger improvements).

PubMed ID: 25825393

Adjunct HA injections improved function after talar microfracture compared with saline.

PubMed ID: 25763853

HA after microfracture resulted in thicker repair cartilage and better AOFAS scores (functional mobility gains).

PubMed ID: 27681813

Injected HA and an oral HA‑containing product both improved knee scores, indicating mobility benefit (oral product included other actives).

PubMed ID: 20151251

IA hyaluronate improved pain and joint biomarkers, implying improved comfort with movement.

PubMed ID: 26133944

HA+CS injections improved pain/function in lateral epicondylosis, suggesting improved mobility/functional range.

PubMed ID: 26577936

IA HA+CS injections markedly reduced knee pain and analgesic use, translating into better comfort during movement over months.

PubMed ID: 31381494

HA‑containing eggshell membrane improved walking performance and reduced pain in knee OA — supports comfort during movement.

PubMed ID: 30794553

Topical HA device produced pain reduction and comparable functional outcomes to diclofenac gel.

PubMed ID: 32598683

Injectable HA/chondroitin reduced walking pain in OA; pain reduction commonly permits improved mobility.

PubMed ID: 33213125

Oral combo improved clinical scores and decreased synovial inflammatory markers, consistent with improved mobility.

PubMed ID: 33592868

Oral low‑MW HA combination improved WOMAC and function over 8 weeks — supports mobility gains.

PubMed ID: 40561485

Regimen including HA produced large symptomatic and functional gains in knee OA exacerbations, supporting movement comfort (multi‑component product).

PubMed ID: 26905565

Knee IA HA produced significant improvements in Lequesne function scores and pain, indicating better mobility.

PubMed ID: 31855906

HA injections improved Knee Society/WOMAC scores; PN+HA gave greater improvements but HA alone improved mobility.

PubMed ID: 25388643

HA produced meaningful improvements in WOMAC pain/function and Lequence score, translating to better movement comfort.

PubMed ID: 28862770

Addition of oral glucosamine to HA injections improved maximal interincisal opening (MMO) long‑term in TMJ OA.

PubMed ID: 29864430

Modest but significant improvement in MMO at 12 months when glucosamine added to HA.

PubMed ID: 38223641

Knee HSS function and lower VAS pain with ozone+HA indicate improved comfort during movement.

PubMed ID: 15906109

IA HA improved WOMAC physical function in knee OA.

PubMed ID: 1814964

IA sodium hyaluronate increased maximum mouth opening in TMJ RA in the short term.

PubMed ID: 1468245

Combination HA+steroid produced faster pain relief and mobility gains in knee OA, improving movement comfort.

PubMed ID: 8403580

Knee OA trial reported greater pain relief and global improvement—translates into better movement comfort.

PubMed ID: 8445463

TMJ subgroup experienced improved joint function after HA injections.

PubMed ID: 8886085

Function (Lequesne) improved more with HA vs placebo.

PubMed ID: 15449510

Functional Lequesne index improved significantly with intra‑articular HA, indicating better mobility.

PubMed ID: 9219678

Hyalgan improved QoL and slowed cartilage deterioration with better functional scores vs control.

PubMed ID: 9175299

Injections improved knee pain on motion and movement in early OA versus placebo.

PubMed ID: 9663358

Hylan G‑F 20 produced substantial, lasting improvements in pain and activity limitation, indicating better mobility.

PubMed ID: 9818665

Large RCT: HA injections improved walking pain and WOMAC physical function up to 26 weeks.

PubMed ID: 10093796

Small study: adding HA to steroid+exercise improved motion in frozen shoulder versus steroid alone (limited sample).

PubMed ID: 10461471

Five weekly HA injections improved walking pain and Lequesne functional index through 6 months.

PubMed ID: 10870655

HA product differences in knee OA efficacy indicate HA can affect short‑term functional outcomes; product dependent.

PubMed ID: 11302304

Knee OA trial showed improved pain and global assessments after HA, consistent with improved mobility.

PubMed ID: 11381380

TMJ arthrocentesis with HA improved mouth opening and lateral movements vs arthrocentesis alone.

PubMed ID: 12202120

Within‑patient trial: objective increase in isokinetic muscle strength and marked reductions in pain and Lequesne score after five injections.

PubMed ID: 12410458

Cross‑linked HA showed one‑year improvements in some pain and function measures compared with oxygen therapy.

PubMed ID: 11822921

HA reduced activity pain and improved objective functional performance versus controls.

PubMed ID: 12127830

Hylan G‑F 20 added to usual care significantly improved WOMAC physical function and overall health utility over 1 year.

PubMed ID: 12421996

Pooled HA groups had slightly longer clinical benefit than placebo in knee OA, supporting moderate mobility improvement.

PubMed ID: 11826641

HA in TMJ produced higher marked‑improvement and lower failure rates vs steroid—supports movement comfort gains.

PubMed ID: 11844036

Objective and subjective TMJ measures improved with HA vs placebo, supporting mobility gains.

PubMed ID: 12740675

IA HA improved joint flexion and functional indices versus steroid at 3 months.

PubMed ID: 12951310

Hylan GF-20 produced clinically meaningful Lequesne index improvement vs conventional treatment.

PubMed ID: 14760806

Hylan G‑F 20 improved pain/function more than steroid at weeks 12 and 26, reflecting mobility gains.

PubMed ID: 15088306

WOMAC pain and stiffness reductions with HA are consistent with better movement comfort.

PubMed ID: 15599642

Knee OA patients had improved function and WOMAC scores following intra-articular HA.

PubMed ID: 16242353

Three IA injections improved lateral pinch power and pain in thumb CMC OA, indicating functional improvement.

PubMed ID: 16242361

Knee OA pain relief and fewer effusions translate to improved comfort with movement.

PubMed ID: 16206349

HMW HA had higher responder rates for pain/function in knee OA (borderline significance).

PubMed ID: 15694572

Hylan G‑F 20 produced large functional gains on WOMAC and responder outcomes.

PubMed ID: 16342083

HA plus exercise produced the greatest increase in walking speed and muscle strength.

PubMed ID: 16319156

Lumbar facet HA reduced pain and improved function—patients reported better movement comfort.

PubMed ID: 15647968

Hip OA injections produced sustained pain/function benefits improving mobility.

PubMed ID: 16091920

Frozen shoulder: HA improved ROM and function though PT best.

PubMed ID: 15918064

Reduced early postoperative pain/swelling and less analgesic use after arthroscopy suggests more comfortable movement early after surgery.

PubMed ID: 15895892

Improved HSS knee scores indicate better pain/function and therefore mobility for up to 1 year.

PubMed ID: 16652426

Early functional improvements at 3 weeks suggest short-term mobility benefits.

PubMed ID: 16751166

Hylan provided greater functional improvement by 6 months vs TENS.

PubMed ID: 17187274

Arthroscopy plus HA instillation preserved or improved walking function and clinical global improvement up to 1 year.

PubMed ID: 16416102

Hyaluronan injections improved knee-OA pain and some function measures versus baseline.

PubMed ID: 17968921

Large viscosupplement trial indicates HA formulations improve symptoms/function in knee OA, supporting mobility gains.

PubMed ID: 17620777

Ankle periarticular HA reduced weight‑bearing pain and sped return to sport, implying better comfort with movement.

PubMed ID: 17650168

IA sodium hyaluronate increased mandibular opening, protrusion and lateral movement in TMJ OA vs steroid.

PubMed ID: 17620776

ACL rehab with HA improved Lysholm scores and muscle peak torque—better mobility.

PubMed ID: 17257536

IA sodium hyaluronate improved gait pain and AOFAS functional score in hallux rigidus vs steroid.

PubMed ID: 17590369

IA hyaluronate in thumb CMC improved function (Dreiser index) indicating better mobility/use.

PubMed ID: 18204873

Large RCT showed marked improvement in walking pain and patient global satisfaction vs placebo.

PubMed ID: 18430574

Hylan G‑F20 produced earlier and longer WOMAC pain/functional improvements indicating improved mobility.

PubMed ID: 19060515

HA after arthroscopy produced greater 12‑month functional improvement vs surgery alone.

PubMed ID: 18365224

Different hylan regimens produced marked 24‑week pain/function gains supportive of mobility improvement.

PubMed ID: 18785414

Ankle HA injections improved AOS total score (includes activity/mobility domains) at 3 months.

PubMed ID: 18940487

IA HA improved TMJ function (jaw opening, mastication) vs oral meds, showing mobility gains in TMJ.

PubMed ID: 19060514

IA HA gave better short‑term function at 6 weeks after arthroscopy, indicating improved movement comfort early on.

PubMed ID: 19539353

Knee OA RCT showed improvements in function, consistent with better joint mobility.

PubMed ID: 20048489

Periarticular HA reduced pain and accelerated return to sport, improving comfort during activity.

PubMed ID: 20003205

Hip IA Hyalubrix improved Lequesne index (function) and pain vs control, indicating better mobility.

PubMed ID: 20145786

Adjunct IA HA after arthroscopy improved knee flexion and functional signs.

PubMed ID: 20023357

Study demonstrated improved proprioception and some muscle strength measures along with pain/function gains after HA.

PubMed ID: 19240522

TMJ IA HA reduced pain and joint sounds, which can improve comfort during jaw movement.

PubMed ID: 19337810

Both home exercise and HA improved mobility; HA produced modest functional improvement but not superior to exercise.

PubMed ID: 19137352

Thumb-base injection reduced pain and improved strength/function at 24 weeks — more comfortable movement.

PubMed ID: 19380288

Knee injection improved clinical function (Lequesne/KSS) though objective gait changes were limited.

PubMed ID: 19362003

Five injections improved clinical scores; objective gait changes minimal but function improved.

PubMed ID: 19963403

Marked and durable improvements in shoulder Constant score indicate substantial functional/mobility gains.

PubMed ID: 20030435

Large RCT: cross‑linked IA HA produced significant improvements in knee OA symptoms including function/mobility.

PubMed ID: 20954664

IA HA after meniscectomy reduced early pain and analgesic use, improving early comfort with knee movement.

PubMed ID: 20111953

Knee OA pain and function improvements imply greater comfort during movement after HA injection.

PubMed ID: 19304567

Hylan injection increased responder rates for walking pain and overall function vs placebo.

PubMed ID: 20467406

Trial reported functional score improvements with HA vs placebo.

PubMed ID: 21875678

Large WOMAC improvements imply meaningful gains in joint function and mobility.

PubMed ID: 21722501

OA trial demonstrated improved function (Lequesne index, VAS) after hyaluronan injections, supporting increased mobility.

PubMed ID: 21852252

Long-term knee OA improvements in pain/function correspond to better comfort during activity.

PubMed ID: 21545190

Conservative injection approach (steroid+HA) produced faster recovery and return to activity than surgery, improving movement comfort.

PubMed ID: 21978211

Weekly sodium hyaluronate improved WOMAC function scores vs placebo, reflecting mobility benefit.

PubMed ID: 22178274

Arthrocentesis + HA improved TMJ range of motion and jaw function from baseline.

PubMed ID: 22509642

HA improved function and stiffness vs steroid in older knee OA patients.

PubMed ID: 23176112

Three HA injections produced moderate IKDC and KOOS improvements including functional domains.

PubMed ID: 22294639

Low‑MW IA HA improved WOMAC function and global pain, reflecting better mobility in knee OA patients.

PubMed ID: 22342928

Single cross‑linked HA injection improved function vs saline at ~3 months.

PubMed ID: 23451445

Knee HA injections improved walking pain and function at 26 weeks vs baseline.

PubMed ID: 23063625

Capsular distension with HA restored external rotation better than steroid injection.

PubMed ID: 23053658

HA‑CMC reduced postoperative shoulder ROM restriction and improved arm function.

PubMed ID: 22366365

Shoulder HA injections produced marked pain reduction during activity, improving comfort on movement.

PubMed ID: 22939642

TMJ HA improved pain at chewing and mouth opening, increasing comfort with jaw movement.

PubMed ID: 24185114

NASHA improved WOMAC function/stiffness with sustained benefits, implying better mobility.

PubMed ID: 24075613

HA improved knee symptoms though PRGF was superior; still supports some increased comfort during activity.

PubMed ID: 23380230

HA supported post-drilling cartilage repair (with better results when combined with PBSC), associated with functional benefit potential.

PubMed ID: 23326188

IA HA produced marked pain reduction in knee OA, translating into improved comfort during movement.

PubMed ID: 23417236

High‑MW IA HA relieved knee pain over 26 weeks; mobility measures commonly improve with pain reduction.

PubMed ID: 24162762

Postoperative IA HA increased cartilage volume and reduced NSAID use, consistent with improved function/mobility.

PubMed ID: 24579221

HA and PRP both improved function and pain in hip OA over 12 months (randomized trial).

PubMed ID: 24089302

Wrist outcomes (MMWS) improved with intra‑articular hyaluronan after arthroscopy (function/mobility signal).

PubMed ID: 24443804

IA HA non‑inferior to oral NSAID on functional JKOM score, consistent with improved mobility/function.

PubMed ID: 25311256

HA improved thumb OA functional index with sustained benefit in more symptomatic patients.

PubMed ID: 25619045

Improved pain and Lequesne index with IA sodium hyaluronate supports increased comfort during activity.

PubMed ID: 25465711

Addition of HA to steroid injections for de Quervain's improved function and reduced recurrence at 6 months.

PubMed ID: 25579006

Inferior TMJ HA injection improved Helkimo index and remodeling—direct improvement in jaw mobility.

PubMed ID: 25340801

HA gel carrier with peptide improved finger motion after tendon repair—direct mobility benefit.

PubMed ID: 26340807

Trigger finger trial: HA improved hand function at 3 months—better mobility of finger joints/tendons.

PubMed ID: 26233594

HA improved subjective IKDC in early knee OA—relevant to knee mobility.

PubMed ID: 25889322

Knee OA trial showed improvements in WOMAC physical function and global self‑assessment.

PubMed ID: 26555862

Large IA HA study demonstrated marked reductions in movement pain and improvements on Lequesne index/function.

PubMed ID: 26346122

HA+LLLT group had lower long‑term pain and fewer joint replacements, consistent with preserved function.

PubMed ID: 25952818

HA produced similar IKDC functional gains as PRP over 12 months.

PubMed ID: 26685691

HA plus tailored exercise produced best 1‑month pain relief; functional improvements early on.

PubMed ID: 25882438

IA HA improved TMJ‑OA symptoms and MVMO short term, aiding movement comfort.

PubMed ID: 25631505

Reductions in synovial IL‑1β after HA support improved joint environment and potential mobility gains.

PubMed ID: 26551066

Post‑arthroscopy intra‑articular HA reduced pain and improved function in early weeks, improving comfort with movement.

PubMed ID: 25704621

Multi‑session TMJ HA treatment produced larger pain decreases and better overall clinical effect, improving comfort during jaw movement.

PubMed ID: 28146403

HA improved knee pain/function though PRP outperformed HA on some functional secondary outcomes.

PubMed ID: 27252432

Single HA injection produced similar 6‑month function to steroid (no loss of mobility), though steroids gave faster short‑term relief.

PubMed ID: 27384560

HA provided symptomatic improvement in knee OA patients, particularly in milder disease, consistent with improved mobility.

PubMed ID: 27364372

TMJ arthrocentesis+HA improved maximum interincisal opening (MIO) vs baseline.

PubMed ID: 27466224

Post‑ACL HA gave modest short‑term ROM gains vs control (objective ROM improvement).

PubMed ID: 28002896

Hybrid HA led to greater short‑term symptomatic improvement in athletes (functional mobility gains at 3–6 months).

PubMed ID: 27358159

HA+oxygen‑ozone combination improved KOOS and VAS vs single modalities (functional gains short term).

PubMed ID: 27639439

Peritendinous HA improved pain and VISA‑A functionVs ESWT, indicating better movement comfort in Achilles tendinopathy.

PubMed ID: 27244700

HYADD 4 group had superior WOMAC/function scores vs steroid up to 26 weeks.

PubMed ID: 27257981

Both HA regimens improved VAS/WOMAC up to 6 months; three‑dose linear HA superior for resting pain at 6 months.

PubMed ID: 27056686

HA improved symptoms through 6 months in knee OA (PRP outlasting at 12 months) — movement comfort gains short term.

PubMed ID: 27709863

HA hip injections provided some delayed functional improvement in FAI patients.

PubMed ID: 27070534

HA injections produced quicker functional improvement in rotator cuff tendinopathy, aiding comfort in movement.

PubMed ID: 27250845

Gel‑200 improved pain during movement (WOMAC), improving comfort while moving.

PubMed ID: 26488145

Aspiration before HA injection improved WOMAC function vs no aspiration.

PubMed ID: 28058962

HA injections reduced pain and improved foot function in RA, supporting movement comfort.

PubMed ID: 28291178

Cross‑linked HA improved pain and function including stiffness and mobility measures.

PubMed ID: 28946838

Single large‑dose HA gave functional symptom relief comparable to standard regimen.

PubMed ID: 29202568

Hybrid HA improved VAS pain and functional scores vs comparator, indicating greater movement comfort.

PubMed ID: 29164399

Hip HA injections improved pain and function, indicating greater comfort during movement.

PubMed ID: 28535076

HA+steroid knee injection produced faster and larger relief in pain and function versus saline → better movement comfort.

PubMed ID: 34477473

Prolonged-release vaginal HA improved epithelial maturation and lowered pH, indicating mucosal hydration.

PubMed ID: 34933842

Oral full-spectrum hyaluronan increased measured skin hydration by ~10.6% in RCT.

PubMed ID: 34743118

HA filler corrected midface volume effectively with high responder rates.

PubMed ID: 33851255

Monophasic HA filler effectively corrected nasolabial folds and increased fullness with high satisfaction.

PubMed ID: 34351386

VYC‑15L HA filler produced large volumetric increases and high responder rates for under‑eye hollows (plumping effect).

PubMed ID: 33534905

PRP+HA combination produced greater subjective facial appearance and objective elasticity; HA is known to increase skin water retention.

PubMed ID: 33476068

Two HA volumizing fillers produced similar, long‑lasting cheek volume restoration up to 2 years.

PubMed ID: 34491026

HA cheek filler delivered lasting midface volume restoration (plumping).

PubMed ID: 33587369

HA lip filler produced reliable, lasting increases in lip fullness (strong plumping effect).

PubMed ID: 34455631

Topical agent that increases epidermal hyaluronan significantly increased skin hydration vs placebo.

PubMed ID: 32506124

Dermal HA fillers improved perioral lines and produced volumizing/plumping effects, especially with small‑particle HA.

PubMed ID: 36126213

HA filler significantly augmented chin volume and projection with durable volumizing effects up to 48 weeks.

PubMed ID: 34282831

Under‑eye HA correction improved contour by adding volume to infraorbital area with good satisfaction.

PubMed ID: 35775872

Adding HA (Profhilo) after botulinum toxin objectively increased skin hydration at 3 months (p<0.001).

PubMed ID: 35020250

HA fillers reduced wrinkle severity and improved aesthetic volume in nasolabial folds for months.

PubMed ID: 35005871

HA lip augmentation produced robust increases in lip fullness with high responder rates and durability.

PubMed ID: 35770300

Tri‑Hyal HA fillers produced sustained facial volume restoration and measurable volume scores up to 18 months.

PubMed ID: 36038984

Topical ectoine + HA cream improved atopic dermatitis measures (implies barrier/skin hydration benefits).

PubMed ID: 35279948

HA filler restored nasolabial fold volume with durable effects up to 12 months.

PubMed ID: 35925834

Firm HA filler produced significant and durable midface volume restoration—direct evidence of plumping.

PubMed ID: 34758056

Non‑cross‑linked HA filling + mesotherapy reduced neck lines and improved patient‑perceived skin quality consistent with increased dermal hydration.

PubMed ID: 36459413

HA lip fillers increased lip volume and reduced perioral lines (clear plumping effect).

PubMed ID: 36103665

Restylane Lyft produced immediate and sustained, quantitatively large increases in nasal dorsum volume (direct filler effect).

PubMed ID: 36564573

Cross‑linked HA filler added to subcision filled atrophic scars, restoring volume and plumping depressed areas.

PubMed ID: 37577796

Injectable HA revitalizing solution improved objective skin hydration vs moisturizer in an RCT.

PubMed ID: 38009035

Randomized trial: daily oral HA (100–200 mg) substantially increased skin moisture in both younger and older adults.

PubMed ID: 37694979

HA dermal filler safely reduced NLF wrinkles via volume replacement (plumping effect).

PubMed ID: 37095274

HA filler delivered immediate nasolabial volume correction (plumping) though waning over months.

PubMed ID: 37074002

VYC‑12L intradermal HA produced large, statistically significant improvements in instrument and PRO skin hydration.

PubMed ID: 37052609

HA fillers reduced scar volume and produced late structural gains consistent with tissue plumping.

PubMed ID: 37163665

Large RCT showed objective MoistureMeterD hydration increases and durable patient‑reported hydration after VYC‑12L intradermal HA.

PubMed ID: 37066828

VYC‑15L significantly improved infraorbital hollowness—effective local volumizing/plumping.

PubMed ID: 39178357

HA was effective at nasolabial fold augmentation, providing localized volume/plumping.

PubMed ID: 38573527

Under‑eye HA filler reliably filled hollows with large, durable aesthetic improvement—strong plumping effect.

PubMed ID: 39542893

Chin HA filler produced meaningful and lasting contour/volume improvement—plumping at the jaw/chin.

PubMed ID: 38487954

Midface HA filler reliably restored cheek volume—clear volumizing/plumping effect.

PubMed ID: 38829483

Double‑blind RCT: low‑MW topical HA markedly improved objective skin capacitance vs HMW HA and vehicle—strong hydration evidence.

PubMed ID: 39004426

Nasolabial HA fillers produced durable fold correction and volume restoration—plumping effect.

PubMed ID: 38985546

VYC‑25L HA injections significantly improved jawline definition/volume—plumping/contour effect.

PubMed ID: 38874166

HA fillers produced meaningful improvement in nasolabial fold volume/appearance up to 6–9 months.

PubMed ID: 39167667

HA lip filler produced substantial and lasting lip augmentation with very high responder rates and satisfaction.

PubMed ID: 38591218

Vectorized high‑MW topical HA produced large, rapid increases in skin suppleness and reduced wrinkle area — consistent with improved hydration.

PubMed ID: 39141784

VYC‑25L HA filler produced substantial, durable jawline volumetric gains (3‑D measured).

PubMed ID: 38315229

Restylane Defyne produced marked and lasting chin augmentation with high patient satisfaction.

PubMed ID: 39808069

Injectable HA filler for temple hollowing produced large, durable volumizing increases and high responder rates.

PubMed ID: 41532837

Non‑crosslinked HA in the product yielded meaningful volume/wrinkle improvements.

PubMed ID: 40589311

HA hydrolifting (skin‑booster) as part of combined therapy produced sustained improvements in inflammatory area/texture, consistent with hydration.

PubMed ID: 40659364

RHA3 filler produced sustained, natural lip augmentation with substantial patient‑reported fullness gains.

PubMed ID: 40830240

STYLAGE filler provided durable nasolabial fold volume/depth reduction consistent with tissue plumping.

PubMed ID: 39873185

Under‑eye nanogel reduced hollowness, indicating local volume/plumping effect.

PubMed ID: 41422283

Oral sodium hyaluronate produced statistically significant and clinically meaningful increases in cheek hydration and reduced TEWL in a well‑powered RCT.

PubMed ID: 40246546

Single HA filler injection produced reliable, durable increases in chin volume and projection (direct, high‑quality evidence of local 'plumping').

PubMed ID: 40259066

Cross‑linked HA filler produced clinically meaningful and durable chin augmentation and volume increase—direct evidence of tissue volumization/plumping.

PubMed ID: 40679154

HA provided midface volumizing though less durable than PLLA—clear short‑term plumping effect.

PubMed ID: 40620129

HA dermal filler softened nasolabial folds and provided facial volumization up to 48 weeks—supports plumping effect.

PubMed ID: 40378267

Cold‑crosslinked HA fillers reduced wrinkle depth and provided volume in nasolabial folds (plumping effect).

PubMed ID: 38713883

Dermal HA filler provided durable correction of nasolabial folds and objective volume changes.

PubMed ID: 38564392

High‑G' HA injectable (HASHA) produced substantial, sustained chin augmentation and high subject satisfaction.

PubMed ID: 38775789

Topical HA lubricants reduced corneal epithelial irregularity and symptoms; suggests HA's hydrating/lubricating properties (ocular surface).

PubMed ID: 39704133

Tri‑Hyal filler produced significant volumizing and persistent aesthetic improvements (Bazin/3‑D metrics).

PubMed ID: 39402200

Cross‑linked HA gel for lip augmentation produced clear, non‑inferior aesthetic volume gains and patient satisfaction (direct plumping).

PubMed ID: 37966371

HA chin augmentation gave substantial midline volumizing improvements lasting months.

PubMed ID: 39717991

Intradermal HA combined with hEGF improved skin symptoms and appearance, consistent with improved local hydration/barrier.

PubMed ID: 23490326

Sodium hyaluronate eye drops improved ocular surface signs; demonstrates HA's hydrating effects on mucosal/epithelial surfaces.

PubMed ID: 32067777

Large randomized trial: nasal hyaluronic acid spray significantly increased perceived moisturisation compared with saline; strong evidence of mucosal hydration which translates to hydration effects of HA formulations.

PubMed ID: 12194076

Topical 0.1% sodium hyaluronate reduced burning and corneal staining in severe dry eye—supports surface hydration properties of HA.

PubMed ID: 31343447

HA dermal fillers increased volume and provided durable wrinkle correction/plumping.

PubMed ID: 18093199

HA dermal filler increased volume in nasolabial folds (plumping effect) though less durable than CaHA.

PubMed ID: 39099032

HA+CaHA forehead filling improved appearance and reduced irregularities compared with CaHA alone — clear volumizing benefit.

PubMed ID: 25732262

Randomized oral low‑MW HA supplement increased measured skin hydration vs placebo.

PubMed ID: 31221944

Increase in dermal collagen and elasticity from an oral HA‑containing supplement is consistent with a plumping effect.

PubMed ID: 12786700

HA gel augmentation produced longer‑lasting volume and wrinkle correction—direct evidence for plumping.

PubMed ID: 15622265

Perlane produced superior augmentation vs collagen consistent with plumping effect.

PubMed ID: 18086061

NASHA fillers produced durable augmentation and wrinkle correction—supporting plumping.

PubMed ID: 18086050

HA fillers preferred and longer lasting, indicating strong volumizing (plumping) effect.

PubMed ID: 19083502

Crosslinked HA fillers produced durable volumizing/wrinkle correction effects (plumping) for >9–12 months.

PubMed ID: 18176233

Juvéderm Ultra Plus maintained clinically significant correction and volume over a year.

PubMed ID: 18986859

Perlane (HA) produced the greatest upper lip volume increase and maintained it across time points.

PubMed ID: 28915283

Topical HA serum increased cutaneous HA content and stratum corneum hydration with reduced TEWL over 12 weeks.

PubMed ID: 28595250

HA fillers increased tissue volume/plumpness and reduced wrinkle severity in RCT split‑face style data.

PubMed ID: 28892233

HA microneedle patches improved hydration and elasticity more than topical essence (split‑face trial).

PubMed ID: 37265096

Dermal filler directly increased residual volume at 12 months vs comparator—strong evidence for plumping effect.

PubMed ID: 38299745

Filler study demonstrated HA provides volume but can have Tyndall complications; combined formulations improved outcomes.

PubMed ID: 40296541

HA injections improved skin fullness and collagen/elastic metrics around treated areas.

PubMed ID: 41454456

HA fillers produced larger increases in nasolabial fold dimensions and depth correction than collagen, consistent with durable volumizing (plumping).

PubMed ID: 9106924

Topical HA cream reduced radiotherapy skin reactions, consistent with preservation of skin barrier and hydration.

PubMed ID: 16083533

Faster burn re-epithelialization with HA+SSD suggests better local moisture/repair environment.

PubMed ID: 16416643

Cross‑linked HA (Restylane Perlane) gave durable nasolabial fold filling and volume restoration.

PubMed ID: 15999421

Topical oral‑mucosa HA reduced inflammation/bleeding and likely improved local hydration.

PubMed ID: 15701590

Topical HA included in a cream improved eczema area/severity and subjective outcomes consistent with improved hydration/barrier.

PubMed ID: 18547177

NASHA filler produced durable plumping/filling of nasolabial folds with high responder rates.

PubMed ID: 18833043

HA preparations improved skin turgidity and had a filling/hydrating effect, stronger at higher concentration.

PubMed ID: 19454518

Puragen persisted longer filling nasolabial folds -> sustained plumping.

PubMed ID: 19207321

HA dermal fillers are designed to restore volume; study showed effective wrinkle/fold correction (plumping).

PubMed ID: 19337944

Split-face trial showed similar cosmetic volumizing with less pain using lidocaine-formulated HA.

PubMed ID: 19207322

HA filler with lidocaine provided equivalent volumizing/plumping effect to the non-lidocaine formulation.

PubMed ID: 20969660

Dermal HA filler produced effective nasolabial fold correction using less volume—direct evidence of plumping action.

PubMed ID: 21134044

HA filler contributed to improved lip and perioral fullness when combined with botulinum toxin.

PubMed ID: 21070457

Patients reported improved look/feel of lips and lower-face after HA filler consistent with plumping.

PubMed ID: 20969659

HA filler produced volumizing effect for nasolabial folds (direct plumping).

PubMed ID: 20969657

Long‑lasting filler effect produces volume restoration and plumping of nasolabial folds.

PubMed ID: 20346777

Topical 0.18% sodium hyaluronate eye drops improved ocular surface signs, demonstrating surface moisture benefit.

PubMed ID: 22052267

Randomized topical study documented significant improvements in skin moisture with HA creams vs vehicle.

PubMed ID: 22759250

Dermal HA fillers reduced wrinkle depth and restore volume in nasolabial folds.

PubMed ID: 22515587

HA fillers gave consistent short‑term volume/contour improvement in treated areas.

PubMed ID: 22399081

Topical HA cream improved ulcer environment and reduced pain; HA is hydrophilic and supports hydration.

PubMed ID: 22759255

Small gel‑particle HA produced a large, durable increase in lip fullness vs no treatment.

PubMed ID: 22728576

High‑MW HA vaginal gel relieved dryness and atrophy symptoms—implies hydration of mucosa.

PubMed ID: 23715889

Intradermal HA increased dermis thickness and complexion radiance, which is consistent with improved skin hydration.

PubMed ID: 24093664

Large RCT showed a volumizing HA gel produced substantial midface volume correction maintained in many patients up to 2 years.

PubMed ID: 25399620

Topical multi‑MW HA dermocosmetic produced rapid increases in cheek/lip volume and reduced wrinkle metrics—consistent with increased skin hydration/plumping.

PubMed ID: 26659938

HA lip filler produced significant and durable fullness—very strong plumping evidence for perioral tissue.

PubMed ID: 25964628

Midface HA volumizing produced durable fullness and perceived younger appearance—very strong plumping evidence.

PubMed ID: 26493557

Lidocaine‑containing HA filler reduced wrinkles and provided volume—supports plumping.

PubMed ID: 25828038

Small‑particle HA lip augmentation showed functional safety and temporary texture changes—supports lip plumping.

PubMed ID: 26432128

Sodium hyaluronate+CMC drops improved tear stability and symptoms post‑cataract, indicating improved ocular surface lubrication/hydration.

PubMed ID: 26618456

HA filler (HYC‑24L) robustly increased lip fullness with high responder rates and durability.

PubMed ID: 26606435

HYC‑24L filler reduced perioral lines and increased local fullness vs comparator.

PubMed ID: 26218727

Voluma restored midface volume with prolonged correction (15–24 months) — strong evidence of plumping.

PubMed ID: 26618455

Repeat HA injections effectively restored midface volume in most patients (82–91% responders).

PubMed ID: 25651494

HA eye drops (and trehalose+HA) increased tear‑film thickness for extended periods in dry‑eye patients (hydration of ocular surface).

PubMed ID: 25521103

HA filler corrected nasolabial folds, reflecting increased soft‑tissue fullness/plumping.

PubMed ID: 26004026

Topical liposomal HA gel produced large reductions in vaginal dryness, showing mucosal hydration benefit.

PubMed ID: 27560289

Both HA fillers corrected nasolabial folds to 24 weeks; one achieved similar correction with less volume (efficiency on plumping).

PubMed ID: 26910660

Monophasic HA filler achieved slightly greater wrinkle/aesthetic improvement consistent with added volume.

PubMed ID: 26741384

Juvéderm Ultra provided comparable nasolabial fold correction (volume restoration) to Restylane.

PubMed ID: 26786710

CO2+HA side maintained better nasolabial correction (longer‑lasting plumping) than HA alone.

PubMed ID: 26924549

HA gel provided volume/structure preservation comparable to Restylane through 6–12+ months (plumping effect).

PubMed ID: 27121901

Concentrated HA filler maintained nasolabial fold volume and aesthetic improvement up to 24 months.

PubMed ID: 28145073

HA volumizing filler produced robust nasolabial fold improvement consistent with increased volume/plumping.

PubMed ID: 28913927

Monophasic HA filler maintained volumizing effect comparable to biphasic product up to 1 year.

PubMed ID: 28005623

HA fillers increased volume in nasolabial area, consistent with plumping effect.

PubMed ID: 28294535

HA filler produced meaningful nasolabial fold correction, a plumping/volumizing effect.

PubMed ID: 28157728

Large RCT: cross‑linked HA filler produced substantial and durable lip fullness through one year.

PubMed ID: 28987023

Microneedle HA patch with cream increased dermal appearance/plumping and reduced wrinkles.

PubMed ID: 28229275

Vaginal HA moisturizer improved symptoms — reflects mucosal hydration effects.

PubMed ID: 28538556

Voluma HA filler produced a mean malar volume increase of ~1.8 mL at 6 months with high responder rates → strong evidence for plumping.

PubMed ID: 28914592

Topical HA accelerated mucosal epithelization and improved color match—consistent with improved local hydration of tissues.

PubMed ID: 29059146

Randomized trial showed HA fillers reliably increase lip fullness with good durability and satisfaction.

PubMed ID: 29059139

Both HA gels increased lip fullness with durable effects through months; one required less volume.

PubMed ID: 30395961

HA‑based ocular lubricants increased tear film thickness (HTP ~40 min, HA ~20 min) and improved subjective symptoms.

PubMed ID: 29543617

Dermal HA filler produced clinically meaningful wrinkle/facial volume improvements similar to comparator product.

PubMed ID: 30325687

Single‑drop HA lubricants temporarily increased tear film thickness and improved symptoms; demonstrates hydrating capacity of topical HA formulations (ocular).

PubMed ID: 29761211

HA dermal filler improved nasolabial fold volume and lip/perioral fullness in a split‑face study.

PubMed ID: 29762642

Dermal HA filler produced consistent volumizing/aesthetic effects (plumping) with high responder rates.

PubMed ID: 31568288

Large-gel HA filler significantly restored dorsal-hand volume and appearance vs no treatment.

PubMed ID: 30607570

HA fillers reduced nasolabial wrinkle severity and increased tissue volume for up to ~9 months.

PubMed ID: 30833149

HA filler produced durable penile girth increase—demonstrates HA's volumizing capacity (extrapolated to plumping concept).

PubMed ID: 31074161

Restylane Lyft provided durable nasolabial fold correction/volume restoration.

PubMed ID: 31735613

Temporary penile augmentation with HA increased girth and satisfaction—evidence of local volumizing/plumping.

PubMed ID: 31769596

Intradermal HA skinboosting objectively increased tissue water content and reduced roughness in hands (split-hand RCT).

PubMed ID: 31135570

Injectable HA filler safely improved chin/jaw shape and sustained contour (volumizing effect).

PubMed ID: 40590113

Composite HA dressing after ablative laser significantly reduced TEWL and improved hydration metrics at day 14.

PubMed ID: 31348336

Dermal thickness increased up to 40% at 2 weeks and remained above baseline at 48 weeks after HA filler—clear volumizing/plumping effect.

PubMed ID: 31769585

HA fillers restored mid-face volume (high responder rates) demonstrating strong volumizing/plumping effect.

PubMed ID: 29506034

HA filler reliably restored and improved lip fullness with high responder rates after repeat treatment.

PubMed ID: 32217842

Resilient HA fillers achieved durable aesthetic improvements including tissue projection/volume.

PubMed ID: 31960896

Volux HA gel produced measurable facial projection increase and high patient satisfaction (direct plumping/volumizing effect).

PubMed ID: 32621657

Intradermal microinjections of HA produced a significant increase in measured facial skin hydration vs placebo (direct hydration effect).

PubMed ID: 32485024

HA microneedles increased dermal echo‑density consistent with dermal volumization/plumping.

PubMed ID: 31689127

Cross‑linked HA filler maintained nasolabial fold correction up to 48 weeks—durable volumizing/plumping.

PubMed ID: 31346621

VYC‑17.5L HA filler produced durable nasolabial fold correction and restored volume on repeat dosing.

PubMed ID: 33347003

VYC-20L HA filler produced substantial durable chin volume increases in a randomized trial.

PubMed ID: 35025757

Topical HA cream improved ulcer healing and likely improved local hydration of wound beds.

PubMed ID: 34758056

Non‑cross‑linked HA filling + mesotherapy produced marked, durable improvement in horizontal neck lines (skin tightening/texture).

PubMed ID: 36459413

HA lip fillers produced similar aesthetic improvements (favoring some products for tolerability) relevant to fine‑line correction.

PubMed ID: 36103665

HA filler increased local volume and surface contour, producing improved smoothness in treated areas.

PubMed ID: 36564573

HA filler + subcision substantially improved atrophic acne scar appearance and quantitative scar reduction, producing smoother skin surface.

PubMed ID: 37577796

HA revitalizing injections improved fine facial/neck/decollete wrinkles versus moisturizer in an RCT.

PubMed ID: 38009035

Oral HA modestly thickened epidermis and improved skin tone/hydration, factors that contribute to smoother skin.

PubMed ID: 37694979

Cross‑linked HA dermal filler produced safe, clinically notable reduction in nasolabial fold wrinkles in a large clinical evaluation.

PubMed ID: 36810835

Two HA injection techniques produced durable nasolabial fold/aesthetic improvements (wrinkle severity outcomes included).

PubMed ID: 37095274

HA filler produced immediate smoothing of nasolabial fold area though less durable than cell‑therapy comparator.

PubMed ID: 37074002

Intradermal HA produced significant patient‑reported improvements in skin smoothness and GAIS responses.

PubMed ID: 37052609

Combined high/low‑MW HA improved acne scar tissue elasticity and mechanical properties versus cross‑linked HA.

PubMed ID: 37163665

Large RCT: ACSS (skin smoothness) responder rates markedly higher with VYC‑12L HA filler vs control.

PubMed ID: 37066828

VYC‑15L improved under‑eye hollowness and aesthetic scales that translate to reduced appearance of fine lines.

PubMed ID: 39178357

Nasolabial/dermal filler trials report improved wrinkle severity and smoother contours with HA.

PubMed ID: 38573527

Periorbital HA filler markedly improved aesthetic smoothness and hollows—high effect on perceived texture.

PubMed ID: 38487954

Midface HA restoration improved volume and surface smoothness in treated patients.

PubMed ID: 39004426

Nasolabial HA fillers produced comparable and durable fold correction—smoother appearance.

PubMed ID: 38985546

Jawline HA improved aesthetic satisfaction and facial definition, contributing to overall glow.

PubMed ID: 38874166

Two HA fillers produced significant improvements in nasolabial fold severity (WSRS) and high patient satisfaction up to 9 months.

PubMed ID: 39167667

Lip augmentation increased fullness and can reduce perioral lines indirectly; primary endpoint was fullness not lines.

PubMed ID: 38591218

Topical vectorized HA rapidly reduced crow's‑feet area (immediate and 28‑day effects).

PubMed ID: 39141784

Jawline volumization improved contour and surface appearance, contributing to overall smoother look.

PubMed ID: 38315229

Chin augmentation with HA improved contour and aesthetic appearance that contributes to perceived skin smoothness.

PubMed ID: 38713883

New HA dermal filler produced durable wrinkle correction (WSRS improved ~1 grade) and objective volume changes.

PubMed ID: 39704133

Cross‑linked Tri‑Hyal filler produced marked wrinkle reduction with persistence to 18 months across facial zones.

PubMed ID: 39402200

Lip augmentation increased patient FACE‑Q satisfaction which can include perceived enhancement of appearance/glow.

PubMed ID: 37966371

Chin HA filler produced aesthetic improvement detectable by live assessment (smoother/contoured appearance).

PubMed ID: 39717991

Intradermal HA + hEGF produced dose‑dependent improvements in skin erythema/symptoms and objective improvement suggesting improved skin quality/elasticity potential.

PubMed ID: 40590113

HA dressing reduced erythema and improved barrier recovery after laser — can enhance post‑procedural skin appearance.

PubMed ID: 18822733

Accelerated healing and reduced residual cavity size indicate better tissue remodeling and smoother local outcomes after wounds.

PubMed ID: 31343447

Randomized split-face RCT showed HA fillers provided wrinkle correction comparable to existing gels.

PubMed ID: 18093199

NASHA (HA) dermal filler improved nasolabial folds (wrinkle reduction) over 12 months though less durable than CaHA — clear evidence for reducing fine lines with filler use.

PubMed ID: 25564797

HA filler improved nasolabial wrinkles but was outperformed in duration and magnitude by PCL filler — supports wrinkle reduction by HA.

PubMed ID: 39099032

Forehead HA+CaHA produced better GAIS and fewer irregularities, consistent with smoother appearance.

PubMed ID: 25732262

Small randomized oral low‑MW HA supplement improved photoaging scores and skin tonicity (elasticity) vs placebo.

PubMed ID: 31221944

12‑week randomized trial of a chicken sternal cartilage supplement (contains HA+collagen+CS) increased skin collagen and improved measured elasticity vs placebo.

PubMed ID: 12786700

Restylane (HA gel) gave longer‑lasting wrinkle correction versus collagen with clear clinical benefit on wrinkles.

PubMed ID: 15622265

Perlane (HA filler) produced significantly superior wrinkle severity improvement vs bovine collagen.

PubMed ID: 18086061

Large RCT with HA dermal filler showing robust wrinkle correction (duplicate supportive entry).

PubMed ID: 18086050

Smooth‑gel HA fillers were preferred and lasted longer than collagen for nasolabial folds—strong evidence for wrinkle correction.

PubMed ID: 19083502

Juvéderm crosslinked HA provided durable, clinically significant wrinkle correction with high maintenance at >9–12 months.

PubMed ID: 18176233

Juvéderm Ultra Plus corrected severe nasolabial folds with 81% maintaining correction ≥1 year.

PubMed ID: 18986859

Perlane (HA filler) increased lip volume and reduced wrinkle severity with sustained volume over 12 months.

PubMed ID: 19735512

Large study showed HA fillers produced sustained wrinkle improvement in darker skin types.

PubMed ID: 23340440

Cross-linked HA filler increased dermal procollagen and TIMP‑1 early after injection, biologically supporting increased elasticity.

PubMed ID: 25473210

Polynucleotide filler was non-inferior to a high‑concentration HA filler for crow's feet correction, supporting HA-class activity in wrinkle reduction.

PubMed ID: 28915283

Topical HA serum improved skin hydration and barrier function, consistent with smoother skin texture.

PubMed ID: 28595250

Injectable HA dermal fillers produced durable, clinically meaningful wrinkle severity improvements up to 6 months.

PubMed ID: 28892233

HA microneedle patches reduced crow's‑feet wrinkle roughness and improved elasticity vs topical essence.

PubMed ID: 37265096

HA filler produced clinically meaningful aesthetic improvement (GAIS) and wrinkle severity reductions—consistent with smoother skin appearance.

PubMed ID: 40296541

HA injections increased skin collagen and elasticity and reduced wrinkles in a clinical study (n=30).

PubMed ID: 41454456

HA fillers maintained greater nasolabial fold correction at 6 months vs collagen — clear anti-wrinkle effect.

PubMed ID: 41117156

Significant periorbital pigmentation and QoL improvements reported with HA‑containing injectable multi‑agent formula.

PubMed ID: 12859378

NASHA filler combined with Botox significantly extended and improved correction of deep frown lines vs filler alone → strong evidence for reducing fine/deeper lines.

PubMed ID: 16416643

Cross‑linked HA filler produced durable nasolabial fold correction vs comparator.

PubMed ID: 17492340

Triple therapy (including low‑weight HA) produced greater improvement in skin texture/firmness vs IPL alone.

PubMed ID: 18547177

NASHA filler substantially softened nasolabial folds with durable effect up to 18 months (strong wrinkle reduction evidence).

PubMed ID: 18833043

Topical/injectable HA improved skin turgidity/elasticity and reduced wrinkle depth; higher concentration gave stronger effect.

PubMed ID: 19454518

Puragen filler persisted longer in nasolabial folds than comparator—longer reduction of fine lines.

PubMed ID: 20002638

Adding lidocaine to HA filler reduced injection pain without compromising short-term aesthetic (wrinkle) outcome.

PubMed ID: 19207321

Large trial of NASHA fillers showed wrinkle-correcting effects up to 24 weeks (direct reduction in fine lines).

PubMed ID: 19337944

Lidocaine-containing HA filler study showed substantially less injection pain with maintained aesthetic results (wrinkle correction).

PubMed ID: 19207322

HA filler with lidocaine produced equivalent cosmetic wrinkle correction while reducing procedural pain.

PubMed ID: 20969660

Cross‑linked HA dermal filler produced durable wrinkle correction with less volume—direct evidence for reducing fine lines.

PubMed ID: 21134044

Combination therapy including HA filler improved perioral aesthetics more than monotherapy—reduced lines implied.

PubMed ID: 21070457

HA filler improved patient-reported lower-face appearance and satisfaction, consistent with reduced fine lines.

PubMed ID: 20969659

NASHA (HA filler) produced wrinkle correction comparable to long‑lasting filler over 12 months (direct reduction of fine lines).

PubMed ID: 20969657

Durable correction of nasolabial folds in ~80% of subjects for ≥48 weeks demonstrates strong reduction of fine lines/wrinkles.

PubMed ID: 22052267

Topical HA creams improved objective skin elasticity vs vehicle in randomized study.

PubMed ID: 22759250

HA fillers produced sustained wrinkle (nasolabial fold) severity reduction up to 12 months.

PubMed ID: 22515587

Two HA fillers yielded substantial short‑term wrinkle improvement in nearly all treated folds.

PubMed ID: 22399081

Topical HA cream improved ulcer area/pain and local skin condition, contributing to smoother surface.

PubMed ID: 22759255

Lip filler produced aesthetic improvements that smooth lip contour and nearby skin.

PubMed ID: 23715889

Intradermal HA microinjections produced objectively measured increases in skin elasticity and dermal thickness.

PubMed ID: 24093664

Volumizing HA filler produced durable midface correction and improved contour, contributing to smoother skin appearance.

PubMed ID: 23574571

Topical HA‑containing product reduced wrinkle index and perceived age vs placebo (combination product).

PubMed ID: 25399620

Topical multi‑MW HA significantly reduced periocular wrinkle depth/volume and wrinkle volume metrics within 30 days.

PubMed ID: 26659938

HA lip filler produced smoother perioral lines up to 12 months—strong evidence for reducing fine lines.

PubMed ID: 25964628

Midface volumizing produced perceived younger appearance and increased satisfaction—strong cosmetic impact including 'glow'.

PubMed ID: 26493557

HA filler reduced nasolabial wrinkles comparably—smoother skin outcome.

PubMed ID: 25828038

Lip filler safety/functional study shows transient texture/firmness changes—relevant to smoother perioral skin.

PubMed ID: 26618456

Lip filler produced durable fullness and aesthetic smoothing.

PubMed ID: 26606435

HYC‑24L HA filler reduced perioral lines more than comparator with durable effects to 6 months.

PubMed ID: 39808069

Temple HA filler produced durable volumizing and aesthetic improvements that can translate to perceived improved elasticity.

PubMed ID: 26218727

Voluma restored midface volume with high responder rates and durable correction, reducing age‑related volume lines.

PubMed ID: 26618455

Repeat midface HA injections yielded consistent aesthetic improvements and smoother contours.

PubMed ID: 25521103

Split‑face RCT: new HA filler produced substantial WSRS (wrinkle) improvement vs established filler at 24 weeks.

PubMed ID: 27560289

Two HA fillers corrected nasolabial folds effectively for 24 weeks, reducing wrinkle appearance.

PubMed ID: 26910660

Monophasic HA filler produced slightly greater wrinkle severity improvement and aesthetic scores vs comparator.

PubMed ID: 26741384

Juvéderm Ultra was noninferior to Restylane in nasolabial fold correction (wrinkle improvement).

PubMed ID: 26786710

Combination therapy (CO2+HA) produced longer‑lasting aesthetic smoothing vs HA alone.

PubMed ID: 26924549

Randomized split‑face trial: HA gel non‑inferior to Restylane for nasolabial fold/wrinkle severity up to 1 year.

PubMed ID: 27121901

Concentrated HA filler produced long‑lasting nasolabial fold improvement up to 24 months.

PubMed ID: 28145073

Monophasic HA filler produced significant and durable improvement in nasolabial wrinkle scores.

PubMed ID: 28913927

Monophasic HA filler noninferior for nasolabial fold correction up to 1 year.

PubMed ID: 28005623

Randomized split‑face trial: HA fillers effectively reduced nasolabial wrinkle severity up to 12 months.

PubMed ID: 28294535

HA filler produced similar nasolabial fold correction to fat for most of the first year.

PubMed ID: 28157728

Cross‑linked HA lip filler improved perioral lines with durable effects through one year.

PubMed ID: 28987023

Microneedle HA patch improved wrinkle scores and global facial appearance (smoother skin).

PubMed ID: 28538556

Voluma HA filler produced measurable midface volumization and strong aesthetic responder rates → likely improves perceived elasticity/tone.

PubMed ID: 29160000

Small series showed autologous filler improved neck wrinkles longer than small HA control, though limited data.

PubMed ID: 29701621

HA filler significantly decreased fold severity and improved appearance measures → smoother surface contours.

PubMed ID: 29059139

Large split‑face trial: HA gels produced similar nasolabial fold severity improvement through 24 weeks.

PubMed ID: 29543617

Well‑powered intraindividual RCT showed HA dermal filler produced wrinkle improvements comparable to Restylane up to 48 weeks.

PubMed ID: 29761211

HA dermal fillers produced durable nasolabial fold/wrinkle improvements in a split‑face RCT; lidocaine improved comfort without reducing efficacy.

PubMed ID: 29762642

HA dermal filler produced large, clinically meaningful aesthetic improvements including wrinkle reduction.

PubMed ID: 31568288

Dorsal-hand HA filler restored volume and smoothed skin surface, per objective/subjective measures.

PubMed ID: 30607570

Two HA fillers similarly reduced nasolabial wrinkle severity with ~9 months durability.

PubMed ID: 31074161

Restylane Lyft produced sustained nasolabial fold correction and aesthetic improvement at 6 months (WSRS/GAIS responders).

PubMed ID: 31769596

Skinboosting HA reduced hand skin roughness (Rz) and increased hydration—objective smoothing effect.

PubMed ID: 40378267

HA fillers produced meaningful wrinkle reduction and global aesthetic improvements (smoother appearance).

PubMed ID: 40620129

HA dermal filler softened nasolabial folds up to 48 weeks—direct wrinkle correction evidence.

PubMed ID: 40679154

HA provided midface volume correction though less durable than PLLA; still supports temporary line/volume improvement.

PubMed ID: 40246546

HA filler increased chin volume and improved aesthetic outcomes (localized smoothing/contour improvement after injection).

PubMed ID: 41422283

Oral sodium hyaluronate produced significant reductions in periorbital wrinkle depth versus placebo in a well‑powered RCT (direct evidence for reducing fine lines).

PubMed ID: 39873185

HA nanogel under‑eye produced substantial reductions in skin roughness and fine lines in a small RCT.

PubMed ID: 40830240

STYLAGE HA filler produced durable nasolabial fold (wrinkle) improvement up to 12 months.

PubMed ID: 40707029

Curea HA filler reduced nasolabial fold severity equivalently to established HA product through 24 weeks.

PubMed ID: 40659364

HA lip augmentation produced marked FACE‑Q satisfaction and appearance improvements (glow/attractiveness).

PubMed ID: 40589311

Triple therapy including HA hydrolifting produced larger and sustained improvements in skin inflammatory area and texture vs controls.

PubMed ID: 41532837

Product containing non‑crosslinked HA improved WSRS for nasolabial folds comparably to PLLA.

PubMed ID: 31348336

Injectable HA fillers thickened dermis and reduced nasolabial wrinkle severity with durable imaging-confirmed effects.

PubMed ID: 31195857

BM-PHA filler non-inferior to Restylane Perlane for nasolabial folds (WSRS improvements).

PubMed ID: 31621189

Intradermal HA for fine lines led to high patient satisfaction with skin appearance (smoother perceived skin).

PubMed ID: 29506034

Repeat HA filler treatment significantly improved perioral line severity with high responder rates in a multicenter trial.

PubMed ID: 32217842

Resilient HA fillers produced significant, long‑lasting improvement in nasolabial folds (wrinkle severity) in a multicenter RCT.

PubMed ID: 32485024

Dissolving HA microneedles reduced periorbital skin roughness by ~65% and waviness by ~67% (large objective smoothing effect).

PubMed ID: 31689127

Cross‑linked HA filler corrected nasolabial folds effectively and durably up to 48 weeks (direct fine‑line reduction).

PubMed ID: 31346621

VYC‑17.5L HA filler produced substantial, durable nasolabial fold improvement up to 18 months (direct wrinkle correction).

PubMed ID: 34933842

Oral hyaluronan RCT reduced wrinkle depth/volume substantially over 28 days.

PubMed ID: 34743118

HA cheek filler produced volume correction and cosmetic improvement contributing to smoother appearance.

PubMed ID: 33638926

Topical HA with depigmenting agent improved melasma severity and homogeneity, enhancing surface appearance.

PubMed ID: 33851255

HA filler produced significant wrinkle (WSRS) improvement in randomized double‑blind trial.

PubMed ID: 34351386

HA filler produced large, durable cosmetic improvement of under‑eye hollows and surface smoothness.

PubMed ID: 33534905

Randomized trial: PRP+HA produced greater objective skin elasticity than either treatment alone.

PubMed ID: 33476068

Sustained midface volumization supports ongoing improved facial aesthetics and glow.

PubMed ID: 34491026

Durable cheek volume restoration and high satisfaction support improved facial radiance.

PubMed ID: 33587369

HA lip filler produced lasting increases in fullness and wrinkle improvement with high satisfaction.

PubMed ID: 34927342

Adding cross‑linked HA to subcision produced markedly higher objective improvement of atrophic acne scars (smoother contour).

PubMed ID: 34455631

Topical epidermal hyaluronan booster increased skin elasticity vs placebo in a randomized half‑face trial.

PubMed ID: 32506124

Two HA fillers reduced perioral rhytids; small‑particle HA produced greater long‑lasting reduction in fine lines.

PubMed ID: 34352146

Low‑crosslinked HA combined with MFU‑V reduced pore volume and increased patient satisfaction (improved skin texture).

PubMed ID: 36126213

HA filler improved facial contours and patient‑reported satisfaction that can be perceived as improved glow.

PubMed ID: 34608092

Resilient HA filler produced marked and lasting improvement in perioral dynamic wrinkles vs no‑treatment (responder rates high through 52 weeks).

PubMed ID: 35020250

HA fillers reduced nasolabial fold severity and improved aesthetic scores for months.

PubMed ID: 35005871

HA gel for lips increased fullness and produced high patient‑reported aesthetic improvement that can reduce appearance of perioral lines.

PubMed ID: 35770300

Tri‑Hyal HA fillers gave sustained volume/dermal density increases yielding smoother contours.

PubMed ID: 35279948

Flexible HA filler was non‑inferior to standard HA for nasolabial fold correction with durable aesthetic improvement.

PubMed ID: 35925834

Firm HA filler improved midface volume and appearance through 12 months—consistent with improved skin support/elasticity.

PubMed ID: 41248880

IA HA provided sustained medium‑term benefit similar to steroid, consistent with a cushioning/viscosupplement role in the joint.

PubMed ID: 27353769

HA formulation provided symptomatic benefit similar to high‑MW HA—consistent with viscoelastic joint effects.

PubMed ID: 28549430

IA HA lowered a cartilage-degradation biomarker, suggesting biological effect on joint cartilage/cushioning.

PubMed ID: 33723790

Single IA HA+sorbitol provided clinically meaningful and sustained pain/function relief in knee OA, consistent with restored lubrication/cushioning.

PubMed ID: 22205098

Post‑microfracture IA hyaluronan improved functional outcomes, consistent with improved joint biomechanics/cushioning.

PubMed ID: 25825393

Adjunct IA HA improved pain/function after talar microfracture vs saline, consistent with better intra‑articular environment.

PubMed ID: 25763853

HA after microfracture yielded thicker reparative cartilage on MRI, implying improved mechanical cushioning.

PubMed ID: 20151251

IA sodium hyaluronate increased synovial HA (directly improving lubricant/viscoelastic properties) and decreased MMP‑9 — mechanistic and clinical support for improved cushioning.

PubMed ID: 26577936

Clinical benefit after IA HA+CS injections (pain/function reduction) is consistent with restored synovial viscoelasticity/cushioning properties.

PubMed ID: 32598683

Injectable hyaluronate used clinically to augment joint lubrication — study showed symptomatic walking pain reductions consistent with improved cushioning.

PubMed ID: 26905565

Clinical knee IA HA improved pain/function consistent with improved intra‑articular lubrication/cushioning.

PubMed ID: 25388643

IA HA improved pain and function in joint disease, consistent with restored viscoelastic/cushioning effects.

PubMed ID: 38223641

Knee injection outcomes (pain/function and biomarker improvements) are consistent with enhanced joint environment/cushioning.

PubMed ID: 15906109

Symptomatic and biochemical improvements after IA HA suggest improved synovial environment and potential cushioning benefits.

PubMed ID: 8403580

Intra‑articular HA produced clinically meaningful pain/function improvements consistent with improved joint viscoelasticity/cushioning.

PubMed ID: 8886085

Weekly knee HA improved pain/function and reduced need for further local treatments—consistent with mechanical/viscoelastic benefit.

PubMed ID: 15449510

Functional improvements vs low‑dose control consistent with restored intra‑articular function.

PubMed ID: 8689457

Durable benefit of hylan G‑F 20 suggests persistent intra‑articular mechanical improvement.

PubMed ID: 9219678

Hyalgan injections were associated with less arthroscopic chondropathy progression, supporting structural cushioning effect.

PubMed ID: 9663358

Hylan G‑F 20 clinical benefits are consistent with improved intra‑articular lubrication/cushioning properties.

PubMed ID: 9818665

Sustained functional and pain improvements after HA viscosupplementation are compatible with enhanced joint lubrication/cushioning.

PubMed ID: 10461471

Observed improvements in walking pain and function after weekly HA injections align with improved joint mechanical environment.

PubMed ID: 10509850

Randomized comparison: higher‑molecular‑weight, more elastoviscous hylan G‑F 20 demonstrated superior pain relief vs lower‑MW HA, supporting improved viscous cushioning.

PubMed ID: 11302304

Symptomatic improvements after HA injections imply improved viscoelastic joint function, consistent with cushioning effects.

PubMed ID: 11447776

Intra‑articular HA injections normalized abnormal synovial fluid viscosity in advanced knee OA—direct mechanistic evidence for improved joint cushioning.

PubMed ID: 12127830

Clinical improvements when adding hylan G‑F 20 to standard care support symptomatic effect via improved joint mechanics/cushioning.

PubMed ID: 12740675

Clinical pain/function improvements after IA HA are consistent with improved joint lubrication/cushioning.

PubMed ID: 12951310

Hylan viscosupplementation (Hylan GF-20) is intended to restore viscoelastic properties and produced better clinical outcomes.

PubMed ID: 12918884

Slowing of JSN in milder OA subgroup implies a structural benefit consistent with preserved cushioning.

PubMed ID: 15487709

IA HA reduced inflammatory adhesion molecules and improved clinical parameters suggesting a rheologic/biologic effect in the joint.

PubMed ID: 15599642

MRI evidence of improved cartilage quality after intra-articular HA suggests improved joint cushioning.

PubMed ID: 16242361

High‑MW bio‑HA provided pain relief and fewer effusions, consistent with improved joint lubrication/cushioning.

PubMed ID: 16206349

Injected HMW HA suggested symptom improvement and functional gains consistent with enhanced viscoelastic joint properties.

PubMed ID: 15694572

Hylan G‑F 20 symptomatic improvements imply restored viscoelastic joint support.

PubMed ID: 15895892

Both high- and low-MW HA improved pain/function, consistent with improved intra-articular viscoelasticity/cushioning.

PubMed ID: 17187274

Synovial substitute HA instillation after arthroscopy gave sustained symptom/function benefits consistent with improved intra-articular cushioning.

PubMed ID: 17968921

Large RCT across viscosupplement HA formulations demonstrates class effect of viscosupplementation—supports HA functioning as joint cushioning/viscosupplement.

PubMed ID: 17257536

IA sodium hyaluronate improved pain/function in stiff toe joint, consistent with restored lubrication/cushioning.

PubMed ID: 18204873

Clinical functional improvements with dual-MW HA are consistent with better intra-articular viscoelastic support.

PubMed ID: 18430574

High‑MW cross‑linked HA (Hylan G‑F20) gave earlier/longer pain relief consistent with better viscosupplementation/cushioning.

PubMed ID: 18451387

Shoulder sodium hyaluronate showed sustained pain relief in OA subgroup, compatible with a viscosupplement effect.

PubMed ID: 18365224

Multiple dosing regimens of hylan G‑F20 produced clinically meaningful pain reductions consistent with cushioning effects.

PubMed ID: 19539353

IA sodium hyaluronate improved pain/function in knee OA; mechanism includes improved viscoelasticity/lubrication (cushioning).

PubMed ID: 20003205

Ultrasound-guided IA Hyalubrix improved hip function/pain, consistent with improved intra-articular mechanics/cushioning.

PubMed ID: 19406908

HA produced symptomatic and functional benefits similar to clodronate in knee OA; implies some mechanical/symptomatic cushioning effect.

PubMed ID: 19963403

Sustained improvements in shoulder function and pain compatible with restored joint lubrication/biomechanics.

PubMed ID: 20030435

Clinical durable symptom relief after cross‑linked IA HA is consistent with improved intra‑articular viscoelastic cushioning.

PubMed ID: 20111953

Intra‑articular hyaluronan reduced knee OA pain consistent with a cushioning/viscosupplement effect.

PubMed ID: 19304567

Hylan G‑F 20 acts as viscosupplementation; clinical pain relief supports improved intra‑articular cushioning.

PubMed ID: 20467406

Reported pain/function benefits vs saline are consistent with improved joint mechanics/ cushioning.

PubMed ID: 21875678

Large trial demonstrating clinically meaningful symptom reduction consistent with restored viscoelastic joint properties.

PubMed ID: 21722501

Intra‑articular HA aims to restore synovial viscosity and cushioning; clinical improvements in pain/function support this mechanism.

PubMed ID: 21852252

Repeated IA HA produced durable symptomatic improvement consistent with improved intra-articular lubrication/cushioning.

PubMed ID: 21978211

Sodium hyaluronate reduced pain and improved function vs saline, consistent with biomechanical cushioning effects.

PubMed ID: 21820521

Repeat IA HA maintained symptom reductions that may reflect ongoing cushioning effect.

PubMed ID: 22509642

Weekly IA HA improved pain/function vs steroid, consistent with improved intra‑articular biomechanics.

PubMed ID: 22294639

Viscosupplementation with low‑MW HA produced pain/function benefits consistent with improved joint lubrication/cushioning.

PubMed ID: 22342928

Cross‑linked HA injection improved pain/function vs saline; effect consistent with mechanical cushioning.

PubMed ID: 22476807

HA produced longer‑lasting symptomatic benefit than meloxicam, consistent with mechanical/viscoelastic actions.

PubMed ID: 23451445

Intra‑articular viscous HA injections reduced pain and improved function, consistent with lubrication/cushioning effects.

PubMed ID: 22366365

Subacromial HA injections reduced shoulder pain, suggesting improved local cushioning/lubrication.

PubMed ID: 24185114

Sustained symptomatic improvement after intra‑articular NASHA is consistent with improved intra‑articular shock absorption/lubrication.

PubMed ID: 23380230

HA used after cartilage drilling supported repair on biopsy/MRI, which may improve joint surface cushioning.

PubMed ID: 23326188

Viscosupplementation with cross‑linked HA reduced knee pain/inflammation—mechanism consistent with improved lubrication/cushioning.

PubMed ID: 23417236

HA injections provided knee pain relief comparable to steroid, implying functional joint cushioning/lubrication effects.

PubMed ID: 24162762

IA HA increased MRI cartilage volume vs control after corrective surgery, suggesting structural support to joint surfaces.

PubMed ID: 24089302

Wrist intra‑articular hyaluronan improved Mayo wrist score, consistent with intra‑articular functional support (mechanistic inference).

PubMed ID: 24443804

IA HA is a viscosupplement intended to restore synovial viscoelasticity; RCT showed symptomatic parity with NSAID, consistent with cushioning/viscosupplement effect.

PubMed ID: 25619045

Improved pain and function in knee OA after IA sodium hyaluronate supports enhanced joint lubrication/cushioning.

PubMed ID: 25579006

HA injection in TMJ improved remodeling and function—supports improved intra‑articular cushioning/lubrication.

PubMed ID: 26233594

HA improved symptoms in early knee OA vs saline—consistent with lubrication/cushioning mechanism.

PubMed ID: 25889322

IA HA viscosupplementation reduced pain and improved function consistent with improved intra‑articular lubrication/cushioning.

PubMed ID: 26555862

Large IA HA injections produced large reductions in movement pain, supporting mechanical/viscoelastic benefits.

PubMed ID: 25887932

Single‑injection HA formulations reduced pain/stiffness/function, consistent with cushioning effects.

PubMed ID: 25952818

Standard HA viscosupplementation produced outcomes comparable to PRP, indicating symptomatic mechanical benefit.

PubMed ID: 26685691

HA improved short‑term pain (with rehab) suggesting immediate mechanical/viscoelastic benefits.

PubMed ID: 25631505

HA reduced inflammatory cytokine IL‑1β in synovial fluid, supporting improved joint milieu alongside mechanical effects.

PubMed ID: 26551066

Intra‑articular sodium hyaluronate had short‑term analgesic/functional benefits after arthroscopy consistent with improved intra‑articular lubrication/cushioning.

PubMed ID: 25704621

Multi‑session HA lavage/viscosupplementation in TMJ produced superior pain outcomes, reflecting improved joint lubrication/cushioning.

PubMed ID: 28146403

HA provided pain relief in knee OA though PRP had better secondary functional/pain outcomes, indicating modest cushioning effect.

PubMed ID: 27252432

HA injection produced similar 6‑month outcomes to steroid, supporting HA's role as a viscosupplement (cushioning) therapy.

PubMed ID: 27244700

HYADD 4 HA injections produced superior symptom control consistent with improved intra‑articular function (cushioning inference).

PubMed ID: 27250845

Cross‑linked Gel‑200 is designed to restore intra‑articular viscoelasticity and produced symptomatic benefit.

PubMed ID: 28058962

HA reduced synovial vascularity and pain in RA foot/ankle, consistent with improved intra‑articular environment.

PubMed ID: 28291178

Cross‑linked hyaluronan reduced pain and improved function consistent with improved joint lubrication/cushioning.

PubMed ID: 28946838

Single larger HA injection provided efficacy comparable to multi‑injection dosing for joint symptom control.

PubMed ID: 29202568

Hybrid HA gave superior symptomatic results vs high‑MW HA, implying better functional cushioning.

PubMed ID: 29164399

HA hip injection improved pain/function—mechanism likely includes viscoelastic cushioning.

PubMed ID: 28535076

HA+steroid provided faster/larger relief in knee OA, consistent with symptomatic cushioning effects.

PubMed ID: 28549436

Intra‑articular HA reduced weight‑bearing pain and improved function, consistent with improved joint lubrication/cushioning.

PubMed ID: 28856435

Crosslinked HA (hylan GF20) improved knee function short‑term, consistent with improved intra‑articular cushioning.

PubMed ID: 28128473

High responder proportion to VS suggests biomechanical/viscoelastic benefit for many patients.

PubMed ID: 30545242

HA treatment produced durable symptomatic improvements consistent with cushioning effects, though PRP had some advantages.

PubMed ID: 30159738

Single IA HA injection produced clinically meaningful pain and function improvements consistent with restored joint lubrication/viscoelastic cushioning.

PubMed ID: 29388085

Intra‑articular HA improved OA symptoms though inferior to PRP combination; still supports viscosupplement role.

PubMed ID: 29644875

Single injection Gel‑200 (viscosupplement) produced clinically meaningful symptom reductions consistent with restored joint viscous properties.

PubMed ID: 29983409

Injections of hyaluronan for knee OA improved pain/function; mechanism consistent with improved intra‑articular viscoelasticity.

PubMed ID: 31064359

HMW IA HA produced modest pain/function improvements and higher responder rates consistent with improved joint environment.

PubMed ID: 31821355

IA HA viscosupplementation provides biomechanical/lubricant effects; RCT demonstrated clinical benefit consistent with improved cushioning.

PubMed ID: 31778431

Symptom improvement after knee HA suggests improved lubricating/cushioning properties.

PubMed ID: 31421686

Intra‑articular HA improved pain/function in knee OA, consistent with improved synovial cushioning/viscosupplementation.

PubMed ID: 31902736

HA provided hip pain and function improvements consistent with a cushioning/viscosupplement effect.

PubMed ID: 32898379

Single HA injection produced moderate symptom improvements in knee OA that may reflect some cushioning effect.

PubMed ID: 33091549

Combined PRP+HA decreased synovial inflammatory markers and improved function—HA likely contributes to viscosupplementation/cushioning.},{

PubMed ID: 32799851

Single HMW HA injection produced pain/function benefits similar to triple low‑MW HA, consistent with improved intra‑articular viscoelastic cushioning.

PubMed ID: 32233245

IA sodium hyaluronate improved symptoms and function over months, consistent with enhanced joint lubrication/cushioning.

PubMed ID: 33536010

IA-HA aims to restore viscoelastic joint properties and produced symptom improvement in knee OA RCT.

PubMed ID: 32514702

Route that distributed HA more fully over cartilage is mechanistically consistent with improved joint lubrication/cushioning and better outcomes.

PubMed ID: 34736768

Cross‑linked HA demonstrated clinically relevant pain/function reductions consistent with improved intra‑articular viscoelastic support.

PubMed ID: 33006602

Diclofenac–HA conjugate (intra‑articular) reduced pain versus placebo, consistent with mechanical and biochemical joint effects.

PubMed ID: 33420185

HA combined with PRP improved pain/function, which may reflect both biological and mechanical improvements in joint environment.

PubMed ID: 34162365

Crosslinked HA gave superior durable symptomatic benefit consistent with improved intra‑articular viscosupplementation/cushioning.

PubMed ID: 36013495

Single crosslinked intra‑articular HA provided clinically meaningful pain/function improvements, consistent with improved joint lubrication/cushioning.

PubMed ID: 35443676

Diclofenac‑conjugated HA provided pain/function improvement in hip OA consistent with improved intra‑articular cushioning/anti‑inflammatory action.

PubMed ID: 36329428

PRP+HA produced large symptomatic improvements for knee OA, but HA contribution to cushioning cannot be isolated.

PubMed ID: 36800668

HA increased femoral cartilage thickness in knee OA, which may reflect improved joint cushioning/protection.

PubMed ID: 37296122

High‑MW IA HA is intended to improve viscoelastic joint lubrication/cushioning and produced clinical benefit in OA.

PubMed ID: 36255262

Viscosupplementation with HA aims to restore synovial viscosity/lubrication and trials showed symptomatic benefit consistent with improved cushioning.

PubMed ID: 39367905

Intra‑articular HA acts as a lubricant/viscoelastic supplement and reduced OA symptoms in trials—functional cushioning support.

PubMed ID: 38160332

HMW‑HA injections produced symptom and function improvements consistent with restored intra‑articular viscosity.

PubMed ID: 38359676

Viscosupplementation with HA led to biomechanical changes consistent with improved joint lubrication/cushioning vs saline.

PubMed ID: 39098893

Intra‑articular HA for TMJ likely provides some lubricating/viscoelastic benefit accounting for symptom improvement.

PubMed ID: 39983793

Intra‑articular HA after ACL provided symptomatic relief consistent with improved lubrication/cushioning in the short term.

PubMed ID: 40858216

IA HA produced symptomatic and functional improvement in patellofemoral OA consistent with improved intra‑articular lubrication/cushioning.

PubMed ID: 40660843

IA HA produced superior medium‑term symptom/function gains in knee OA vs ozone, consistent with improved intra‑articular lubrication/cushioning.

PubMed ID: 26910660

Monophasic HA filler achieved greater wrinkle and aesthetic improvement vs comparator, supporting an anti‑aging effect.

PubMed ID: 26741384

Juvéderm Ultra safely corrected nasolabial folds comparable to Restylane, improving facial aging signs.

PubMed ID: 26786710

Combination CO2+HA therapy prolonged nasolabial fold correction compared with HA alone, supporting longer anti‑aging benefit.

PubMed ID: 26924549

HA filler produced durable wrinkle reduction and aesthetic improvement comparable to Restylane, supporting youthful appearance.

PubMed ID: 27121901

Concentrated HA filler delivered long‑lasting nasolabial fold improvement up to 24 months (supports healthy‑looking aging).

PubMed ID: 28145073

HA filler improved wrinkle severity and produced durable cosmetic benefit consistent with healthy‑looking aging.

PubMed ID: 28913927

Filler provided sustained nasolabial fold correction up to 1 year—contributes to perceived healthy aging.

PubMed ID: 28005623

HA fillers reduced wrinkle severity with durable aesthetic benefit, contributing to healthy‑looking aging.

PubMed ID: 28157728

Lip fullness and perioral line improvement sustained through one year supports youthful appearance.

PubMed ID: 28987023

Microneedle HA patch (with cream) improved wrinkles and global facial scores (anti‑aging effect).

PubMed ID: 28538556

Voluma midface volumization produced durable aesthetic improvement and high satisfaction → strong support for healthy-looking facial aging.

PubMed ID: 29701621

HA filler reduced nasolabial folds and improved FACE‑Q scores, indicating improved perceived aging outcomes.

PubMed ID: 29059146

HA fillers reliably increased lip fullness with lasting aesthetic benefit, supporting a more youthful appearance.

PubMed ID: 29543617

Dermal HA filler produced durable wrinkle improvements comparable to an established product up to 48 weeks.

PubMed ID: 29762642

HA dermal filler produced high rates of aesthetic improvement and perceived younger appearance.

PubMed ID: 31568288

HA hand filler restored volume and improved appearance consistent with healthier-looking aging.

PubMed ID: 30607570

Two HA fillers reduced wrinkle severity and improved aesthetics for ~9 months, supporting youthful appearance.

PubMed ID: 31348336

Durable increases in dermal thickness and wrinkle reduction from HA fillers support healthier-looking aging of treated areas.

PubMed ID: 31769585

Mid-face volume restoration with HA fillers yields aesthetic outcomes associated with rejuvenation.

PubMed ID: 31621189

Intradermal HA for fine lines produced sustained patient satisfaction and return-to-activity, consistent with perceived youthful appearance.

PubMed ID: 29506034

HA filler treatments produced meaningful aesthetic improvements and high patient satisfaction consistent with healthier-looking aging.

PubMed ID: 32506124

HA fillers reduced perioral fine lines and sustained aesthetic improvements out to 6 months, supporting youthful appearance.

PubMed ID: 36126213

HA filler safely and effectively augmented chin, improving shape and patient satisfaction with sustained volume.

PubMed ID: 37074002

Intradermal HA improved multiple validated appearance endpoints, supporting healthier‑looking aging.

PubMed ID: 34608092

HA filler produced durable perioral wrinkle improvement and maintained patient‑reported aesthetics up to 52 weeks, consistent with healthy aging appearance.

PubMed ID: 35770300

Tri‑Hyal fillers restored volume and increased skin density with durable effects up to 18 months, supporting youthful appearance.

PubMed ID: 35279948

HA filler produced durable nasolabial fold correction and sustained aesthetic improvement—supports healthy‑looking aging.

PubMed ID: 35925834

Midface volumization with HA filler improved facial contours and patient satisfaction up to 12 months—consistent with rejuvenation.

PubMed ID: 34758056

Non‑cross‑linked HA neck filling produced long‑lasting improvements in neck lines and appearance vs botulinum toxin.

PubMed ID: 37095274

HA filler gave immediate nasolabial improvement contributing to a more youthful appearance, though less durable than cell therapy.

PubMed ID: 32217842

RHA fillers delivered durable aesthetic improvement noninferior to established products, supporting anti‑aging appearance goals.

PubMed ID: 32485024

HA microneedles produced large objective improvements in periorbital texture and dermal density consistent with healthier, younger‑looking skin.

PubMed ID: 31689127

Cross‑linked HA filler produced durable wrinkle correction and sustained aesthetic improvement up to 48 weeks (direct appearance/aging benefit).

PubMed ID: 31346621

VYC‑17.5L HA filler improved nasolabial folds and patient satisfaction through 18 months—supports youthful appearance.

PubMed ID: 34933842

Oral HA improved multiple objective skin-aging parameters (hydration, wrinkle depth, firmness) in RCT.

PubMed ID: 34743118

HA midface filler produced cosmetic volume restoration contributing to youthful appearance.

PubMed ID: 33851255

Monophasic HA filler corrected folds and improved satisfaction—consistent with youthful appearance improvement.

PubMed ID: 34351386

Under‑eye filler produced large durable aesthetic improvements consistent with a more youthful periorbital appearance.

PubMed ID: 37163665

VYC‑12L intradermal HA produced durable improvements in smoothness, fine lines, and hydration—consistent with healthier aging appearance.

PubMed ID: 37066828

HA filler significantly improved infraorbital hollowness with sustained patient satisfaction—aesthetic anti‑aging benefit.

PubMed ID: 39178357

HA was effective in nasolabial augmentation though comparators varied—contributes to rejuvenated look.

PubMed ID: 38573527

Under‑eye HA filler produced large, durable aesthetic improvements and high satisfaction—strong aging‑appearance benefit.

PubMed ID: 39542893

Chin filler provided meaningful long‑term shape improvement and high satisfaction—contributes to youthful facial contours.

PubMed ID: 38487954

Midface HA filler restored cheek volume and produced sustained aesthetic improvement—clear anti‑aging visual impact.

PubMed ID: 39004426

Commercial HA fillers gave durable nasolabial fold correction—improves perceived facial age lines.

PubMed ID: 38985546

VYC‑25L jawline HA improved definition and patient‑reported outcomes up to 12 months—enhances perceived aging.

PubMed ID: 38874166

HA fillers reduced nasolabial fold severity and increased patient satisfaction, consistent with healthier, younger look.

PubMed ID: 39141784

VYC‑25L jawline filler produced substantial, durable facial restoration and large FACE‑Q satisfaction improvements.

PubMed ID: 38315229

Restylane Defyne produced marked long‑lasting chin augmentation and high aesthetic/responder rates.

PubMed ID: 38713883

New HA filler achieved durable wrinkle correction and objective volume improvements — supports rejuvenation.

PubMed ID: 38564392

High‑G' HA injectable produced sustained chin augmentation and high satisfaction contributing to healthier, younger appearance.

PubMed ID: 39704133

Tri‑Hyal filler produced durable aesthetic improvements (wrinkle scores) with long persistence — supports youthful appearance.

PubMed ID: 37966371

Chin augmentation improved aesthetic metrics that contribute to a more youthful facial profile.

PubMed ID: 39808069

Temple HA filler produced durable volumizing and high patient satisfaction, improving perceived aging signs.

PubMed ID: 40378267

Cold‑crosslinked HA fillers reduced wrinkle severity and improved patient satisfaction — supports youthful appearance.

PubMed ID: 40620129

HA filler softened nasolabial folds up to 48 weeks—contributes to age‑appearance improvement.

PubMed ID: 40679154

HA provided midface volume correction (shorter durability than PLLA) but still supports temporary rejuvenation.

PubMed ID: 40259066

Cross‑linked HA filler produced robust, durable chin augmentation and large aesthetic improvements—direct aging‑appearance benefit.

PubMed ID: 40246546

HA filler reliably increased chin projection, volume and patient satisfaction for up to a year—strong direct aesthetic evidence for supporting a more youthful appearance.

PubMed ID: 41422283

Oral HA improved hydration, barrier function and reduced wrinkle depth (RCT evidence supporting healthier-looking aging via non‑invasive supplementation).

PubMed ID: 39873185

Topical HA nanogel markedly improved under‑eye hollowness and fine lines that contribute to aged appearance.

PubMed ID: 40830240

STYLAGE filler provided sustained nasolabial fold improvement and high satisfaction, reflecting aesthetic anti‑aging benefit.

PubMed ID: 40659364

Lip augmentation with HA produced sustained improvements in fullness and satisfaction that contribute to youthful appearance.

PubMed ID: 40589311

HA hydrolift as part of combined therapy improved and sustained aesthetic/inflammatory outcomes—supports healthier appearance with aging.

PubMed ID: 26606435

HYC‑24L filler reduced perioral lines more than comparator with durable improvements, consistent with anti‑aging effects.

PubMed ID: 26618456

HA lip filler produced durable fullness and aesthetic improvement up to 12 months for many subjects.

PubMed ID: 26493557

Lidocaine‑containing HA filler reduced nasolabial wrinkles—supports improved aging appearance.

PubMed ID: 25964628

Midface HA volumizing produced durable improvements in appearance and perceived age reduction—very strong evidence for healthier-looking aging.

PubMed ID: 26659938

HA lip filler improved fullness and perioral lines for up to 12 months—strong support for healthier-looking aging in perioral region.

PubMed ID: 25399620

Topical HA improved facial contour, volumes and reduced wrinkle metrics—outcomes aligning with healthier‑looking aging.

PubMed ID: 23574571

Topical product with HA + retinol reduced wrinkle measures and perceived age vs placebo (combination therapy).

PubMed ID: 24093664

Volumizing HA filler produced durable midface correction and aesthetic improvement supporting a more youthful look.

PubMed ID: 23715889

Intradermal HA improved elasticity, dermis thickness and radiance, changes consistent with healthier-looking aging skin.

PubMed ID: 23545926

Objective dermal changes (DEJ height increase) after filler use align with healthier skin architecture over time.

PubMed ID: 22759255

Lip HA produced marked fullness and aesthetic improvement consistent with rejuvenation goals.

PubMed ID: 22515587

HA fillers yielded clear cosmetic wrinkle reduction in treated nasolabial folds.

PubMed ID: 22759250

Dermal HA fillers produced durable wrinkle improvements and aesthetic benefit.

PubMed ID: 22052267

Topical HA improved hydration/elasticity and reduced periocular wrinkles—features associated with healthier‑looking skin/aging.

PubMed ID: 20969657

Durable wrinkle correction and long‑term cosmetic benefit strongly support a more youthful appearance.

PubMed ID: 20969659

NASHA filler provided durable wrinkle correction and acceptable safety over 12 months (supports aesthetic aging outcomes).

PubMed ID: 21070457

HA filler improved patient satisfaction and self-perception in lower-face rejuvenation—supports youthful appearance.

PubMed ID: 21134044

Combination HA filler + toxin outperformed monotherapies for lower-face rejuvenation.

PubMed ID: 20969660

Cross-linked HA filler delivered durable wrinkle correction with less product/pain—strong cosmetic rejuvenation evidence.

PubMed ID: 19207321

HA dermal fillers produced wrinkle correction and cosmetic improvement up to 24 weeks—directly supports healthy-looking aging.

PubMed ID: 19454518

Longer-lasting filler effect contributes to more sustained anti-aging cosmetic benefit.

PubMed ID: 19807760

Safety data in skin-of-color supports use of HA fillers for cosmetic aging goals in diverse populations.

PubMed ID: 18833043

HA revitalizing product improved skin firmness, elasticity and wrinkle filling—attributes of healthy aging appearance.

PubMed ID: 18547177

NASHA filler produced durable improvement in nasolabial folds and facial appearance, supporting a more youthful look.

PubMed ID: 16416643

Durable nasolabial-fold correction with cross‑linked HA filler supports more youthful facial appearance.

PubMed ID: 12859378

Combining NASHA with Botox extended and improved wrinkle correction, supporting longer-lasting youthful appearance.

PubMed ID: 41117156

Under‑eye pigmentation and QoL improved after injectable HA‑containing treatment, consistent with improved youthful appearance (confounded).

PubMed ID: 33534905

PRP+HA improved FACE‑Q and objective elasticity, indicating rejuvenative effects.

PubMed ID: 41454456

HA fillers maintained better nasolabial fold correction at 6 months vs collagen — supports longer-lasting youthful contours.

PubMed ID: 40296541

HA injections increased collagen and elasticity and reduced wrinkles — mechanisms consistent with promoting a more youthful appearance.

PubMed ID: 37265096

HA filler produced lasting volume, wrinkle improvement and favorable aesthetic scores—directly supports a more youthful appearance.

PubMed ID: 28892233

Microneedle HA improved wrinkles/elasticity vs topical essence, supporting an anti‑aging aesthetic effect.

PubMed ID: 28595250

HA fillers produced durable wrinkle improvement and increased collagen markers—consistent with more youthful appearance.

PubMed ID: 28915283

Topical HA increased skin HA and hydration, improving skin quality consistent with healthier aging appearance.

PubMed ID: 23340440

HA-driven increases in procollagen and TIMP‑1 early after injection support tissue remodeling consistent with healthy-looking aging.

PubMed ID: 19735512

HA fillers provided sustained wrinkle improvement and good safety in darker skin — supports cosmetic aspects of healthy-looking aging.

PubMed ID: 18986859

Perlane lip augmentation maintained volume and improved lip appearance over 12 months (supports youthful look).

PubMed ID: 18176233

Long-lasting correction of severe nasolabial folds with reduced retreatment volume supports lasting youthful appearance.

PubMed ID: 19083502

Crosslinked HA filler delivered durable wrinkle correction and volume restoration — strong evidence for a more youthful appearance.

PubMed ID: 18086050

Large trial found broad patient preference and longer‑lasting correction with HA fillers—strong cosmetic aging benefit.

PubMed ID: 15622265

Perlane filler gave sustained wrinkle correction and aesthetic benefit supportive of healthy‑looking aging.

PubMed ID: 12786700

HA dermal fillers produced durable aesthetic improvements consistent with a more youthful appearance.

PubMed ID: 31221944

Oral HA‑containing supplement increased skin collagen and elasticity and reduced wrinkles — outcomes consistent with supporting healthy-looking aging.

PubMed ID: 25732262

Oral low‑MW HA improved photoaging severity and skin parameters in a randomized trial, supporting perceived healthier-looking aging of skin.

PubMed ID: 39099032

HA+CaHA forehead treatment improved aesthetics and reduced irregularities with fewer nodules, supporting improved aging appearance.

PubMed ID: 31343447

HA fillers provided durable wrinkle correction and higher satisfaction—supports aesthetic aging outcomes.

PubMed ID: 33476068

HA volumizers provided durable midface correction over 2 years, supporting youthful contour maintenance.

PubMed ID: 34491026

HA cheek filler produced lasting volume and high satisfaction—supports healthy looking aging.

PubMed ID: 33587369

HA lip filler reduced perioral wrinkles and increased fullness—youthful aesthetic effect.

PubMed ID: 34927342

HA added to subcision improved scar appearance and satisfaction—improves perceived skin aging related to scarring.

PubMed ID: 34455631

Topical HA booster improved hydration, elasticity and wrinkle scores, consistent with anti‑aging skin effects.

PubMed ID: 41532837

Combination product with HA produced meaningful wrinkle improvements consistent with a more youthful look.

PubMed ID: 26218727

Voluma midface HA restored volume with long durability (15–24 months) and high satisfaction—strong anti‑aging aesthetic evidence.

PubMed ID: 26618455

Repeat midface HA injections restored volume for most patients with high satisfaction, supporting ongoing aesthetic aging benefits.

PubMed ID: 25521103

HA filler produced sustained nasolabial wrinkle improvement and good tolerability, a direct cosmetic anti‑aging effect.

PubMed ID: 27560289

Both HA fillers corrected nasolabial folds for 24 weeks, a visible marker of facial aging improvement.

PubMed ID: 2008293

Topical hyaluronan produced modest closure rates in chronic tympanic membrane perforations (epithelial repair).

PubMed ID: 41235610

HMW‑HA mixed into dentin graft increased mineralized bone percentage (pilot RCT) — supports tissue repair in dental sockets.

PubMed ID: 40444505

Topical HA gel added to laser depigmentation accelerated healing and markedly improved appearance vs laser alone (direct evidence of enhanced tissue repair/healing).

PubMed ID: 40198407

Topical HA + photobiomodulation sped healing and analgesia of dry socket in diabetics—strong evidence for local repair.

PubMed ID: 41162972

Topical HA accelerated palatal donor‑site healing, improved wound‑healing scores and reduced pain—direct wound‑repair evidence.

PubMed ID: 40106008

Crosslinked HA produced clinical/radiographic periodontal regeneration comparable to enamel matrix derivative over 18 months.

PubMed ID: 39930405

Intra‑socket HA after tooth extraction accelerated soft‑tissue healing and bone fill — strong wound‑healing effect (mucosal/bone).

PubMed ID: 40590113

HA composite dressing after CO2 laser markedly accelerated barrier repair (TEWL) and reduced erythema and pain — direct skin repair evidence.

PubMed ID: 39717991

Intradermal HA + hEGF improved redness and physician/patient scores, indicating enhanced repair/barrier recovery in a high‑altitude population.

PubMed ID: 39473003

HA‑impregnated floss produced greater reductions in interdental inflammation and bleeding — local tissue benefit.

PubMed ID: 39279207

Topical HA in extraction sockets reduced pain and improved socket soft‑tissue healing vs control.

PubMed ID: 38793012

Cross‑linked HA gel added to periodontal flap surgery produced greater attachment and pocket reductions — mucosal/periodontal repair effect.

PubMed ID: 39304658

HA‑containing biodegradable sponge improved sinonasal mucosal healing and reduced adhesions after endoscopic sinus surgery (multi‑component device).

PubMed ID: 39114889

0.8% HA gel adjunct to MINST produced greater early pocket/attachment improvements and less recession, implying enhanced soft‑tissue repair.

PubMed ID: 38279075

Topical 0.6% HA after pediatric frenectomy reduced early inflammation and improved short‑term healing metrics.

PubMed ID: 38994786

HA gel in intrabony periodontal surgery produced clinically and radiographically significant defect fill—direct regenerative effect.

PubMed ID: 39235513

Adjunct xHyA + hypochlorite gel during non‑surgical therapy produced greater attachment gain and pocket closure—promotes tissue repair.

PubMed ID: 39402910

Cross‑linked HA adjunct to non‑surgical periodontal therapy accelerated early healing and greater defect fill.

PubMed ID: 38833009

Topical HA plus CHX sped periodontal surgical wound closure and reduced bleeding—clear tissue‑healing benefit.

PubMed ID: 37052609

HA fillers improved acne scar volume and eventual structural/biostimulatory tissue improvements indicating support for scar remodeling.

PubMed ID: 37572339

Hyaluronan + antiseptic dressing gave greater wound‑area reduction and improved surrounding skin versus silver dressing (clinical wound‑healing benefit).

PubMed ID: 35732749

Mucosamin® mouth spray (multi‑ingredient including HA) reduced incidence/severity and duration of oral mucositis in pediatric HSCT patients (HA contribution plausible but not isolated).

PubMed ID: 35328990

Topical HA + amino acids after tooth extraction reduced early swelling, pain and analgesic use—consistent with accelerated mucosal/soft tissue healing.

PubMed ID: 35795593

Single 2% sodium hyaluronate application after pterygium surgery reduced early ocular pain and accelerated epithelial healing.

PubMed ID: 36038984

Ectoine + low‑concentration HA cream significantly improved pediatric atopic dermatitis severity and symptoms vs vehicle, indicating enhanced skin repair/barrier.

PubMed ID: 35667420

Applying HA gel after D&C halved intrauterine adhesion risk, consistent with improved mucosal healing/repair.

PubMed ID: 34927342

Cross‑linked HA added to subcision substantially increased acne scar clinical improvement—direct enhancement of dermal repair/fill.

PubMed ID: 34230975

Epidermal cell grafts resuspended in HA produced markedly higher repigmentation and lesion reduction vs HA alone—HA served as a graft matrix supporting repair.

PubMed ID: 33427772

Self‑cross‑linked HA hydrogel used in dacryocystorhinostomy improved epithelialization and long‑term ostial patency (enhanced mucosal healing).

PubMed ID: 34737549

Single topical 2% HA accelerated corneal epithelial healing after pterygium excision.

PubMed ID: 34680123

Local HA gel added to non-surgical periodontal therapy improved attachment and reduced bleeding.

PubMed ID: 33872196

HA-impregnated gauze markedly increased complete healing of chronic venous/mixed leg ulcers.

PubMed ID: 35025757

Topical 0.2% HA cream significantly increased complete healing of chronic leg ulcers in RCT.

PubMed ID: 32701012

Cross‑linked HA ocular gel accelerated corneal epithelial closure after PRK (direct mucosal/epithelial repair).

PubMed ID: 32040462

Topical HA in extraction sockets for poorly controlled diabetics markedly increased early wound closure rates (direct healing effect).

PubMed ID: 31781694

Topical HA gel after frenectomy significantly accelerated wound‑area reduction and patient satisfaction (direct wound healing).

PubMed ID: 32032408

Topical HA under free gingival grafts increased perfusion and reduced graft shrinkage, improving early healing outcomes.

PubMed ID: 30967159

Sodium hyaluronate added to nasal irrigation improved postoperative mucosal healing appearance after sinus surgery.

PubMed ID: 30084900

Topical product containing HA + growth factors improved surgical scar appearance vs silicone; HA likely contributed though product combined actives.

PubMed ID: 30861510

Vaginal HA suppositories greatly reduced radiotherapy-induced mucosal side effects and pain, supporting mucosal repair/protection.

PubMed ID: 31604061

Subcutaneous HA during brachytherapy markedly reduced acute skin toxicity and lowered skin radiation dose—direct protective/repair effect.

PubMed ID: 30536185

Topical sodium hyaluronate significantly accelerated corneal epithelial healing after debridement.

PubMed ID: 30579747

HA combined with platelet‑rich fibrin improved early soft‑tissue healing and eliminated observed dry socket/infections post‑extraction.

PubMed ID: 29961138

Adding HA to coronally advanced flap surgery improved root coverage and reduced early swelling/discomfort vs surgery alone.

PubMed ID: 29678756

Large multicenter RCT showed NCH gel greatly reduced incidence and severity of intrauterine adhesions after D&C → strong evidence of a favorable effect on postoperative tissue healing.

PubMed ID: 28914592

Topical HA significantly reduced pain and accelerated palatal wound epithelization (CE by day 21 vs day 42) → strong evidence for mucosal/soft‑tissue repair.

PubMed ID: 29202566

Nebulized sodium hyaluronate after FESS produced faster symptom relief and improved endoscopic healing vs standard spray → supports mucosal repair/healing.

PubMed ID: 28387882

Double‑blind RCT: topical HA+collagenase increased debridement and accelerated ulcer bed preparation.

PubMed ID: 29304325

Topical HA + L‑PRF after extraction reduced swelling and analgesic need, supporting faster local healing.

PubMed ID: 28707086

HA anti‑adhesion agents after sinus surgery reduced early postoperative adhesions → improved surgical tissue outcomes.

PubMed ID: 28390688

Cross‑linked HA gel applied after D&C halved risk/severity of intrauterine adhesions (promotes tissue repair/anti‑adhesion).

PubMed ID: 27571124

HA‑containing mouthwash reduced mucositis severity and oral pain in children (mucosal healing support).

PubMed ID: 26980389

Aerosolized HMW HA sped cilia recovery and improved mucosal healing after nasal surgery.

PubMed ID: 26972358

Randomized trial: pure HA dressing markedly increased complete healing rate and sped healing of diabetic foot ulcers.

PubMed ID: 29328639

Topical HA shortened pain duration and reduced symptoms in dry socket, accelerating mucosal/soft‑tissue recovery.

PubMed ID: 25678773

0.3% sodium hyaluronate eye drops promoted corneal epithelial wound healing comparable to bFGF.

PubMed ID: 26788875

Vaginal suppository with low‑MW HA reduced radiation‑induced vaginal atrophy/biopsy inflammation vs no treatment.

PubMed ID: 25877422

Auto‑crosslinked HA gel placed after hysteroscopic adhesiolysis markedly reduced recurrence/severity of intrauterine adhesions.

PubMed ID: 25906706

Crosslinked HA gel markedly reduced postoperative adhesions—strong tissue modulation/repair benefit.

PubMed ID: 26493557

NAF lidocaine HA filler improved wrinkles—cosmetic tissue repair/augmentation.

PubMed ID: 25964628

Midface HA volumizing produced durable aesthetic improvements—supports dermal augmentation/repair.

PubMed ID: 25933201

rhFGF‑2 in HA gel substantially improved periodontal attachment/regeneration—strong tissue repair evidence.

PubMed ID: 26659938

HA lip filler produced durable tissue augmentation/repair of perioral rhytides.

PubMed ID: 25197922

Nasal nebulized HA reduced CRS symptoms and endoscopic edema—supports mucosal healing.

PubMed ID: 24591296

Intranasal sodium hyaluronate improved mucosal healing after sinus surgery—direct support for tissue repair.

PubMed ID: 25340801

PXL01 delivered in HA gel improved tendon repair and motion—direct tissue repair support (HA carrier role).

PubMed ID: 24668456

Early intracordal HA reduced need for later surgery and improved glottal gap—supports mucosal/tissue repair.

PubMed ID: 24848975

Platelet‑rich growth factors combined with HA produced large ulcer‑area reductions and higher complete healing for pressure ulcers.

PubMed ID: 25375400

Autologous fibroblast+HA markedly increased complete healing rates and sped healing of diabetic foot ulcers vs standard care.

PubMed ID: 24328847

Topical gel with sodium hyaluronate + amino acids significantly sped oral mucosal wound closure at 7 days (randomized clinical study).

PubMed ID: 23527716

Nebulized sodium hyaluronate after FESS improved mucosal appearance, ciliary function and reduced biofilm vs saline.

PubMed ID: 23710960

Topical HA after turbinate surgery reduced crusting and improved nasal mucosal symptoms (randomized study).

PubMed ID: 23716986

Sodium hyaluronate improved usefulness of submucosal injection for gastric ESD (procedural/repair context) in a multicenter RCT.

PubMed ID: 23368701

Instilling HA/CMC after TURP reduced early pain and urethral stricture rates, indicating improved mucosal healing.

PubMed ID: 23444204

Topical HA in infrabony periodontal defects improved attachment and pocket depth, indicating tissue repair effects (oral mucosa).

PubMed ID: 23426344

HA/CMC membranes applied at hepatectomy reduced adhesions and severity, indicating improved tissue healing/repair.

PubMed ID: 23470209

HA/CMC instillation after urethrotomy lowered stricture recurrence and early postoperative pain, supporting mucosal repair.

PubMed ID: 23413492

HA‑impregnated gauze was non‑inferior for leg-ulcer healing and reduced peri‑ulcer skin problems, directly supporting wound repair.

PubMed ID: 22728576

Topical high‑MW HA gel improved vaginal atrophy signs and symptoms vs placebo.

PubMed ID: 22399081

Topical HA cream significantly reduced leg ulcer area and pain vs vehicle.

PubMed ID: 22405094

HA gauze markedly sped venous leg‑ulcer healing and reduced pain vs vehicle.

PubMed ID: 23088524

Topical HA after scaling/root planing improved periodontal pocket depth and pathogen counts (mucosal repair).

PubMed ID: 21394118

Large RCT: HA‑based barrier improved epithelialization and reduced scarring after surgery (clear tissue‑repair benefit).

PubMed ID: 21159036

HA/CMC membrane reduced postoperative uterine adhesions in animals, suggesting tissue‑healing modulation.

PubMed ID: 20538398

Topical PVP–sodium hyaluronate gel after oral biopsy reduced peak postoperative pain, implying improved mucosal healing/comfort.

PubMed ID: 20453546

HA/CMC dressing after sinus surgery reduced early adhesions and congestion, indicating improved mucosal postoperative healing.

PubMed ID: 19267842

Topical 0.2% HA gel reduced soreness and erosive/ulcerative area size in oral lichen planus versus baseline.

PubMed ID: 19703948

Randomized trial: HA-containing gel improved healing rates and sped diabetic neuropathic leg ulcer closure.

PubMed ID: 19709346

Topical diclofenac delivered in HA gel produced histologic regression of actinic keratoses (supports tissue repair/regression).

PubMed ID: 18946677

Resorbable hyaluronan nasal packing reduced adhesions and improved mucosal re‑epithelialization after sinus surgery (strong healing benefit).

PubMed ID: 18474463

Tested cream reduced radiation‑induced redness, burning and desquamation vs vehicle (supports epidermal/dermal protection/healing).

PubMed ID: 18713490

HA hydrocolloid dressing showed trend to greater ulcer-area reduction and less fibrinous tissue.

PubMed ID: 17205576

Topical hyaluronan gel around repaired hand nerves improved early pain relief and accelerated sensory recovery (enhanced local healing).

PubMed ID: 17461960

Daily HA gel around immediate-function mandibular implants improved early bleeding scores, suggesting peri‑implant tissue benefits.

PubMed ID: 16918596

Topical 0.2% HA reduced aphthous-ulcer counts and early recurrence vs placebo.

PubMed ID: 16497479

Oral HA-containing gel reduced pain after CO2 laser oral surgery, supporting mucosal healing/comfort.

PubMed ID: 16249848

Seprafilm at colorectal closure reduced adhesions and eased reoperations—demonstrates HA effect on tissue healing.

PubMed ID: 16080936

Hyaluronate‑CMC membrane significantly reduced surgical adhesions in children—HA used to modulate healing/repair.

PubMed ID: 15999421

Topical HA spray substantially reduced gum bleeding and inflammatory fluid vs control—strong mucosal/repair signal.

PubMed ID: 16083533

Topical HA+SSD healed second‑degree burns ~4.5 days faster in a multicentre RCT.

PubMed ID: 12923149

Auto‑cross‑linked HA gel after adhesiolysis decreased intrauterine adhesions → indicates improved mucosal healing/prevention of pathologic scarring.

PubMed ID: 12909511

Autocrosslinked HA gel markedly reduced postoperative adhesions after myomectomy → supports improved healing environment and tissue repair.

PubMed ID: 14514591

Autologous HA‑based grafts improved foot ulcer healing and reduced time to closure (not significant overall but significant for dorsal ulcers) → good evidence for wound repair support.

PubMed ID: 11787023

RCT: intrauterine HA membrane after curettage reduced adhesions and substantially increased pregnancy rates (improved uterine surface healing).

PubMed ID: 11807358

Randomized trial: HA–CMC membrane significantly lowered adhesion severity after abdominal surgery (relevant to surgical surface repair).

PubMed ID: 10912689

Randomized multicenter trial: HA biomembrane after ear surgery sped and improved re‑epithelialization (direct tissue repair evidence).

PubMed ID: 9715497

Viscoelastic application during cataract surgery markedly reduced need for irrigation, indirectly indicating better ocular surface protection during surgery.

PubMed ID: 9627294

Randomized blinded multicenter trial: intraoperative HA coating reduced de novo adhesions and severity, indicating improved tissue surface healing.

PubMed ID: 9076452

Large randomized multicenter trial: HA membrane applied intra‑abdominally greatly reduced incidence, extent and severity of postoperative adhesions (improved healing environment).

PubMed ID: 9106924

Topical HA cream significantly reduced radiotherapy‑induced skin reactions, indicating support of skin repair.

PubMed ID: 39435599

Topical HA improved lesion severity and pain in oral lichen planus (mucosal/epithelial healing/comfort).

PubMed ID: 40295318

HA+glutamine adjunct reduced severe oral mucositis and improved symptoms/QoL (mucosal repair).

PubMed ID: 21499725

Randomized trial: lysine‑HA produced substantially faster and larger pressure‑ulcer healing vs standard HA—strong direct evidence for wound repair.

PubMed ID: 40781616

PVP‑HA film on palatal donor site accelerated epithelialization, reduced pain and bleeding in RCT—strong topical repair signal.

PubMed ID: 39012233

H2O2+HA mouthwash improved early socket healing after extraction in an RCT—supports mucosal/soft‑tissue repair.

PubMed ID: 36595064

After gum graft surgery topical HA sped healing, reduced pain and increased complete epithelialization—direct wound‑repair benefit.

PubMed ID: 22492249

Topical gel containing HA reduced pain/bleeding/itching in hemorrhoid patients, consistent with mucocutaneous soothing and repair.

PubMed ID: 34837931

Sodium hyaluronate‑amino acid spray (Mucosamin®) reduced radiotherapy mucositis severity and shortened duration in oral cancer patients.

PubMed ID: 32333512

Noncross‑linked HA injection improved acne scars clinically and histologically (increased collagen/elastic fibers).

PubMed ID: 32710584

Polynucleotide‑HA dressings significantly enhanced re‑epithelialization, angiogenesis and collagen in chronic human ulcers.

PubMed ID: 32131656

HA‑based dermal matrix doubled wound closure rate and reduced inflammation/oxidative stress in diabetic foot ulcers (human RCT/data).

PubMed ID: 29921408

HA‑based oral spray reduced severity/duration of oral mucositis and improved healing outcomes after stem cell transplant.

PubMed ID: 26027861

Topical HA after molar extraction reduced inflammatory infiltration and increased angiogenesis in wound tissue at 1 week.

PubMed ID: 23340440

Injected cross-linked HA increased procollagen early after injection — a mechanism supporting tissue repair/remodeling.

PubMed ID: 31221944

Supplement increased dermal collagen and reduced lines — supports cutaneous repair/renewal though product contained multiple actives.

PubMed ID: 26705233

Topical sodium-hyaluronate gel at stoma creation reduced adhesion severity and dense adhesions at closure — supports healing/repair processes.

PubMed ID: 39304548

Adjunctive sodium-hyaluronate-containing gel improved peri-implant mucositis resolution rates versus cleaning alone, aiding mucosal healing.

PubMed ID: 33374791

HA-containing mouthwash reduced pain in oral lichen planus and provided symptomatic mucosal benefit (less inflammation/irritation).

PubMed ID: 40157723

HMW HA sped corneal nerve/surface recovery after crosslinking — supports ocular surface repair.

PubMed ID: 36725463

Topical low‑MW HA cream shortened healing time after phenol matricectomy vs standard care in a randomized trial.

PubMed ID: 29703289

Crosslinked HA ocular gel accelerated corneal reepithelialization after laser surgery.

PubMed ID: 25316142

Intranasal HA with antibiotic accelerated symptom resolution and reduced inflammatory cells, consistent with mucosal healing.

PubMed ID: 25217122

Self-cross-linked HA improved remucosalization and reduced scarring post‑sinus surgery.

PubMed ID: 23406605

Absorbable hyaluronan nasal hydrogel significantly promoted reepithelialization after sinus surgery.

PubMed ID: 18822733

Randomized trial: sodium hyaluronate hydrogel markedly accelerated abscess-cavity healing, reduced cavity volume and healing time—strong direct support for topical skin repair.

PubMed ID: 15868230

Randomized multicentre study: glycerol–hyaluronate/CMC membrane significantly reduced incidence/extent/severity of postoperative adhesions, indicating strong tissue-healing/anti-adhesion effects.

PubMed ID: 33615815

Sodium hyaluronate eye drops improved multiple dry‑eye metrics (hydration/tear film stability) vs baseline.

PubMed ID: 23490326

Topical sodium hyaluronate improved ocular surface signs—supports HA's hydrating action on epithelial surfaces.

PubMed ID: 32067777

Large RCT: nasal hyaluronic acid spray produced significant symptom and endoscopic improvements and greater perceived moisturisation—robust evidence for HA's hydration effect on mucosa.

PubMed ID: 12194076

Topical HA improved burning symptom and corneal staining in severe dry eye, consistent with improved surface hydration.

PubMed ID: 22287172

Sodium hyaluronate improved ocular surface measures associated with hydration in dry eye RCT.

PubMed ID: 38389327

HA tear substitute improved dry-eye symptoms consistent with improved ocular surface hydration.

PubMed ID: 40120935

Nebulized HA+xylitol reduced crusting and improved nasal obstruction/bleeding vs saline, consistent with improved mucosal hydration.

PubMed ID: 33832645

Vaginal gel containing HA improved signs/symptoms of atrophy and vaginal pH, indicating mucosal rehydration.

PubMed ID: 39099032

HA+CaHA forehead filling improved metrics related to skin quality including hydration.

PubMed ID: 25732262

Oral low‑MW HA increased skin hydration and serum HA in a randomized trial — direct evidence for systemic/skin hydration effects of oral HA‑containing formulation.

PubMed ID: 33289602

HA/CS preservative‑free eye drops improved tear film metrics and symptom scores — clear evidence of improved mucosal hydration (ocular surface).

PubMed ID: 28915283

Topical HA increased skin HA content and SC hydration with decreased TEWL (improved overall skin hydration).

PubMed ID: 22914501

Sodium hyaluronate improved tear film stability and staining—evidence of improved ocular surface hydration.

PubMed ID: 25055152

Adding preservative‑free HA increased TBUT/staining improvement and goblet cell density, consistent with better mucosal hydration.

PubMed ID: 25631485

Large RCT showed TBUT and staining improvements with topical HA, supporting enhanced ocular hydration.

PubMed ID: 27049103

Intranasal lysine‑hyaluronate formulation reduced symptoms and endoscopic signs after FESS—supports improved nasal mucosal condition/hydration.

PubMed ID: 27049100

Adjunctive intranasal T‑LysYal improved rhinitis symptoms and cytology vs saline—indicates mucosal hydration/condition benefits.

PubMed ID: 35749148

HA‑containing artificial tear improved tear film stability and reduced evaporation — supports local hydration.

PubMed ID: 8501639

Healon GV (higher MW HA) maintained anterior chamber better and required less viscoelastic—directly relevant to local hydration/volume maintenance.

PubMed ID: 7995064

Healon GV maintained a larger anterior chamber during keratoplasty—supports improved local hydration/space maintenance.

PubMed ID: 9106924

Topical HA reduced radiotherapy dermatitis, consistent with preserved skin hydration/barrier function.

PubMed ID: 11584850

Hypotonic HA drops significantly reduced tear osmolarity and improved tear film metrics—evidence of local hydration improvement (ocular).

PubMed ID: 11815344

Regular sodium hyaluronate eye drops improved ocular surface measures and symptoms—supports hydration effects for mucosal surface.

PubMed ID: 15999421

Topical HA reduced gingival inflammation and GCF—indirect sign of improved local moisture/condition.

PubMed ID: 15701590

Topical HA cream improved dermatitis signs consistent with improved skin hydration/barrier function.

PubMed ID: 18833043

Topical/injectable HA improved skin turgidity/hydration measures in a randomized trial.

PubMed ID: 19207321

Dermal HA fillers increase local dermal hydration and volume (cosmetic outcomes demonstrated).

PubMed ID: 19709346

HA gel vehicle used for topical diclofenac supported lesion regression and histologic changes, indicating improved local tissue condition/hydration.

PubMed ID: 20346777

Topical ocular HA improved ocular surface staining and symptoms (surface hydration benefit).

PubMed ID: 22052267

Topical HA creams produced clear objective improvements in skin moisture versus vehicle.

PubMed ID: 21045674

HA eyedrops improved tear film stability and ocular surface hydration measures.

PubMed ID: 22399081

Topical HA cream improved wound environment; HA's hygroscopic properties support tissue hydration.

PubMed ID: 23574713

HA vaginal gel effectively relieved postmenopausal vaginal dryness, showing mucosal hydration benefit.

PubMed ID: 23715889

Dermal thickness increases after HA microinjection imply improved skin water content and local hydration.

PubMed ID: 24030535

HA‑containing artificial tear improved symptomatic dryness and maintains tear film, indicating surface hydration benefits.

PubMed ID: 23710960

Topical HA after turbinate surgery reduced crusting and obstruction, consistent with improved nasal mucosal hydration.

PubMed ID: 23527716

Nebulized HA after FESS improved mucosal healing and symptoms, consistent with improved mucosal hydration.

PubMed ID: 25399620

Topical multi‑MW HA produced rapid volumizing/contour effects consistent with increased cutaneous hydration and water retention.

PubMed ID: 25398660

HA+B12 eye drops increased Schirmer/BUT and reduced oxidative stress—supports improved tear/ocular surface hydration (local).

PubMed ID: 24591296

Intranasal sodium hyaluronate improved mucosal edema and discharge—clear local hydration/conditioning effect.

PubMed ID: 25197922

Monthly nebulized nasal HA reduced edema and secretions—improves mucosal hydration overall.

PubMed ID: 25487027

Preservative‑free HA eye drops improved TBUT and Schirmer—strong ocular surface hydration evidence.

PubMed ID: 26659938

Lip filler increases tissue fullness/hydration—perioral hydration effect.

PubMed ID: 25964628

Midface volumizing produced durable fullness—strong localized dermal hydration/volume effect.

PubMed ID: 26493557

Nasolabial filler improved wrinkle severity via volume/hydration.

PubMed ID: 25828038

Lip HA augmentation changed texture/firmness transiently—localized hydration/volume effects.

PubMed ID: 26432128

HA+CMC eye drops improved tear stability and dry‑eye symptoms, reflecting enhanced ocular surface hydration.

PubMed ID: 25651494

HA (especially trehalose+HA) produced sustained increases in tear film thickness up to 4 hours.

PubMed ID: 26004026

Topical liposomal HA produced large reductions in vaginal dryness and improved Vaginal Health Index, indicating strong hydration of mucosa.

PubMed ID: 26972358

HA dressing accelerated ulcer healing (wound environment hydration/maintenance likely contributed).

PubMed ID: 26924549

Dermal HA filler volumizes and can increase local tissue hydration (aesthetic trial outcomes).

PubMed ID: 27121901

Concentrated HA filler maintained volume and appearance for up to 2 years consistent with local hydration effects.

PubMed ID: 27254807

HA+CMC drops improved ocular symptoms and signs in contact lens wearers (better tear/ocular surface hydration).

PubMed ID: 27049107

Nasal sodium hyaluronate improved symptoms and mucosal oedema in children with URTIs (mucosal hydration/comfort).

PubMed ID: 26980389

Aerosolized HMW HA accelerated mucosal healing and mucociliary clearance — reflects improved mucosal hydration.

PubMed ID: 27571124

HA mouthwash alleviated mucositis — implies mucosal hydration/soothing.

PubMed ID: 28452989

HA eye drops improved ocular surface staining/symptoms indicating better tear/ surface hydration.

PubMed ID: 28145073

HA filler provides localized tissue hydration/volume.

PubMed ID: 28987023

Microneedle HA + cream improved facial appearance—likely associated with increased dermal hydration.

PubMed ID: 29077152

Nasal sodium hyaluronate improved mucociliary transport and reduced neutrophils/bacteria, consistent with mucosal hydration.

PubMed ID: 28229275

Vaginal HA moisturizer improved sexual function/dyspareunia, reflecting improved mucosal hydration.

PubMed ID: 28606267

Sodium hyaluronate eye drops improved tear breakup time and symptoms vs control after cataract surgery → supports improved hydration of ocular surface.

PubMed ID: 28914592

Topical HA accelerated mucosal epithelization and improved color match, consistent with improved local tissue hydration.

PubMed ID: 29687335

Ophthalmic HA + taurine meaningfully improved tear film stability and goblet cell density → strong evidence for ocular surface hydration.

PubMed ID: 30395961

HA‑based ocular formulations increased tear film thickness and improved subjective ocular comfort after single instillation.

PubMed ID: 30325687

HA eye drops increased tear film thickness and improved symptoms transiently, demonstrating hydration effect on ocular surface.

PubMed ID: 29762642

Dermal HA filler volumizes tissue and is associated with improved skin hydration/appearance.

PubMed ID: 31769596

Objective increases in tissue water content after intradermal HA (hand skinboosting) demonstrate improved local hydration.

PubMed ID: 29506034

Dermal HA fillers increase local tissue water content/volume, contributing to local hydration.

PubMed ID: 32621657

Intradermal HA increased measured skin hydration (direct local hydration effect).

PubMed ID: 32485024

HA microneedles increased epidermal echo‑density and improved topography consistent with improved tissue water content.},{

PubMed ID: 34477473

Vaginal prolonged-release HA improved epithelial maturation and lowered pH, consistent with mucosal hydration.

PubMed ID: 33956256

Trehalose+HA eye gel increased tear production (Schirmer) and tear stability (TBUT).

PubMed ID: 34933842

Oral HA increased skin hydration objectively over 28 days.

PubMed ID: 33534905

PRP+HA increased facial appearance metrics—HA likely increased dermal water retention contributing to overall hydration.

PubMed ID: 34455631

Topical epidermal HA markedly increased skin hydration vs placebo in a randomized trial.

PubMed ID: 34096694

Vaginal HA gel improved VVA dryness scores and Vaginal Health Index (mucosal hydration benefit).

PubMed ID: 34043117

Trehalose + HA eye drops increased tear volume (TMH) vs HA alone, showing mucosal hydration benefit.

PubMed ID: 36279690

HA vaginal suppositories improved Vaginal Health Index and symptoms (mucosal hydration) in breast‑cancer survivors.

PubMed ID: 36038984

Topical ectoine + HA cream improved atopic dermatitis outcomes, reflecting improved barrier/hydration.

PubMed ID: 35279948

HA filler effects on fold correction imply localized hydration/volume benefits.

PubMed ID: 35925834

Midface HA filler restores volume and tissue turgor via HA's hydrophilic properties.

PubMed ID: 34758056

HA filling + mesotherapy improved neck line appearance and patient satisfaction, consistent with improved dermal hydration/plumpness.

PubMed ID: 38009035

Oral HA increased skin moisture and had systemic effects on skin hydration metrics in a randomized trial.

PubMed ID: 37074002

Intradermal HA produced large hydration and patient satisfaction gains consistent with systemic appearance of improved hydration.

PubMed ID: 37163665

Objective moisture meter increases and sustained hydration after intradermal HA demonstrate improved overall skin hydration.

PubMed ID: 38829483

Topical low‑MW HA significantly increased objective skin capacitance—strong evidence for improved skin hydration.

PubMed ID: 38305601

Large RCT: vaginal HA therapy improved vaginal health/symptoms comparably to local estrogen—supports mucosal hydration.

PubMed ID: 39495047

Vaginal HA tablets added to erbium laser improved GSM symptoms more than laser alone—supports improved mucosal hydration.

PubMed ID: 38591218

Topical HA markedly increased skin suppleness and reduced wrinkle area, consistent with improved cutaneous hydration.

PubMed ID: 39078835

Higher‑concentration HA eye drops improved TBUT and LLT implying better tear‑film hydration.

PubMed ID: 38775789

HA-containing ocular lubricants improved epithelial regularity and symptoms — reflects improved surface hydration.

PubMed ID: 39251947

HA eye drops increased tear film stability and tear volume measures modestly (improved ocular surface hydration).

PubMed ID: 38875184

Canalicular crosslinked HA increased tear production (Schirmer) and meniscus height — increased ocular hydration.

PubMed ID: 40590113

HA dressing significantly reduced TEWL and improved hydration metrics after laser — supports improved local hydration.

PubMed ID: 40273666

Single cross‑linked HA injection into vaginal tissues substantially reduced dryness and improved symptoms—strong evidence for improved local hydration.

PubMed ID: 39962158

Sodium hyaluronate eye drops improved tear stability and production—strong evidence for improved ocular surface hydration.

PubMed ID: 40773978

Single cross‑linked HA vulvovaginal injection produced durable reductions in atrophy symptoms and improved sexual function—direct evidence of improved mucosal hydration.

PubMed ID: 41422283

Oral sodium hyaluronate RCT showed significant increases in facial skin hydration and reduced TEWL—strong evidence for improved tissue hydration (systemic oral supplementation).

PubMed ID: 40589311

HA hydrolifting contributed to sustained improvements in skin inflammatory area and texture consistent with improved local hydration.

PubMed ID: 17394642

Randomized trial: HA eye drops (0.2%) improved tear break‑up time, symptoms, and surface staining over 90 days (strong, direct evidence).

PubMed ID: 9368169

Hylan surgical shield kept cornea moist much longer during surgery versus standard solution (improved intraoperative corneal moisture).

PubMed ID: 10502570

Double‑blind randomized crossover: 0.1% sodium hyaluronate eye drops improved Schirmer scores, rose bengal staining and symptoms vs saline.

PubMed ID: 11584850

Large randomized trial: hypotonic 0.4% HA eye drops improved tear osmolarity, tear film quality and epithelial health vs control (strong evidence for reducing eye dryness).

PubMed ID: 11244343

Crossover trial: HA‑containing drops (hypotonic/isotonic) provided symptomatic relief for dry eye (good supportive evidence).

PubMed ID: 11815344

Randomized double‑blind trial: regular sodium hyaluronate eye drops improved ocular surface health and symptoms in dry eye patients (strong clinical evidence).

PubMed ID: 17173009

Postoperative HA drops associated with healthier bleb status and less progression to leakage, indicating improved ocular surface condition.

PubMed ID: 18677239

Sodium HA drops improved corneal/conjunctival staining and caused less visual blurring than carbomer for moderate dry eye.

PubMed ID: 41176487

Randomized double‑blind trial showed sodium hyaluronate eye drops (0.15% and 0.38%) significantly reduced dry‑eye symptoms and improved TBUT and staining over 6 weeks (strong direct evidence).

PubMed ID: 39934351

HA‑containing multi‑action eye drops (cross‑linked HA formula) improved dry eye symptoms and tear stability more than standard HA drops over 6 months (direct ocular surface benefit).

PubMed ID: 39962158

0.3% sodium hyaluronate eye drops (with additive formulation) improved OSDI, TBUT and Schirmer more rapidly and to a greater extent than HA alone — strong evidence HA improves dry‑eye symptoms/tear stability.

PubMed ID: 38875184

Crosslinked HA canalicular gel improved tear production and dry eye signs/symptoms with benefits up to 6 months (strong evidence).

PubMed ID: 38296318

In meibomian gland dysfunction, adding cyclosporine A to HA drops improved TBUT and gland secretion vs HA alone — supports relevance of HA drops.

PubMed ID: 40369920

Sodium hyaluronate drops improved dry eye signs and symptoms; adding acupuncture amplified effects but HA alone had benefit.

PubMed ID: 39134473

Sodium hyaluronate drops improved symptoms and visual function in a large cohort; combination therapy outperformed single agents.

PubMed ID: 39251947

Topical 0.15% HA eye drops improved TBUT, corneal staining and modest Schirmer increases vs baseline in mild‑moderate dry eye.

PubMed ID: 38775789

Lubricating eye drops including HA reduced corneal epithelial irregularity and dry‑eye symptoms over 4 weeks.

PubMed ID: 39078835

0.15% HA eye drops improved OSDI, TBUT and lipid layer thickness more than 0.1% HA after cataract surgery.

PubMed ID: 39260878

RCT: 0.1% sodium hyaluronate eyedrops improved OSDI and tear stability vs baseline (HA effective for dry‑eye symptoms).

PubMed ID: 38131131

Very‑high‑MW HA markedly reduced drop frequency and OSDI scores in severe dry eye—strong symptomatic benefit.

PubMed ID: 37334889

HA tear formulation with low‑dose hydrocortisone produced sustained symptom relief and TBUT improvement vs HA alone.

PubMed ID: 36924514

0.18% sodium hyaluronate + eyelid hygiene improved preoperative dry‑eye symptoms and TBUT versus HA alone.

PubMed ID: 36803227

0.1% sodium hyaluronate eye drops improved OSDI symptoms and corneal staining in thyroid‑associated dry eye.

PubMed ID: 37986246

Both acupuncture and sodium hyaluronate improved tear measures; HA drops were an effective comparator (duplicate entry reflects strong support).

PubMed ID: 35450456

Randomized trial: two sodium hyaluronate formulations both improved signs/symptoms of moderate–severe dry eye; 0.30% non‑inferior.

PubMed ID: 35795593

Topical 2% sodium hyaluronate after pterygium surgery reduced ocular pain and sped epithelial healing; supports ocular surface lubrication/rehabilitation.

PubMed ID: 37199202

Sodium hyaluronate eye drops improved tear stability, Schirmer scores and corneal staining in dry eye patients (though acupuncture was superior in that trial).

PubMed ID: 34043117

Trehalose + HA drops improved tear stability, tear volume and optical quality more than HA alone in symptomatic dry eye.

PubMed ID: 33615815

Sodium hyaluronate eye drops improved dry‑eye signs/symptoms compared with baseline in a randomized trial (DCBE had superior pain reduction).

PubMed ID: 35039260

Adding rhEGF to sodium hyaluronate drops produced greater increases in BUT/Schirmer and reduced OSDI vs HA alone after cataract surgery.

PubMed ID: 34698461

Randomized study: Lingnan fire needling + sodium hyaluronate eye drops improved OSDI, BUT, Schirmer and tear meniscus more than HA alone (HA used in both arms).

PubMed ID: 34843023

Sequential higher-then-lower concentration HA drops improved dry-eye signs/symptoms vs single-concentration regimens.

PubMed ID: 33956256

Trehalose+sodium hyaluronate eye gel improved TBUT, Schirmer and corneal staining after cataract surgery.

PubMed ID: 32701012

Cross‑linked HA ocular gel accelerated corneal re‑epithelialization after PRK, implying improved ocular surface healing and symptom mitigation (relevant to dryness/comfort).

PubMed ID: 30830076

0.15% HA tears supported corneal epithelialization in severe dry eye, though antioxidant tears produced greater functional gains.

PubMed ID: 31397128

HA eye drops were used as comparator in a dry‑eye trial; acupuncture outperformed HA drops but HA still had some effectiveness.

PubMed ID: 29377842

Sodium hyaluronate improved Schirmer/TBUT and symptoms in mild–moderate dry eye patients.

PubMed ID: 30536185

Topical HA accelerated corneal epithelial healing — beneficial for ocular surface health, indirectly reducing dryness.

PubMed ID: 30325687

Single‑dose trial showed HA (and HA+lipid) increased tear film thickness and improved symptoms short‑term vs control.

PubMed ID: 29381080

Phase III RCT: HA+trehalose eye drops relieved dry‑eye symptoms more than HA alone over 84 days (higher proportion reaching low symptom threshold).

PubMed ID: 30497904

Eyelid spray containing sea buckthorn oil + sodium hyaluronate reduced OSDI and dryness scores vs control in randomized portion.

PubMed ID: 29687335

0.4% HA + taurine ophthalmic solution improved BUT, staining, goblet cell density and symptoms in glaucoma patients → strong evidence for reducing eye dryness.

PubMed ID: 28606267

Randomized trial: sodium hyaluronate eye drops improved OSDI scores and tear breakup time after cataract surgery → clear benefit for eye dryness.

PubMed ID: 28452989

HA eye drops improved ocular surface staining and symptoms in moderate–severe dry eye.

PubMed ID: 28820156

Intraoperative sodium hyaluronate reduced complications and improved outcomes after trabeculectomy—supports ocular surface protection.

PubMed ID: 27614318

Study showed lubricin > HA for dry eye, but HA still produced some sign/symptom improvement.

PubMed ID: 27254807

Large RCT of lens wearers: HA+CMC drops improved ocular comfort and signs vs CMC alone over 90 days.

PubMed ID: 27929721

Large RCT: topical sodium hyaluronate (0.1–0.3%) was noninferior to cyclosporine and improved corneal/conjunctival staining, TBUT and symptoms.

PubMed ID: 27445067

HA+trehalose drops were noninferior to HA alone and improved several dry‑eye symptoms and satisfaction.

PubMed ID: 26547229

Hypertonic drops containing HA improved early postoperative vision and reduced corneal swelling, indicating ocular surface benefit.

PubMed ID: 25651494

HA‑containing drops increased tear‑film thickness; trehalose+HA had longer residence up to 4 hours in dry‑eye patients.

PubMed ID: 26090941

Sodium hyaluronate drops improved OSDI, FBUT and Schirmer vs HPMC in glaucoma patients on preserved meds.

PubMed ID: 26432128

Post‑cataract randomized trial: sodium hyaluronate+CMC drops improved TBUT, symptoms, and corneal staining.

PubMed ID: 25487027

Preservative‑free sodium hyaluronate eye drops significantly improved postoperative dry‑eye signs and symptoms—direct evidence.

PubMed ID: 24366433

Single drop hypotonic sodium hyaluronate reliably relieved dry‑eye symptoms (subjective improvement) though objective higher‑order aberrations unchanged.

PubMed ID: 25398660

HA + vitamin B12 eye drops reduced oxidative stress and improved Schirmer/BUT and symptoms in dry‑eye patients (strong ocular dryness signal though combined formulation).

PubMed ID: 24030535

Artificial tear combining HA and tamarind polysaccharide reduced dry eye symptoms vs comparator (randomized double‑masked trial).

PubMed ID: 24133024

Sodium hyaluronate eye drops produced objective and subjective improvements in dry eye signs and symptoms versus baseline.

PubMed ID: 22483761

Large phase III RCT: hypotonic 0.18% sodium hyaluronate eye drops improved dry-eye symptoms and corneal staining vs saline.

PubMed ID: 21968605

Sodium hyaluronate eye drops improved dry‑eye symptoms and tear‑film stability (emulsion performed best).

PubMed ID: 21045674

Randomized trial: preservative‑free sodium hyaluronate eyedrops improved staining, TBUT and symptoms similar to CMC.

PubMed ID: 20346777

Large RCT: 0.18% sodium hyaluronate eye drops improved ocular staining and symptoms vs vehicle over 7 days.

PubMed ID: 19757354

Hyaluronate artificial tears produced symptomatic and tear-stability improvements in dry eye patients (less effective than alternative spray).

PubMed ID: 23490326

Repeated for emphasis: demonstrated noninferiority/some superiority vs comparator for objective dry-eye signs with sodium hyaluronate.

PubMed ID: 12194076

Randomized crossover trial in severe dry eye showing significant symptom (burning VAS) and corneal staining improvements with topical 0.1% sodium hyaluronate.

PubMed ID: 22287172

Phase III noninferiority RCT showed sodium hyaluronate improved dry-eye signs/symptoms comparable to osmoprotective formula.

PubMed ID: 27515572

Hyaluronate eye solutions improved dry-eye signs and symptoms; one emulsion reduced discomfort more than HA alone.

PubMed ID: 27989018

HA-containing lubricant gels increased tear-film thickness; best effects with HA+trehalose formulation.

PubMed ID: 31298607

Topical sodium hyaluronate/trehalose gel reduced early postoperative ocular discomfort.

PubMed ID: 36269661

HA+PEG tear substitute was noninferior and in some measures superior to standard HA drops for moderate‑to‑severe dry eye (improved staining, TBUT, symptoms).

PubMed ID: 38389327

HA-containing tear substitute reduced patient-reported dry-eye symptoms after intravitreal injections.

PubMed ID: 40157723

HMW HA eye drops improved corneal nerve recovery and symptoms after crosslinking, supporting ocular comfort.

PubMed ID: 41546565

Randomized study: adding sodium hyaluronate to postoperative drops relieved dry‑eye symptoms and improved TBUT/Schirmer vs PVA.

PubMed ID: 39681489

HA eye drops improved tear production, TBUT and symptoms vs baseline in dry eye patients (though combined traditional therapy outperformed HA alone).

PubMed ID: 23617248

Randomized clinical comparison showed amino acids + sodium hyaluronate eye drops improved TBUT, corneal staining, and Schirmer faster and more than HA alone — strong ocular dryness benefit for HA formulations.

PubMed ID: 33289602

Large RCT: preservative‑free sodium hyaluronate/chondroitin drops improved TBUT, goblet cell density and symptom scores — directly reduces eye dryness.

PubMed ID: 28777385

Randomized trial: cross‑linked HA + CoQ10 eye drops improved dry eye symptoms and objective ocular surface signs vs HA alone.

PubMed ID: 22878452

In HA non‑responders, adding diquafosol improved tear metrics—shows HA monotherapy has some effect but may need adjuncts.

PubMed ID: 22914501

Large RCT: sodium hyaluronate improved corneal staining and tear stability in dry eye patients (direct, high‑quality evidence).

PubMed ID: 24528935

Combination HA+diquafosol after LASIK improved early visual performance and dry‑eye metrics vs monotherapies (supports HA utility post‑op).

PubMed ID: 25055152

(duplicate support) HA additive effects on OSDI, staining and goblet cells vs diquafosol alone indicate improved ocular surface hydration/symptoms.

PubMed ID: 26685791

Post‑cataract dry eye trial: HA provided benefit but diquafosol produced faster/greater recovery (HA effective but less so than comparator).

PubMed ID: 25631485

Large multinational RCT showing sodium hyaluronate improved ocular surface staining and modest TBUT benefits (robust comparator data).

PubMed ID: 37682142

Large RCT: 0.15% HA eye drops improved corneal staining, TBUT and symptoms as effectively as active comparators—strong direct evidence.

PubMed ID: 37905613

Adding diquafosol to HA produced superior tear stability and symptoms vs HA alone after SMILE—supports HA's baseline efficacy and benefit when combined.

PubMed ID: 34675150

Trehalose+HA tear substitute significantly improved TBUT, Schirmer and symptoms after cataract surgery vs HA alone or none.

PubMed ID: 31579987

Microemulsion eye drop containing HA improved TBUT and symptoms in moderate–severe dry eye vs control in randomized trial.

PubMed ID: 19396774

Ginkgo+HA drops improved allergic conjunctivitis signs/symptoms more than HA alone, supporting HA's ocular symptom benefits.

PubMed ID: 35442771

Post‑op RCT: HA+Ginkgo improved TBUT and symptoms after cataract surgery vs standard care—direct dry‑eye benefit.

PubMed ID: 35749148

Artificial tear containing HA improved tear stability (NIBUT), reduced evaporation and relieved dry‑eye symptoms.

PubMed ID: 8534643

Larger trial in dry eye: significant improvement in fluorescein staining (objective), though symptoms unchanged.

PubMed ID: 15868230

Hyaluronate/CMC membrane reduced postoperative adhesions and severity, likely speeding postoperative recovery/function.

PubMed ID: 38359676

IA HA produced early improvements in gait kinematics and stance parameters, which may translate to quicker functional recovery after activity.

PubMed ID: 38279075

Topical HA after frenectomy reduced early inflammation and analgesic use, indicating quicker early recovery.

PubMed ID: 39128172

Adjunct intra‑articular ozonized PRP+HA after meniscal repair produced markedly better long‑term pain/function and fewer complications—faster/better recovery context.

PubMed ID: 35328990

Topical HA + amino acids after tooth extraction reduced early edema/pain and decreased analgesic use, indicating faster short‑term recovery.

PubMed ID: 35679902

IA HA after TMJ arthrocentesis produced substantial improvements in pain and opening vs baseline, facilitating functional recovery.

PubMed ID: 36128500

HA + PRP after arthroscopic knee debridement improved pain/function and biomarkers vs debridement alone—suggests enhanced recovery though HA was combined with PRP.

PubMed ID: 34983471

Single IA HA at partial meniscectomy reduced pain and improved knee ROM in early postoperative period (faster functional recovery).

PubMed ID: 35686864

Peritendinous HA + ESWT reduced pain and disability faster than ESWT alone, indicating faster functional recovery.

PubMed ID: 35835925

Nebulized HA after maxillary osteotomy sped symptomatic recovery of nasal breathing during the first two postoperative weeks.

PubMed ID: 33407337

Adjunct HA after arthroscopic lateral release produced faster early pain/function improvements.

PubMed ID: 32701012

HA ocular gel increased proportion healed earlier after PRK (faster epithelial recovery).

PubMed ID: 32040462

HA sped early wound closure after dental extraction in diabetics—earlier tissue recovery vs control.

PubMed ID: 31781694

Topical HA accelerated postoperative wound shrinkage after frenectomy, indicating faster local recovery.

PubMed ID: 31778431

Knee viscosupplementation improved symptoms and muscle strength—could support quicker return to activity.

PubMed ID: 31451342

TMJ arthrocentesis + HA improved chewing efficiency and QoL—functional recovery aspects.

PubMed ID: 30199423

SH + PRP around partial rotator-cuff tears produced superior functional/pain improvements and better MRI healing—consistent with faster recovery.

PubMed ID: 30395961

HA‑CMC added to nerve root block reduced early rebound leg pain, facilitating earlier symptomatic recovery after the procedure.

PubMed ID: 30579747

HA+PRF improved early mucosal healing after tooth extraction and eliminated observed dry socket/infections vs control (faster post‑procedure recovery).

PubMed ID: 30159738

Single IA HA (Monovisc) produced clinically meaningful pain relief within 2 weeks → suggests earlier functional recovery after activity.

PubMed ID: 28914592

HA markedly accelerated palatal wound healing (complete epithelization earlier) and reduced pain → clear faster local recovery.

PubMed ID: 29073815

Esterified HA middle‑ear packing produced better postoperative ABG closure → suggests improved surgical recovery outcomes.

PubMed ID: 29077152

Nasal sodium hyaluronate shortened mucociliary transport time and improved symptoms in rhinosinusitis, aiding recovery.

PubMed ID: 29304325

HA + L‑PRF after extraction reduced swelling and immediate analgesic need → faster short‑term postoperative recovery.

PubMed ID: 28489239

Topical sodium hyaluronate after septoplasty accelerated mucociliary recovery (faster return of function).

PubMed ID: 29202568

Hybrid HA produced earlier and larger pain/function gains in obese OA patients vs high‑MW HA.

PubMed ID: 28058962

HA improved pain and function in RA foot/ankle at short‑term follow‑up.

PubMed ID: 27250845

Gel‑200 provided measurable symptomatic relief within weeks in knee OA.

PubMed ID: 27070534

HA injections gave quicker pain/function improvement than shockwave therapy in tendinopathy (faster symptomatic recovery).

PubMed ID: 27639439

Peritendinous HA led to earlier and greater pain/function gains vs ESWT in Achilles tendinopathy.

PubMed ID: 28002896

Hybrid HA produced faster/greater short‑term symptom relief in athletes with knee lesions vs PRP (3–6 months).

PubMed ID: 27466224

Single HA after ACL surgery gave modest short‑term ROM gains and reduced swelling (faster early recovery markers).

PubMed ID: 29328639

Topical HA for alveolar osteitis shortened pain duration and time to symptom resolution after tooth extraction.

PubMed ID: 26551066

Immediate intra‑articular HA at arthroscopy reduced pain and improved function during the 3–6 week postoperative period.

PubMed ID: 25906706

Crosslinked HA gel reduced postoperative adhesions significantly—improves surgical recovery/ morbidity.

PubMed ID: 25933201

rhFGF‑2/HA substantially improved periodontal attachment—strong post‑surgical tissue recovery evidence.

PubMed ID: 25340801

Peptide in HA gel improved finger motion/sensation after tendon repair—direct evidence of faster/ better functional recovery.

PubMed ID: 24848975

PRGF+HA accelerated pressure‑ulcer area reduction and increased healing frequency vs standard care.

PubMed ID: 25375400

Markedly faster and higher rates of diabetic foot ulcer healing when HA used in autologous fibroblast matrix—clear faster recovery.

PubMed ID: 24924267

HA spray after wisdom‑tooth removal reduced early swelling and improved mouth opening (earlier functional recovery), though pain unchanged.

PubMed ID: 24328847

HA‑containing gel accelerated oral wound closure at 7 days vs no treatment (randomized clinical trial).

PubMed ID: 23710960

Topical HA after turbinate surgery led to earlier symptomatic improvement vs saline (patients felt better sooner).

PubMed ID: 23426344

HA/CMC membranes reduced adhesions and shortened liver mobilization time at reoperation, indicating faster surgical recovery.

PubMed ID: 22933671

Intra‑articular HA at ACL surgery reduced pain/swelling in first 1–2 days post‑op, aiding early recovery.

PubMed ID: 22512127

Use of IA preparation including HA improved postoperative knee function and recovery curve vs control in prospective trial.

PubMed ID: 21545190

Corticosteroid followed by HA injections led to faster recovery and quicker return to function vs surgery for trigger finger.

PubMed ID: 20144496

Sodium hyaluronate after TMJ arthroscopy reduced pain at 2 and 12 weeks, implying quicker symptomatic recovery.

PubMed ID: 20954664

After arthroscopic meniscectomy IA HA reduced early pain and analgesic use, indicating faster symptomatic recovery.

PubMed ID: 19710086

Hyaluronan anti-adhesion gel after tenolysis accelerated return of finger motion and return to work.

PubMed ID: 20145786

Adjunct IA HA after knee arthroscopy produced less pain and better motion versus surgery alone (supports quicker functional recovery).

PubMed ID: 20003205

Hip IA HA improved function and reduced NSAID use vs mepivacaine, consistent with improved short-term recovery.

PubMed ID: 20048489

Athlete RCT: periarticular HA shortened time to pain-free sport and reduced days missed and reinjury.

PubMed ID: 19539353

Knee OA trial showed durable functional improvement which can facilitate activity/recovery, though not an acute sports trial.

PubMed ID: 19060514

IA HA gave better short‑term functional improvement at 6 weeks after arthroscopy (improved early recovery/function).

PubMed ID: 19060515

Post‑arthroscopy HA groups had better pain/function at 12 months than surgery alone, suggesting improved recovery trajectory.

PubMed ID: 17620776

ACL rehab trial: intra‑articular HA improved function and muscle strength—supports faster functional recovery.

PubMed ID: 17620777

Periarticular HA for acute lateral ankle sprain shortened time to pain‑free/return-to-sport by ~6 days vs placebo.

PubMed ID: 17187274

Instillation of HA after arthroscopy led to maintained improvements in pain/function over time — indicates improved recovery trajectory vs lavage alone.

PubMed ID: 15918064

Viscoseal instillation after arthroscopy reduced early pain, swelling and analgesic use — supports faster early recovery.

PubMed ID: 16342083

HA combined with exercise/ultrasound produced largest gains in walking speed and strength vs other groups.

PubMed ID: 15694572

Hylan G‑F 20 produced large symptom improvements that could permit faster return to activity.

PubMed ID: 16242361

Knee OA pain relief from bio‑HA may facilitate quicker recovery/activity; direct recovery metrics limited.

PubMed ID: 14514591

HA‑based grafts reduced mean time to ulcer closure by ~20 days for foot ulcers → supports faster recovery.

PubMed ID: 12127830

Hylan G‑F 20 added to usual care improved pain/function and health utility over 1 year, suggesting better activity tolerance and recovery.

PubMed ID: 11822921

HA improved activity pain and objective walking/stepping performance versus placebo/NSAID in randomized trial.

PubMed ID: 12202120

Within‑patient study: HA injections increased muscle strength and reduced weightbearing pain, implying improved functional recovery after activity.

PubMed ID: 11532487

Intraperitoneal ferric hyaluronate gel markedly reduced postoperative adhesions and severity—clinically meaningful improvement in surgical recovery endpoints.

PubMed ID: 9818665

HA reduced walking pain and improved function over 26 weeks, which can support faster/less symptomatic recovery during activity.

PubMed ID: 8886085

Year‑long trial showed reduced need for supplementary local therapies and sustained benefit—implies faster/persistent recovery.

PubMed ID: 1468245

HA plus low‑dose steroid produced faster symptom improvement in knee OA, implying quicker functional gains.

PubMed ID: 34675150

Trehalose+HA tear substitute sped objective and symptomatic ocular surface recovery after cataract surgery vs HA or no treatment.

PubMed ID: 20026488

Larger CABG study corroborated perioperative preservation of platelets/proteins with HA‑coated circuits, supporting improved perioperative recovery.

PubMed ID: 16350383

HA‑based heparin‑bonded extracorporeal circuits reduced inflammation/bleeding and preserved platelets in cardiac reoperations—may speed perioperative recovery.

PubMed ID: 12603352

Intrathoracic HA gel reduced pleural thickening and improved lung function after tuberculous effusion, suggesting faster recovery of pulmonary mechanics.

PubMed ID: 40781616

HA film reduced healing time and bleeding after graft harvesting—supports faster recovery from oral surgery.

PubMed ID: 39012233

H2O2+HA rinse after extraction decreased pain and improved early socket healing—accelerates recovery from dental procedure.

PubMed ID: 36595064

Topical HA after palatal graft sped wound healing, reduced pain and earlier epithelialization—faster recovery.

PubMed ID: 31381494

Egsshell membrane (contains HA) improved walking performance in knee OA, suggesting quicker functional recovery in worse performers.

PubMed ID: 26577936

Sustained pain and analgesic reduction after IA HA+CS may facilitate faster recovery of activity tolerance.

PubMed ID: 26133944

HA+CS injection produced durable pain/function improvements at 3–6 months in tennis elbow, implying faster or more complete functional recovery vs steroid.

PubMed ID: 35210111

HA + berberine gel shortened hospital stay and improved early postoperative scores after sinus surgery — indicates faster early recovery (confounded).

PubMed ID: 25763853

Post‑microfracture HA produced better cartilage repair on MRI and improved ankle scores, indicating improved recovery quality.

PubMed ID: 25825393

IA HA as adjunct to microfracture produced better midterm function and less pain vs saline, consistent with faster functional recovery.

PubMed ID: 22205098

Adjunct IA hyaluronan after microfracture improved functional recovery versus surgery alone.

PubMed ID: 36725463

Topical HA shortened postoperative healing time by ~4 days after nail surgery—direct faster recovery evidence.

PubMed ID: 18822733

HA hydrogel significantly shortened healing time for abscess cavities (~12.7 vs 20.3 days), strong evidence for faster local recovery.

PubMed ID: 40590113

HA dressing after laser shortened pain duration and accelerated skin barrier recovery — faster procedural recovery.

PubMed ID: 39983793

Early post‑ACL intra‑articular HA reduced pain and improved ROM and function in first 1–2 months, accelerating early recovery.

PubMed ID: 39930405

HA in extraction sockets sped soft tissue healing and bone density improvements — faster healing course.

PubMed ID: 40660843

HA injections yielded superior medium‑term symptom and function benefits in knee OA versus ozone, suggesting faster functional improvement over time.

PubMed ID: 39892589

HA added to steroids in thumb‑base produced greater activity‑related pain reduction at 3 months, implying functional recovery benefit.

PubMed ID: 39279207

Intra‑socket HA after third molar extraction reduced pain and improved wound healing — faster postoperative recovery.

PubMed ID: 26004026

Topical liposomal HA reduced vaginal dryness and pain, reducing mucosal irritation.

PubMed ID: 33374791

HA-containing mouthwash reduced pain symptoms in oral lichen planus, implying reduced mucosal irritation.

PubMed ID: 40157723

HMW HA improved ocular symptoms and nerve recovery after crosslinking, lowering irritation.

PubMed ID: 29703289

Crosslinked HA ocular gel reduced corneal wound size and accelerated healing, decreasing irritation.

PubMed ID: 25217122

Self-cross-linked HA lowered endoscopic wound grade (edema/crusting) after sinus surgery.

PubMed ID: 23406605

HA nasal hydrogel reduced edema, crusting and mucopurulent drainage—reduced local inflammation.

PubMed ID: 18822733

HA hydrogel reduced wound size and healing time, likely decreasing local irritation and inflammation during healing.

PubMed ID: 29921408

HA oral spray decreased mucositis severity and pain after stem cell transplant, indicating reduced mucosal irritation.

PubMed ID: 32131656

HA dermal matrix reduced inflammatory markers and improved wound healing in diabetic foot ulcers (anti‑inflammatory effect).

PubMed ID: 32710584

PAHA dressings reduced inflammation and enhanced re‑epithelialization in chronic skin ulcers.

PubMed ID: 34837931

Mucosamin® significantly reduced radiation‑induced mucositis severity and shortened symptom duration (strong clinical evidence).

PubMed ID: 38494975

Adjunct topical HA gel improved periodontal indices and reduced inflammatory markers in chronic periodontitis — supports anti‑inflammatory/soothing mucosal effect.

PubMed ID: 22492249

Topical HA-containing gel reduced anal pain, itching, bleeding and irritation vs placebo in hemorrhoid patients — consistent anti‑irritant effect on mucocutaneous tissue.

PubMed ID: 35191198

HA+H2O2 mouthrinse reduced gingival inflammation significantly vs placebo—evidence HA can reduce mucosal irritation/inflammation.

PubMed ID: 36595064

Topical HA after grafting reduced pain and accelerated healing—consistent with reduced irritation.

PubMed ID: 39012233

Mouthwash containing HA reduced postoperative pain and improved socket healing—less irritation and inflammation.

PubMed ID: 40781616

HA film reduced postoperative pain and burning sensation at palatal donor site—supports calming effect on irritated mucosa/skin.

PubMed ID: 27049103

Intranasal T‑LysYal reduced inflammatory cells and endoscopic signs post‑FESS—HA‑based formulation showed anti‑inflammatory/mucosal calming effects.

PubMed ID: 27049100

Adjunctive intranasal T‑LysYal improved nasal cytology and symptoms across rhinitis types, indicating reduced mucosal irritation/inflammation.

PubMed ID: 40295318

HA with other agents reduced severe oral mucositis and symptom burden (calming inflamed mucosa).

PubMed ID: 39435599

Topical HA reduced pain and lesion severity in oral lichen planus, indicating calmer irritated mucosa/skin‑like tissue.

PubMed ID: 9106924

HA cream significantly reduced severity of radiation‑induced skin reactions vs placebo.

PubMed ID: 12622859

Topical HA gel reduced plaque and gingival bleeding and decreased inflammatory crevicular enzymes (anti‑inflammatory effect).

PubMed ID: 16083533

HA+SSD led to faster healing of burns, implying reduced inflammatory irritation duration.

PubMed ID: 15999421

Topical HA spray markedly reduced bleeding/inflammatory fluid in gingiva—strong anti‑inflammatory/soothing effect at mucosal surface.

PubMed ID: 15701590

HA-containing cream modestly reduced eczema severity/area and improved patient-reported itch control vs vehicle.

PubMed ID: 16573256

Emollient/repair cream containing HA improved eczema severity and itch vs vehicle in a randomized trial—suggests HA‑containing formulations can calm irritated skin (though multi‑ingredient).

PubMed ID: 17461960

HA gel use in peri‑implant tissue reduced early bleeding index vs chlorhexidine, indicating reduced local irritation/inflammation.

PubMed ID: 18713490

HA dressing reduced fibrinous tissue and trended toward better wound conditions vs control.

PubMed ID: 18474463

Cream reduced radiation‑induced redness, burning and desquamation vs vehicle (reduced irritation).

PubMed ID: 18946677

Hyaluronan packing improved mucosal healing and reduced adhesions after sinus surgery, consistent with less local irritation.

PubMed ID: 19709346

Topical HA gel vehicle with diclofenac reduced AK grade and cell proliferation, indicating reduced skin irritation/inflammation mechanisms.

PubMed ID: 19703948

HA-containing gel improved ulcer healing and reduced ulcer area rapidly, consistent with reduced local irritation/inflammation.

PubMed ID: 20135132

Vaginal HA improved symptoms of atrophy/irritation in postmenopausal women.

PubMed ID: 20577750

Vaginal HA reduced genital symptom scores and colposcopic signs (reduced irritation/inflammation).

PubMed ID: 22405094

HA gauze reduced wound pain and sped healing vs non‑HA dressing.

PubMed ID: 22399081

Topical HA reduced ulcer pain and improved local condition vs vehicle.

PubMed ID: 22728576

Topical HA gel reduced itching and burning and improved signs of atrophy vs placebo.

PubMed ID: 23413492

HA gauze caused fewer peri‑ulcer skin problems (edema, purpura, maceration), indicating calmer periwound skin.

PubMed ID: 23710960

Topical HA after turbinate surgery reduced crusting and improved nasal breathing/comfort vs saline.

PubMed ID: 23801461

Adding intranasal sodium hyaluronate to standard rhinitis therapy reduced neutrophils and improved symptoms (randomized trial).

PubMed ID: 23527716

Nebulized sodium hyaluronate after FESS improved mucosal signs and reduced biofilm, reflecting calmer mucosal inflammation.

PubMed ID: 23527715

Intranasal sodium hyaluronate reduced neutrophils and inflammation in children with recurrent URTI—anti‑inflammatory mucosal effect.

PubMed ID: 24355241

Intranasal HA improved olfactory‑related QoL and anxiety in multiple chemical sensitivity, consistent with symptomatic calming of mucosa.

PubMed ID: 25123116

Intravesical HA reduced BCG‑induced bladder pain and LUTS during induction—calming mucosal irritation in urinary tract context.

PubMed ID: 24591296

Intranasal sodium hyaluronate improved mucosal edema/discharge and QoL after sinus surgery—direct calming of irritated mucosa.

PubMed ID: 25197922

Nebulized nasal HA reduced CRS symptoms, edema and secretions—calms irritated sinonasal mucosa.

PubMed ID: 25487027

Preservative‑free HA eye drops lowered inflammatory markers and improved signs—calms ocular surface irritation.

PubMed ID: 26084554

Adding HA to CHX mouthwash reduced early post‑op oedema—reduced local irritation and swelling.

PubMed ID: 25906706

Crosslinked HA gel markedly reduced postoperative adhesions and related morbidity—strong calming/reduction of surgical tissue irritation.

PubMed ID: 25877422

Auto‑crosslinked HA gel reduced intrauterine adhesions and severity after surgery, indicating reduced local irritation/scar.

PubMed ID: 26432128

HA+CMC drops reduced corneal staining and dry‑eye symptoms post‑cataract (reduced ocular surface irritation).

PubMed ID: 26788875

Low‑MW HA suppository reduced biopsy markers of inflammation/atrophy after radiation and improved symptoms.

PubMed ID: 26070127

Topical vaginal HA improved dyspareunia and mucosal status vs baseline, indicating reduced irritation.

PubMed ID: 25678773

HA eye drops supported faster corneal re‑epithelialization, relevant to calming/repairing irritated ocular surface.

PubMed ID: 29328639

Topical HA reduced pain and symptoms in alveolar osteitis (oral mucosal irritation) versus standard paste.

PubMed ID: 26972358

HA dressing sped diabetic foot ulcer healing and reduced signs/symptoms, indicating reduced local irritation/inflammation.

PubMed ID: 27445067

HA‑trehalose drops improved dry‑eye symptoms (stinging/itching/blurred vision), indicating reduced ocular irritation.

PubMed ID: 27049107

Nasal SH improved nasal symptoms and reduced mucosal oedema in children.

PubMed ID: 26980389

Postoperative nasal HA decreased symptoms and cellular impairment—soothing/repairing effect.

PubMed ID: 27571124

HA mouthwash reduced mucositis severity and pain, indicating anti‑irritant/mucosal calming effect.

PubMed ID: 28387882

HA‑collagenase ointment accelerated debridement and likely reduced devitalized/inflamed tissue burden in venous ulcers.

PubMed ID: 29202566

Nebulized sodium hyaluronate after FESS produced faster symptom relief and improved endoscopic signs (less crusting/edema) → reduces mucosal irritation/inflammation.

PubMed ID: 28927491

Intranasal HA reduced CPAP-related nasal symptoms and inflammatory marker increases vs saline → supports calming of irritated nasal mucosa.

PubMed ID: 28914592

Topical oral HA lowered pain and sped mucosal healing after graft harvesting → calmer/less irritated mucosa.

PubMed ID: 29961138

Adding HA to periodontal surgery reduced early postoperative swelling and discomfort vs surgery alone.

PubMed ID: 30579747

HA+PRF after tooth extraction improved early soft‑tissue healing and reduced postoperative complications/swelling vs control.

PubMed ID: 30556961

Topical HA reduced pain, erythema and lesion size in oral lichen planus comparable to topical steroid.

PubMed ID: 31604061

Subcutaneous HA injection during brachytherapy markedly reduced acute skin toxicity incidence (strong anti-irritant/protective effect).

PubMed ID: 30861510

Vaginal HA markedly reduced radiotherapy-induced mucosal side effects and pain, reflecting calmer mucosa.

PubMed ID: 32051972

HA mouthwash limited gingival inflammation vs water in a 4‑day model (anti‑inflammatory/soothing mucosal effect).

PubMed ID: 35025757

Topical HA increased ulcer healing and would reduce local irritation/inflammation in wounds.

PubMed ID: 33872196

HA dressing improved ulcer healing rates, implying reduced chronic irritation.

PubMed ID: 34096694

Vaginal HA gel improved symptoms of vulvovaginal atrophy, consistent with reduced irritation.

PubMed ID: 36038984

Ectoine + HA cream significantly reduced AD severity and pruritus vs vehicle, indicating reduction of irritation/inflammation.

PubMed ID: 35732749

Mucosamin® mouth spray (multi‑ingredient including HA) decreased oral mucositis incidence/severity, consistent with reduced mucosal irritation.

PubMed ID: 38833009

HA + CHX rinse reduced bleeding and sped early periodontal wound healing—reduced local irritation/inflammation.

PubMed ID: 38279075

Topical HA after frenectomy reduced early postoperative inflammation (BOP) and analgesic use in children.

PubMed ID: 39304658

HA‑containing drug sponge improved sinonasal healing and reduced symptoms/adhesions indicating calmer mucosa (multi‑component device).

PubMed ID: 39717991

Intradermal HA + hEGF produced marked dose‑dependent reductions in red area and symptom scores (calming of irritated skin).

PubMed ID: 40590113

HA dressing after laser reduced erythema index and shortened pain duration — clear calming/anti‑irritant effect post‑procedure.

PubMed ID: 41162972

Topical HA reduced palatal donor‑site pain and improved wound healing scores—evidence of reduced local irritation/discomfort.

PubMed ID: 39304548

Adjunctive sodium hyaluronate gel improved peri-implant mucositis resolution and reduced bleeding sites (less inflammation/irritation).

PubMed ID: 37851095

Sodium‑hyaluronate mouthwash significantly reduced xerostomia scores and improved patient satisfaction in irradiated H&N survivors.

PubMed ID: 35732749

Mucosamin® mouth spray (contains HA‑related components) reduced incidence/severity/duration of oral mucositis, which includes symptomatic oral dryness/discomfort.

PubMed ID: 36529530

Sodium‑hyaluronate oral rinse reduced dry mouth symptoms and increased unstimulated saliva flow above hyposalivation threshold.

PubMed ID: 27571124

HA‑containing mouthwash reduced chemotherapy‑induced oral mucositis severity and pain (improved oral mucosal comfort).

PubMed ID: 38494975

Topical sodium hyaluronate gel as adjunct in periodontal cleaning improved mucosal indices and reduced inflammatory markers — supports improved oral mucosal hydration/comfort.

PubMed ID: 34837931

Mucosamin® (sodium hyaluronate + amino acids) significantly reduced radiotherapy‑induced mucositis severity and shortened duration.

PubMed ID: 29921408

HA‑based oral spray reduced severity and duration of oral mucositis and related symptoms after stem cell transplant.

PubMed ID: 31904175

Oral eggshell‑membrane (contains HA) modestly improved hair density; effect confounded by multiple components.